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Emilia M. Zywot: Pre-Clinical Development of Vitamin B12 Photoactivatable 
Therapeutics 
(Under the direction of David S. Lawrence) 
 
Photoactivatable therapeutics are targeted light-activated drug delivery systems 
composed of a therapeutic cargo appended to a photoresponsive moiety, which releases the 
cargo upon illumination. These targeted therapeutics have the potential to diminish toxicity and 
improve efficacy of the therapeutic cargo due to the temporal and spatial control provided by 
external light controlled therapeutic release. The introduction of this dissertation describes the 
precedent set by clinically approved photodynamic therapy and currently available 
photoresponsive moieties. Together, this background contributes to the proposed pre-clinical 
development plan for photoactivatable therapeutics.  
Vitamin B12, or cobalamin (Cbl), has shown exciting potential as a photoresponsive 
moiety with inherent photoresponsivity and minimal toxicity. Herein, two Cbl-based 
photoactivatable therapeutics encapsulated in red blood cells (RBCs) are developed. In vivo 
studies of a Cbl RBC chemotherapeutic and anti-inflammatory drug demonstrate localized 
delivery and efficacy comparable to standard of care respectively. Together, the advances 
contribute to the pre-clinical development plan for Cy5-Cbl photoactivatable therapeutics 
proposed in the conclusion. Overall, photoactivatable therapeutics, and Cy5-Cbl therapies 
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1 CHAPTER 1: SUCCESSFUL TRANSLATION OF PHOTOACTIVATED 
DRUG DELIVERY SYSTEMS INTO THE CLINIC 
 
1.1 An Introduction to Personalized Medicine and the Advent of Externally 
Controlled Drug Delivery Systems (DDSs) 
Since the 1950s, scientists and clinicians have observed substantial variability in patient 
response to therapeutics. With the mapping of the human genome in 2003, this variability was 
correlated to the uniqueness of each person’s genome. This discovery birthed the field of 
pharmacogenomics which seeks to understand how the genetic variation (among other individual 
variations) affect patient response to therapeutics.1 Since pharmacogenomics, personalized 
medicine has expanded with the development of targeted therapies, especially in the field of 
cancer. These therapies include monoclonal antibodies and drugs conjugated to antibodies 
(antibody drug conjugates, ADCs) that target specific cellular biomarkers based on a cell’s 
expressed genetics.2 Such targeted therapies have been extremely successful as they minimize 
toxicity and improve efficacy in the treatment of cancer.  
However, therapies developed specifically for a patient’s genome – or in the case of 
cancer, the cancer’s mutated genome – can only be applied to a small number of patients and a 
small number of cancers.3 These limitations, as well as current scientific limitations in 
understanding how pharmacogenomics relate to complex diseases, contribute to the 
development of targeted therapies that do not rely on a patient’s genome. Instead these targeted 
therapies seek to optimize when, where, and how much therapeutic is delivered based on the 
patient’s unique needs. Scientists developed stimuli-responsive drug delivery systems (DDSs) to 
achieve such control. Stimuli-responsive DDSs employ a small-molecule or nanomaterial carrier 





Table 1-1 highlights many of the stimuli investigated for DDSs and provides a brief summation of 
limitations and advantages of each system.4  
Externally controlled DDSs (with responsivity to heat, light, magnetics, ultrasound, or 
electrical stimuli) provide clinicians and patients with control over the location of therapeutic 
delivery, when therapeutic release occurs, and potentially what dosage of therapeutic is delivered 
by controlling the location of stimulation, when the stimulation is applied, and how long the 
stimulation is applied respectively. Externally controlled DDSs can therefore minimize therapeutic 
toxicity and maximize therapeutic efficacy by minimizing therapeutic exposure systemically and 
improving the pharmacokinetics (PK) of therapeutic exposure at the target site. Consequently, 
these improvements lead to targeted cellular uptake and effect (pharmacodynamics, PD).  
The range of safety and efficacy of any given drug is quantified by its therapeutic index 
(TI). The TI is calculated by the ratio of the highest dose of drug that results in no toxicity (also 
known as maximum tolerated dose, MTD) to the required dose to produce the desired efficacy.5 
There are many ways to determine the therapeutic index between in vitro cellular endpoints, in 
vivo animal endpoints, and clinical endpoints in patients. It is important to note that toxicologists 
and the Food and Drug Administration (FDA) often discuss safety in terms of the “No Observed 
Adverse Effect Level” (NOAEL) that indicates the MTD and the “No Observed Effect Level” (NOEL) 
which indicates the highest dose that has no effect (efficacious or adverse) on the subject. These 
data points are commonly used to determine an initial starting dose for Phase I clinical trials and 
relate to measuring a drug’s TI.6, 7  
Externally stimulated DDSs improve the TI by minimizing therapeutic toxicity and 







Table 1-1 Advantages and limitations of stimuli-responsive DDSs for personalized 














1.2 Photoactivatable DDSs Advance Personalized Medicine 
Photoactivatable, or light-activated, DDSs are poised to advance personalized medicine 
by enabling patient directed treatment and clinical theranostic control (the combination of imaging 
both treatment location and releasing therapeutic). Considering both the sensitivity and external 
devices for the technology currently under development in Table 1-1, light is currently the most 
sensitive and accessible DDS. There are many light-based FDA approved home devices, 
including simple laser pointers and light emitting diodes (LED) systems.8 To feasibly develop 
patient-controlled stimuli-responsive DDSs, patients need to have access to devices sufficiently 
powerful to stimulate therapeutic delivery. Further, to feasibly develop clinician-controlled 
theranostic drug imaging and delivery, imaging technology needs to be clinically available. LED-
based systems are FDA approved for superficial applications, as well as biomedical imaging.9 
Conversely, current heat-based systems under development require high intensity heat sources, 
while magnetic systems depend on magnetic nanomaterials for control.10, 11  
Thus, light-based DDSs only require clinical approval of a photoresponsive therapeutic to 
the available home devices or a DDS that provides both photoresponsive imaging and therapeutic 
delivery detectable by the clinically approved imaging devices to advance personalized medicine. 
Patient-controlled treatments would further personalize medicine by allowing patients to dose 
themselves in response to symptom development with more localized control and safety than 
even an oral pill may provide. Photoactivatable DDSs can also further personalize medicine by 
providing clinicians with the ability to optimize therapeutic distribution before activation, potentially 
diagnose the diseased tissue with imaging, and immediately measure and deliver quantified 
therapeutic doses. Both systems are close to reaching human translation as in vivo animal studies 
are already underway.   
Beyond these novel applications of photoactivatable DDSs, photoresponsive therapies 





therapy in which an injected photosensitizer (PS) produces cytotoxic reactive oxygen species 
(ROS) after exposure to light.12 FDA approved lasers and fiber optic devices are employed in PDT 
to provide very high spatial and temporal control over the cytotoxic effects of ROS. PDT has 
proven that long wavelength light in the near infrared (NIR) spectrum (600 - 950 nm) – also known 
as the optical window of tissue – can successfully penetrate tissue to cm depths. Other 
wavelengths, outside of the optical window of tissue, are predominantly absorbed by water and 
























Figure 1.1 The optical window of tissue presented by a) a schematic of how different 
wavelengths of light propagate through tissue and b) absorbance of water, oxygenated 
hemoglobin, and deoxygenated hemoglobin, across the visible wavelength spectra. The optical 







Photoactivatable DDSs and therapeutics differ from PDT, which are both included in the 
umbrella term “photoresponsive therapies”. Photoactivatable DDSs release and deliver 
therapeutic cargo upon illumination, while PDT PSs generate ROS species by reducing 
environmental oxygen upon illumination. Photoactivatable DDSs are composed of therapeutic 
cargo and a photoresponsive moiety, that releases the therapeutic in response to illumination 
which then proceeds to produce the desired pharmacological effect. These photoresponsive 
therapies can also include carriers (nanomaterial or cellular drug delivery vehicles) and require 
light and a light source (Figure 1.2). Since PDT has already achieved FDA approval, it is important 
to consider the challenges this photoresponsive therapy faced to achieve approval as precedent 
for similar challenges photoactivatable therapeutics may encounter. 
NIR responsive systems are amenable to the desired safety and accessibility for patient-
controlled stimulation, provide means by which to both image and deliver therapeutics, and have 
achieved precedential approval with PDT. This Chapter will thus focus on DDSs which release an 
active therapeutic substance in response to light, while considering the precedent PDT has 
already established in the clinic (section 1.4 and section 1.3 respectively). The Chapter will then 
describe the components of photoactivatable DDSs in the context of biological relevance and the 












Figure 1.2 Designing Photoactivatable DDSs. a) The components of photoactivatable 
DDSs. b) A schematic illustrating the components of a photoactivatable DDS. The 





































1.3 Current FDA Approved Photoresponsive Therapies and Devices 
With the isolation of naturally photoresponsive chemicals in the early 1900’s by Professor 
Herman von Tappeiner, light-responsive therapeutics were introduced into Western medicine and 
the first PDT tested for cancer.15 After the work of Tappeiner, the PS haematoporphyrin and its 
derivatives (HPD) were discovered, developed, and finally tested in systematic human trials in 
1978.15 Dougherty and Gomer worked on the development of HPD from 1978 to the early 1990’s, 
finally achieving approval of Photofrin in 1993 for the treatment of bladder cancer and in 1995 for 
esophageal cancer.16, 17 Since then, multiple second-generation PSs have been clinically 
approved, with now even third-generation PSs that employ nanocarriers and ADCs under clinical 
development.17 With more than 100 years of development, PDT and its associated approved 
irradiation sources light the stage for the clinical approval of photoactivatable DDSs.  
 
1.3.1 Photosensitizers (PSs) 
PSs are substances that interact with cellular substrates to produce ROS after exposure 
to light. These ROS, frequently singlet oxygen, induce cell death by multiple mechanisms 
including apoptosis, necrosis, and autophagy of cells as well as damaging surrounding 
vasculature.18 Thus, PSs have been heavily developed for cancer applications due to their 
localized toxicity, but have also been applied in dermatological indications and age-related 
macular degeneration (AMD) (Table 1-2). PSs are commonly macrocyclic compounds which 









Table 1-2 Clinical characteristics of FDA approved photosensitizers, including their clinical 
excitation wavelength (l), quantum yield (Φ), extinction coefficient (e) at the clinical wavelength, 
approved indications, and method of administration.  




Hematoporphyrin Photofrin 630 IV 0.2519 3,000 Esophageal 
cancer, 
endobronchial non-
small cell lung 





monoacid ring A 
(BPDMA), 
Verteporfin 








635  Oral, topical gel, 
and solution 





Metvixia  63520 Topical cream NA NA Actinic keratoses 
Hexyl amino 
levulinate 
Cysview 380-45020 Solution NA NA Photo diagnosis of 
bladder cancer 
Riboflavin Photrexa 365 Solution 0.5421 13,00022 Keratoconus and 
Corneal Ectasia 














1.3.1.1  Quantifying Photosensitizer Efficacy and Light Dosimetry 
A PS’s efficacy depends on its sensitivity to light, the amount of light exposure, and its 
ability to efficiently convert light to the pharmacological singlet oxygen. While these factors are 
easily measured during in vitro studies, in vivo measurements are complicated by the need to 
account for light attenuation, geometry, and penetration depth. Although more complex equations 
are required to truly assess PS efficiency, the following simple equation takes into account the 
necessary variables: 
!"	$%%&'&$(') = 	#	,&(-.$/	01)-$(	23045'$4 ∝ #	2ℎ0/0(,	89,039$4	9)	/ℎ$	!"	1	Φ	0%	/ℎ$	!"		 
Quantum yield (Φ), an intrinsic property of PSs, is the ratio of singlet oxygen generated 
to the number of photons absorbed and reported as a number between zero (no singlet oxygen 
generated) and one (all absorbed photons produce singlet oxygen). This probability of producing 
singlet oxygen is commonly measured under perfect conditions of excess PS, light, and oxygen, 
meaning the only limiting step in the process is how effectively the energy absorbed is transferred 
into producing ROS.23 Poor PSs with a low Φ, release the absorbed energy as fluorescence, 
phosphorescence, or through other forms of vibrational energy (Figure 1.3). A PS with a Φ of one, 
will conversely always transform the energy from absorbed photons into singlet oxygen. Thus, 
multiplying the number of photons absorbed by Φ produces the total quantity of singlet oxygen 
generated. Limitations of an optimized PS occur due to limited environmental oxygen, such as in 
hypoxic cancers, and when few photons penetrate tissue. It is important to note, Φ does not 
indicate the rate of release. Therefore, even high Φs may require an hour or longer of illumination 
to produce enough therapeutic to produce the desired effect. Such periods may be unfeasible in 
the clinic due to the photoactivatable DDS diffusing away from the light source as well as the 






Figure 1.3 Jablonski Diagram illustrating light absorbed by PS (red) to excite electrons to the 
excited singlet state which can be converted to a triplet state by intersystem crossing (black). 
ROS can be generated by Type 1 and Type 2 mechanisms from the longer-lived triplet state. 
Energy can be lost by fluorescence or phosphorescence (blue arrows) decreasing the Φ. 












Multiple factors contribute to the number (#) of photons absorbed by the PS, including: the 
PS’s extinction coefficient (e) at the wavelength of treatment, the local dosage of light (J/cm2), and 
the PS’s concentration in the illuminated tissue.  
A PS’s ability to absorb photons at a specific wavelength of light, e (M-1 cm-1), is dependent 
on the solvent and concentration of PS.25 Though the e is easily measurable in solutions of water 
and ethanol, the environment of in vivo tissues can make quantifying the e challenging.26 Figure 
1.1b demonstrates how the e of hemoglobin and oxidized hemoglobin (left axis) as well as the e 
of water, which is a 1x106 magnitude lower (right axis), vary with wavelength. Within the optical 
window of tissue, the e of hemoglobin ranges from 400 - 2,400 M-1 cm-1.27 The PS’s e should be 
sufficiently high to absorb as many photons as possible and outcompete the absorbance of 
hemoglobin and water, especially at NIR wavelengths.28 
The local dosage of light the PS is exposed to within tissue is assessed by dosimetry.28-31 
Dosimetry evaluates the properties of the tissue (such as refractive index and architecture), the 
wavelength of light, geometry and intensity (mW/cm2) of the light source, and the time of 
illumination to optimize the light penetrance and distribution through tissue. Tissue affects light 
penetrance by scattering, reflecting, refracting, and absorbing light. Scattering occurs at all visible 
wavelengths and is described by the transport scattering coefficient which is commonly found to 
be 1 - 2 orders of magnitude larger than the absorption coefficients of tissue.28 However, the 
degree of scattering is very hard to accurately assess as it is highly dependent on the architecture 
of the tissue and the fluctuations in the tissue’s refractive index.32 Scattering leads to the 
dispersion of light and reduction in its intensity. Light is also reflected and refracted at the surface 
of tissue due to the refractive index mismatch at this boundary.31 Light is then absorbed by water, 
hemoglobin, and pigments, such as melanin within tissue (Figure 1.1).28 Wavelengths between 





The light device’s geometry is also crucial to ensure the desired tissue is uniformly 
illuminated. To achieve optimal irradiation geometry, multiple delivery devices have been 
developed which include contact, non-contact, and interstitial (inserted into the tissue) optical 
fibers. These fibers can be applied individually, in a 3D array, by scanning mechanisms, and in 
light-diffusing mediums (Figure 1.4).30, 31 Dosimetry is still limited in its ability to measure light 
distribution in human patients, while in vitro measurements do not truly mimic the complexity of 
tissue.28   
The dosage (J/cm2) of light the tissue is exposed to is measured by multiplying the 
intensity of the device by the total illumination time. For PSs, an optimal rate of illumination is 
required to ensure that the oxygen is being replenished at a similar rate in tissue.28 The dosage 
can also be modulated by irradiating the target tissue for one continuous period of time, for 
staggered periods of times, or metronomically. Light sources with high power can cause tissue 
heating and eventual damage with prolonged periods of high intensity exposure. Metronomic 
treatments apply light at lower intensities for extended periods of time, which has been found to 






Figure 1.4 Examples of the diverse geometries of delivery devices for PDT. a) Microlens 
used for flat surfaces, b) spherical diffusor and c) cylindrical diffuser used in contact and 
interstitial applications, and d) balloon applicator scattering medium used for contact irradiation 















Finally, the PS’s concentration in the irradiated tissue is measurable by PK methods in 
vivo and theranostic methods in the clinic. The concentration will correlate to the total amount of 
ROS produced and consequently the efficacy of the treatment. Thus, to achieve an optimal 
concentration it is crucial to understand how the PS distributes, the dosage to administer to the 
patient, and how much time after administration is required before irradiation. The concentration 
will vary between tissues in the body, between individual patients, and over time will undergo 
metabolism and clearance emphasizing the potential theranostics provide to PDT.28  
Thus, optimal PSs should have a high Φ as well as a high e at long wavelengths (especially 
for interstitial applications). Beyond photophysical considerations, optimal PSs also distribute well 
in the desired tissue, have minimal phototoxicity (lingering light sensitivity after treatment), and 
are patentable. Interestingly, the first developed PS, Photofrin, does not follow the prescribed 
guidelines closely.  
 
1.3.1.2 FDA Approved Photosensitizers 
Photofrin is known as the first PS developed and approved in 1995 for the treatment of 
esophageal cancer, which has since expanded to include treatment of lung cancer and early-
stage cervical cancer. Due to its precedent in the PDT field as well as what are now considered 
sub-optimal properties, Photofrin is classified as a first-generation PS. Photofrin treatment occurs 
at 630 nm to achieve sufficient tissue penetration and efficacy in the clinic, even though its 
maximal absorbance peak occurs at 400 nm.33 Photofrin treatment requires intravenous injection 
followed by illumination 48 h later with a laser connected to optical fibers or endoscopes.12, 20 The 
Φ of Photofrin is a modest 0.25 while its e is a subpar 3,000 cm-1 M-1, which is within the range of 
hemoglobin’s e in the optical window of tissue. [14] Although, Photofrin was approved early on for 
the treatment of bladder cancer, over time adverse stenosis and other obstructive structures 





of Photofrin include its weak absorption of NIR light, up to 90 days of phototoxicity, and solubility 
issues due to its hydrophobicity. Thus, Photofrin is limited to externally accessible tissues.18  
Second generation PSs have been developed by discovering new photosensitizing 
macrocycles or modifying the core porphyrin structure to improve long wavelength sensitivity and 
Φs. In 1999, the PS 5-aminolevulinic acid (ALA) was approved for actinic keratoses and since 
has been also approved for acne, esophageal cancer, gastrointestinal cancer, and basal cell 
carcinoma, as well as imaging gliomas during brain surgery (Gleolan). Though not a macrocycle 
itself, ALA induces the cellular production of protoporphyrin IX, a derivative of porphyrin and highly 
photosensitive compound.18 Although, ALA does not have an excessively high e, its Φ is an 
efficient 0.54. ALA treatment requires topical or oral administration and laser or LED illumination 
for internal indications or skin cancers respectively. Derivatives of ALA have been developed and 
include methyl aminolevulinate (Metvixia) and hexyl 5-aminolevulinate (Cysview) which have 
been approved by the FDA for skin and bladder cancer respectively.20 Metvixia was a topical 
cream with improved water solubility and efficacy which was used in the treatment of skin cancers. 
Metvixia was withdrawn in 2015 for undisclosed reasons (though not for safety concerns).34  
Cysview and Gleolan are employed for PS fluorescence detection (PSFD) in bladder 
cancer and brain cancer respectively. PSFD improves established techniques to identify pre-
invasive and early stage cancer by autofluorescence in the lungs, bladder, ovaries, skin, brain, 
and gastrointestinal tract. PSs act in general by selective uptake and retention in abnormal tissue 
which allows for imaging or treatment of this tissue. Both Gleolan and Cysview are fluorescently 
excited at their higher absorbance peaks in the short, 375 to 440 nm, wavelength range with low 
power devices (such as LEDs). PS-based diagnostic systems are currently being further 
developed into theranostic applications that would allow detection of abnormal tissue by 





then exciting PSs by high intensity lasers in the NIR range to treat the identified tissue.35 Current 
applications of PSFD are limited to diagnosis and guided imaging for surgery.  
Benzoporphyrin derivative monoacid ring A (BPMDA, commonly known as Verteporfin) 
has been approved for AMD. BPDMA acts by accumulating in abnormal blood vessels and can 
successfully damage these vessels when illuminated with long wavelength light.12 BPDMA is 
administered intravenously followed by activation with an ophthalmoscope equipped with a 690 
nm diode.36 BPDMA has a very efficient Φ of 0.84 and an e of 13,500 cm-1 M-1. Further, Verteporfin 
induces minimal phototoxicity with complete systemic clearance of clinical doses after 2 days. 
Verteporfin PDT is now undergoing clinical investigation for cancer treatment after monoclonal 
antibody treatments surpassed BPMDA in the clinical treatment of AMD.19  
Ultraviolet (UV) based PSs have also been approved in ophthalmologic indications with 
the approval of Riboflavin in 2016 for the treatment of keratoconus and ectasia. Topical 
application of a riboflavin solution to the eye is followed by ultraviolet A illumination to induce 
corneal crosslinking. ROS improve the stiffness of the cornea by creating crosslinked covalent 
connections between collagen molecules of the eye. Although, riboflavin has high Φ and e, the 
need for UV illumination limits the treatment to superficial applications and low concentrations to 
avoid UV damage. Riboflavin itself is a natural vitamin and thus poses minimal toxicity and 
solubility concerns.37  
Second generation PSs still produce adverse side effects, including phototoxicity, due to 
systemic administration, which have led to more targeted third generation PSs with improved 
solubility and clearance. By conjugating PSs to carrier biomolecules or targeting agents the 
specificity of treatment, safety, and efficacy can be improved. Though none of these systems 
have yet to be approved, they are under investigation with targeting tags, polymeric nanoparticles 
(NPs), polymeric micelles, nanostructured lipids, liposomes, and metallic NP carriers as methods 





chlorins which are more responsive to long wavelength) and macrocycles (such as 
phthalocyanines) are being investigated for their use as PSs and have been approved by other 
regulatory administrations.  
 In general, further development of PSs faces many challenges that should be considered 
in the development of photoactivatable DDSs. The current FDA approved systems are limited to 
externally accessible regions of the body due to the minimal sensitivity of current PSs to long 
wavelength light. Second generation PSs that have high photosensitivity, such as Foscan (which 
has reached regulatory approval in Europe but was denied by the FDA), were discovered to be 
too potent and present high phototoxicity for multiple weeks. These more potent PSs also are 
commonly hydrophobic and face solubility issues.12 In general, PSs are cytotoxic therapeutics 
and thus are limited to destructive applications (cancer, dermatologic and ophthalmic abnormal 
tissue). However, the clinical approval of these more toxic therapeutic systems with a limited 
range of applications, when compared to the photoactivatable DDSs described herein, provides 
precedent and promise for the eventual approval of photoactivatable DDSs. 
 
1.3.2 Photosensitizer Light Sources 
Devices for PDT include noncoherent light sources (e.g., conventional arc lamps, LEDs, 
and sunlight) and coherent light sources limited to lasers most commonly connected to fiber optics 
or endoscopy tubes. PDT light sources are currently used for surface illumination during skin 
treatment, intra-operative illumination using operating microscopes and endoscopes adapted with 
a light emitting source, or optical fibers coupled to a laser used intra-operatively and interstitially. 
Optical fibers are classified as non-contact, contact, and interstitial and are made from glasses 
and plastics which act to guide light through the fiber. Microlenses and diffusing tips are often 
added to optical fibers to modify the geometry of illumination (Figure 1.4). Optical fibers have 





must be approved as medical devices with specifications for the light dose (J/cm2), wavelength of 
absorption (nm), and total time of exposure (min, s). FDA approved devices and doses are 














Treatment Site & 
Indication 











small cell lung 
cancer,& high-grade 
dysplasia in Barrett’s 
Esophagus 
DIOMED solid-state laser 
diode OR 
Argon-pumped 
Rhodamine B-dye laser 
(Laserscope series 600 
PDT dye molecule) OR 
Modulight ML7710  



















Microlens optical fiber 0.4 mm core for 
surface treatment  
 
Interstitial cylindrical Optiguide™ optical 
fiber diffuser (1 cm tip inserted 12-gauge 
angiocatch implantation)  
 
X-Cell Photodynamic Therapy Balloon with 
Fiber Optic Diffuser  
Verteporfin 
(Visudyne)39 




Non-thermal diode laser: 
Lumenis Coherent Opal 
Photoactivator  Zeiss 
Visulas 690s  
Biolitec Ceralas I   
Quantel Activis 
689 50 
(600 mW/ cm2) 
1 min 
23 s 
Fiber optic with a slit lamp and circular 
opening with ophthalmic magnification lens: 
Lumenis Coherent LaserLink adapter 
Zeiss Visulink PDT adapter 
Biolitec Ceralink Slit lamp adapter 
Quantel ZSL30 ACT, ZSL20 ACT, 
HSBMBQ ACT 
ALA (Ameluz)40 Topical gel Superficial (scalp, 
facial) FOR 
Actinic Keratoses 
BF-Rhodo LED lamp 635 37 10 min NA 
ALA (Levulan)41 Topical 
solution 
Superficial (scalp, 
facial) FOR Actinic 
Keratoses 
BLU-U fluorescent lamp 
 
LumaCare Lamp 
400-450 10 16 min 
40 s 
LumaCare Lamp has a variety of adjustable 
fiberoptic adapters 
ALA (Gleolan)42 Oral brain during surgery 
FOR imaging of 
grade III or IV glioma  
LEDs with fluorescence 
guided imaging devices 
375-440 40-80 mW/cm2 * NA Standard Surgical operating microscope 






(scalp, facial) FOR 
Actinic Keratoses 







Bladder installation  
FOR diagnosis of 
bladder cancer 
Karl Storz D-light C 
photodynamic diagnostic 
system using a Xenon 
lamp (Cermax Lamp) 









and corneal ectasia 
KXL system using a UVA 
laser 
365 3 mW/cm2 30 min KXL system with circular delivery pattern 
† measured per length of diffuser for the treatment of esophageal cancer 








Non-coherent light sources are preferred for PDT as they are safer, easier to use, and 
less expensive.36 Initially, filtered lamps were used, especially in applications requiring surface 
irradiation. Non-coherent lamp sources used for PDT include fluorescent, incandescent, metal 
halide, xenon arc, and sodium arc lamps. Excessive filtering is required to remove ultraviolet and 
infrared wavelengths which could cause thermal or genetic damage to the tissue.31 Currently 
approved lamps for PDT include the BLU-U light illuminator in combination with ALA PDT for 
actinic keratosis and the LumaCare lamp for acne vulgaris. The BLU-U lamp is a fluorescent lamp 
which requires a dosage of 10 J/cm2 (power output of 10 mW/cm2) in the 402 - 432 nm region.46, 
47 The LumaCare lamp is a quartz halogen mixed lamp with a wavelength range of 400 - 800 nm 
and output power of 20 mW/cm2 - 1000 mW/cm2. The LumaCare’s main strength is its adjustability 
in power and wavelength output which makes it amenable to a variety of PDT treatment 
protocols.36  
 LEDs have recently surpassed lamps due to their accessibility and compatibility with fiber 
optics, low cost, large application areas (treatments up to 150 mW/cm2 over a 20 cm2 area),  
arrangeable geometries, and variety of wavelengths (350 nm to 1100 nm).46 Superficial 
applications using LEDs are considered FDA approved cosmetic procedures and are used in low 
level laser therapy.9 Due to the generic clearance of LED light application, a multitude of light 
applicators exist and some have been approved in combination with ALA and methyl-ALA for 
actinic keratoses.48, 49 Diagnostic systems such as Gleolan and Cysview also take advantage of 
cheap incoherent light sources, such as LEDs and lamps, as fluorescent excitation of PSs 
requires low power treatments.  
Daylight is also gaining prominence as a cheaper light source for superficial PDT due to 
its high area of application, ability to achieve therapeutic activation, and decrease patient pain 
during treatment. With an approximate power of 2.5 mW/cm2 in the 620 - 640 nm range, the sun 





exposure to UV-radiation.30 Daylight PDT is being investigated with ALA and Metvixia in Europe. 
One very desirable aspect of the sun as a light source is that this “device” requires no FDA 
regulation.50  
However, lasers (monochromatic, coherent light sources) are still the preferred light 
source for PDT due to their compatibility with optical fibers and production of high-power 
monochromatic light at the required wavelength. There are multiple kinds of lasers including dye 
lasers, diode lasers, and optical parametric oscillator lasers. Initially, the Laserscope PDT Dye 
Module, a potassium-titanyl-phosphate dye laser, was the most widely used laser for PDT 
treatment. It was then surpassed by the Diomed 630 PDT diode laser which was more portable, 
light weight, easier to use, and less expensive.36 Since then the Modulight ML7710, a diode laser, 
has also been developed as a multichannel laser with laser outputs of 405 - 1064 nm and power 
output from 4.5 W to 70 W depending on the wavelength. Multiple diode lasers have been 
approved in combination with Verteporfin for retinal treatment of AMD. It is important to note that 
other lasers not specifically indicated for PDT are medically approved including excimer-based 
lasers for LASIK, home device lasers, the ND:YAG laser used for non-ablative dermatological 
purposes, and the Erbium-YAG lasers used for ablative dermatological purposes.8, 51, 52  
 
1.4 Long-wavelength Photoactivated DDSs Under Development 
To establish the current photoresponsive moieties for photoactivatable DDSs, the 
following section reviews photoremovable protecting groups (PPGs), photoswitches, and 
photogates (Figure 1.5). NIR photoresponsive moieties are crucial for any medical applications 
beyond dermatological indications as demonstrated by clinical PSs. Thus, the following review 
focuses on systems that are responsive to NIR wavelengths.  
The first subsection describes PPGs, also known as photolabile, photoprotecting, 





are photoresponsive moieties (or scaffolds) that protect the therapeutic deliverable by inactivating 
it. Inactivation is commonly achieved by binding the therapeutic to a scaffold which cannot 
permeate into cells or by synthetically blocking a portion of the therapeutic that is crucial to its 
pharmacology. Upon irradiation by light the PPG irreversibly releases the therapeutic, most 
commonly by cleavage of the bond that binds the therapeutic to the PPG. The released 
therapeutic can then distribute into and effect the local tissue at the site of illumination.53-55  
The second subsection describes NIR photoswitches under development that activate the 
therapeutic by undergoing reversable isomerization upon illumination. This photoisomerization 
includes double bond rotation, photo-oxidation, electrocyclization, and photo-crosslinking that can 
change conformation to improve therapeutic activity or induce drug release by hydrophilic/ 
hydrophobic transitions of nanocarriers. Photoswitches are being developed as molecular 
scaffolds as well as, more successfully, being integrated in liposome membranes, NPs, and other 
nanocarriers.53, 56-59 Nanocarriers that employ photoswitches or PPGs as a photoresponsive gate 








































Both sections describe systems that are responsive to long wavelengths of light within the 
optical window of tissue (600 - 950 nm). Similar to ideal PSs, photoactivable DDSs require a high 
Φ of therapeutic release, which is achieved by removal of the scaffold for PPGs or isomerization 
of the photoswitch. Ideal photoactivatable therapeutics also require high e at NIR wavelengths as 
these systems need to respond efficiently to minimal light penetration.60 Prominent PPGs include 
boron-dipyrromethene (BODIPY), cyanine, cobalamin (Cbl), phthalocyanine (Pc), ruthenium (Ru), 
and amino-1,4-benzoquinones (AQ) while prominent photoisomerizers are azobenzenes (azo) 
and donor acceptor Stenhouse adducts (DASAs). Photogated nanomaterials under development 
with both systems include mesoporous nanoparticles (MSNs), micelles, hydrogels, red blood cells 
(RBCs), and other NPs. Table 1-4 describes these prominent examples under pre-clinical 
development from both sections as well as the associated Φs and es. Note, the Φ for PPGs is 
measured by calculating the released therapeutic per photons absorbed, while the Φ for 
photoswitches is calculated based on the desired isomerization product per photons absorbed.  
In vivo studies include only animal studies while in vitro studies comprise benchtop studies outside 












Table 1-4 The photophysical properties, stage of development, and potential indications 






lmax (nm) εmax  
(M-1 cm-1) 
Φa,b,c,d,e Stage Potential Indications 
BODIPY Dopamine61 643 63,000 0.0001f In Vitro Cardiac function, neuronal 
signaling 
BODIPY NO62 677 >40,000f NR In Vivo Cardiovascular, neuronal 
signaling, inflammatory 
conditions, cancer 
BODIPY H2S63 688 55,400 0.00036
a,g
 






In Vivo Cardiovascular;  
anti-inflammatory;  
anti-microbial; antineoplastic 
Cyanine NA, ICG65, 66 800-850 121,000 0.03-0.12b,h FDA 
approved 
Imaging of cardiac output, 
hepatic function, blood flow 
before during and after surgery; 
imaging lymph nodes in cervical 
and uterine tumors; ophthalmic 
angiography, 
Cyanine CO67 793 251,000 0.0003a In Vivo Cardiovascular;  
anti-inflammatory;  
anti-microbial; antineoplastic  
Cyanine Camptothecin68 720 N.R. NR In Vivo Cancer 
Cyanine Duomarcyin69 750 70,000 NR In Vivo Cancer 
Cyanine Cisplatin70 790 45,000 NR In Vitro Cancer 
Cbl Colchicine71 780 NR NR In Vitro Cancer 
Cbl Docetaxel72 645 250,000 NR In Vivo Cancer 








SiPc Combretastatin75 693 99,700 0.1b,i  In Vitro Cancer 
Ru (II) Abiraterone76  535 9,850c 0.018b In Vitro Prostate Cancer 
Ru (II) NAMPT inhibitor77 535 609j 0.013j In Vitro Cancer 
Ru (II) Rigidin77 530 1,510 0.0038e In Vivo Cancer 
1.4.2 Photoswitches and Photogates 
Azo DENAQ78 
~480 26,772f 
NR In Vivo Age-Related Macular 
Degeneration;  
Retinitis Pigmentosa 
trans-Azo Trimethoprim79 365 18,111 0.18
a, g, k
 
In Vitro Anti-bacterial 
Cis-Azo Trimethoprim79 NR 1,282 0.02
a, g, k
 
In Vitro Anti-bacterial 
Azo MSN Doxorubicin80 ~480 low NR In Vitro Cancer 
DASA 
micelle 




lactamase83 450 6,400 0.63 




660 127,500 0.074 
In Vitro Wound healing, Bone Defects, 
Protein Delivery 




749 83,000f NR 
In Vivo Theranostics for Cancer 
NA not applicable; NR not reported; Φ were acquired in MeOHa, aqueous mediab, DMSOc, 
CH2Cl2d, ACNe; fbased on structurally related derivatives; gIrradiation was performed at 365 nm;  







1.4.1 Long-wavelength Photolabile Protecting Groups (PPGs) 
The first PPGs served to protect functional groups during synthesis in the 1960’s.87-89 The 
first biological applications of PPGs were in vitro tests releasing adenosine triphosphate and cyclic 
adenosine monophosphate.90, 91 However, these groups were limited to in vitro applications due 
to their responsivity to only UV-light. Since then, many scaffolds have been structurally modified 
or discovered to respond to long wavelength light. 
 
Boron-dipyrromethene (BODIPY) Scaffolds 
BODIPY scaffolds are UV-responsive fluorescent dyes with high e discovered in 1968. 
With pronounced stability in physiological conditions, inherent hydrophobicity, and subsequent 
cell permeability, these dyes originally gained biological prominence in uses for labelling proteins 
and DNA in cellular investigations.92 Since their original discovery, modified meso-methyl 
BODIPYs have been developed with improved water solubility and photoresponsiveness to longer 
wavelengths of light (600 - 800 nm) by extending the p system and addition of polyethylene glycol 
(PEG) chains.93  
Long wavelength BODIPY scaffolds have been developed for the delivery of dopamine61, 
nitric oxide (NO),62 carbon monoxide (CO),64 and hydrogen sulfide (H2S).63 Many of these systems 
have been tested in cell lines, but only NO62 and CO DDSs64 have begun in vivo testing. In vivo 
results have demonstrated the safety of NO and CO systems and assessed the extent of 
therapeutic inactivation by BODIPY PPGs. BODIPY-NO have also been successfully developed 
for photoacoustic theranostic applications with detectable changes in their signal upon therapeutic 
release. Studies have successfully demonstrated localized treatment of xenografted mouse 
breast cancer by dual implantation of cancer into both mouse flanks and subsequent illumination 
of only 1 flank with the other flank acting as the “dark control”. Applications of these BODIPY 





(dopamine, NO), inflammatory conditions (NO, CO, H2S), diabetes (H2S), and cancer (NO, CO).62, 
94 Specifically, the gaseous molecules under investigation are established endogenous signaling 
molecules and thus have far reaching effects.95 BODIPY scaffolds are also being modified for 
PDT.19, 59  
Challenges facing BODIPY scaffolds include their low Φ, inherent hydrophobicity, and 
short wavelength responsivity of the core scaffold. Many synthetic modifications may be required 
to improve the Φ, potentially limiting structural flexibility to optimize multiple properties.96, 97 
Combinations with nanomaterials may improve the challenges associated with BODIPY’s 
inherent cell permeability. However, the scaffold’s low toxicity and strong fluorescence (with noted 
change in photoacoustic signal upon release of therapeutic) makes this a promising scaffold with 
theranostic potential.58 Further, preliminary in vivo results demonstrate localized efficacy and 
minimal toxicity. Scientists moving forward with BODIPY photoactivatable DDSs should carefully 
consider the design to optimize the many strengths of BODIPY.  
 
Cyanine Scaffolds 
Like BODIPY dyes, cyanine scaffolds were first made in 1856 and have since become 
crucial fluorophores in chemistry and biology. Specifically, the heptamethine cyanine dyes have 
demonstrated long wavelength responsivity and minimal toxicity in the clinic. Indocyanine green 
(ICG) has been FDA-approved since 1959 for medical fluorescence imaging of ophthalmic 
angiography, cardiac output, hepatic function, liver blood flow, blood flow before, during, and after 
surgery, and imaging lymph nodes in cervical and uterine tumors.98-100 Inherently, the cyanine 
scaffold is able to produce singlet oxygen in response to light which leads to the eventual 
photooxidative cleavage reaction and therapeutic release.101 This multi-step reaction is a limiting 
factor for cyanine as the half-life of therapeutic release can take up to 20 - 30 min after illumination 





Cyanine scaffolds have been developed as a source of ROS for PDT, and as a PPG for 
the therapeutic release of CO,67 duocarmycin with the ADC panitumumab targeting agent,69 
cisplatin,70 and camptothecin with a biotin targeting agent.68 For PDT applications, cyanine PPGs 
had to be modified with a 2,2,6,6-tetramethylpiperidinyloxy ring to improve the singlet oxygen Φ 
from a sub-optimal 0.006 to a modest 0.20.103 Again, in vitro and cellular testing have been 
mainstay testing methods of all these applications with CO, cyanine-camptothecin-biotin, and 
ADC-cyanine-duocarmycin systems additionally tested in vivo. Animal studies have demonstrated 
biocompatibility of the PPG therapeutics and successful enhanced targeting of systems with 
multiple layers of targeting. ADC-cyanine-duocarmycin and cyanine-camptothecin-biotin target 
cancer tumors externally by illumination and internally by a covalently bound targeting agent (in 
effect multiple layers of targeting, “multi-layered targeting”) as demonstrated in metastatic breast 
cancer xenografted mice and in HeLa xenografted mice respectively.67-69 Disease applications of 
the developed systems include the previously discussed applications of CO, as well as 
applications in cancer due to the highly cytotoxic nature of duocarmycin, camptothecin, and 
cisplatin. Duocarmycin is so cytotoxic that an additional targeting method with an ADC must be 
employed.69 
For both multi-layered targeted systems, researchers imaged the time to achieve ideal 
biodistribution in vivo. Cyanine-camptothecin-biotin further displayed the biodistribution of 
inactivated and activated photoactivatable therapeutic due to its theranostic capabilities. By 
fluorescent imaging at 535 nm, which is only observed after therapeutic release, the cyanine PPG 
was observed to be activated in the liver and tumor even though only the tumor was exposed to 
200 mW/cm2 680 nm illumination. Further, control cyanine-camptothecin-alkyne was more 
extensively distributed throughout tissue for longer periods of time.68 For treatment purposes, the 





Efficacy of duocarmycin was assessed by both tumor size and survival rate from localized 
illumination for 2 min from an 800 mW/cm2 laser.69  
Multi-layered targeting of cyanines has extended beyond ADCs and biotin with the in vitro 
and in vivo development of the next-generation carrier-based theranostic cyanine-camptothecin. 
Cyanine-camptothecin was modified to create a self-assembling micelle that undergoes photolytic 
cleavage and therapeutic release only in hypoxic conditions. Excitingly, this micelle is responsive 
to both photoacoustic imaging and fluorescent imaging further enhancing the potential for 
theranostic applications. The micelle was also rendered pH-sensitive to improve therapeutic 
concentration in the acidic tumor environment (Figure 1.6). In vivo studies were completed by 
first imaging the biodistribution using photoacoustic imaging, and then releasing camptothecin 
from the cyanine micelles by NIR irradiation while monitoring the fluorescence shift of the system. 
Results validated the theranostic potential as well as the persistent localization of the cyanine 
therapeutic after 24 h.86 
Although the ROS generated by cyanine PPGs are much more limited than Photofrin and 
other porphyrin-based PSs (due to the resulting cleavage and destruction of the cyanine after 
ROS release), it is important for PPG investigations with cyanine to differentiate between the 
clinical impact of ROS and the impact of the released therapeutic. Furthermore, like BODIPY 
scaffolds, cyanines are ideal fluorophores (as exemplified clinically by ICG) and thus face 
synthetic challenges to modify them into high Φ PPGs. These synthetic challenges have been 
addressed with more promising results as compared to BODIPY scaffolds due to the synthetic 
malleability of cyanine with multiple modification points, as demonstrated by the cisplatin scaffold 
and its 0.32 Φ. However, the success of the cisplatin scaffold’s Φ may be potentially outweighed 
by the 5-fold decrease in e. As previously discussed in section 1.3.1.1, therapeutic release 
depends heavily on the number of photons absorbed (which is significantly influenced by e). 





optimally absorbed and that the absorbed photons are successfully translated to therapeutic 
release is crucial. 
Cyanine is a promising PPG as the scaffold has high inherent es and there is extensive 
literary precedent beginning to overcome the previously discussed synthetic challenges.69, 98 The 
major limitation of cyanine is its extremely low half-time of release (as previously noted 20 - 30 
min in vitro with a dose of 30 J/cm2), given the multi-step mechanism for therapeutic release.102 
In vivo testing may also require further analysis of the generated ROS species as well as 
distribution and clearance studies given the temporal sensitivity challenges facing therapeutic 
release. However, cyanine scaffolds may have minimal safety risks given the historical data of 
ICG. The novel pH sensitive self-assembling micelle seems to solve some of the previously 
presented issues of cyanine-based PPGs. This system provides multiple layers of targeting and 
a transition in structure and clearance properties upon encountering tumor tissue.86 Although, this 
system provides potentially exciting applications for NIR theranostic PPG nanomaterials in the 
treatment of cancer, release rates and Φ still need to be improved to achieve high levels of 












Figure 1.6 Self-assembling cyanine theranostic micelles can be imaged by photoacoustic 
imaging in the micellar form or by fluorescence-based imaging after pH driven reversible 





















Cobalamin (Cbl) Scaffolds 
Cbl, more commonly known as vitamin B12, is an essential vitamin. The photoresponsivity 
of Cbl was initially discovered in the 1950’s by observing cyanocobalamin degrade into 
hydroxocobalamin after being exposed to light during storage.104 The axial bond appended to the 
cobalt core photocleaves after exposure to short wavelengths of light outside the optimal window 
of tissue (330 - 580 nm). However, by synthetically appending a fluorophore antenna to the ribose 
hydroxyl end of Cbl, the photoresponsive properties are extended to the wavelength of the 
antenna (645 nm in the case of cyanine5, Cy5).105 This antenna also attributes potential 
theranostic applications to Cbl by allowing for fluorescent imaging of its biodistribution.106  
Cbl scaffolds have been developed to deliver multiple cancer therapeutics, including 
colchicine,71, 107 paclitaxel,71 methotrexate,71, 107 dexamethasone,71, 107 and docetaxel.72 
Dexamethasone is also a treatment in inflammatory conditions, such as rheumatoid arthritis. Cbl 
scaffolds that take advantage of the endogenous uptake of Cbl and the overexpression of 
transcobalamin receptors on a variety of cancer types are under development. Researchers have 
employed a Cbl-antenna species to image distribution. Although an enhanced degree of uptake 
in tumor tissue was observed, the Cbl species was distributed throughout all tissue, including the 
brain. No therapeutic release was tested in these studies.106 
Due to the low levels of uptake of orally ingested vitamin B12 and previously demonstrated 
systematic recognition of Cbl PPGs, novel methods of sheltering the Cbl scaffold have been 
developed to minimize dark activity.106, 108 Colchicine, paclitaxel, methotrexate, docetaxel, and 
dexamethasone (Dex) have all been successfully loaded into and released from RBCs. Cbl and 
the covalently appended therapeutic are successfully retained within RBCs until illumination due 
to Cbl’s membrane impermeable nature. Upon irradiation, the hydrophobic therapeutic can 
permeate through the cell membrane and affect the surrounding tissue (Figure 1.7a).71-73 Another 





fluorophore antenna onto the surface of RBCs by synthetic lipid modifications (Figure 1.7b).107 
Although promising cellular data was observed in the externally loaded system, only the internally 
loaded docetaxel and Dex RBC systems have been tested to date in mice.72, 73 In vivo studies 
have successfully validated localized release as intravenously administered internally loaded 
Cy5-Cbl-docetexal RBCs cause endothelial damage only to the irradiated mouse ear and no 
damage to the mouse’s other non-irradiated ear.72 Further, comparable therapeutic efficacy of 
Cy5-Cbl-Dex RBCs to standard of care Dex treatment has been observed in treatments of a 
collagen antibody induced arthritis mouse model.73 Both in vivo findings demonstrate the potential 
of Cbl loaded RBCs to provide spatiotemporally controlled release.  
The Cbl scaffold retains its natural vitamin structure and thus should be minimally toxic, is 
not cell permeable, and can retain the high e of appended fluorophore antennas.109 Furthermore, 
studies of photocleavage of biological Cbls have found that Co-C breaks with near unity Φ in 100 
ps, however only about 25% of cargo does not recombine with the Cbl scaffold.104 Challenges of 
this PPG arise due to inherent qualities of vitamin B12 persisting. The modified Cbl scaffold is still 
recognizable by transcobalamin II in the blood and the transcobalamin II-receptor on cell 
membranes leading to non-specific cell uptake. Recent biodistribution studies have demonstrated 
Cbl disseminates into sensitive tissues such as the brain, heart, and lungs which will need to be 
thoroughly studied to address potential toxicity concerns.72, 106 Though synthetic modifications to 
block interaction with natural transport proteins of Cbl are available, the exposure of the weaker 
axial bond may lead to metabolic therapeutic release.108 Thus, more complex delivery systems 
have been considered as intravenous and oral delivery methods pose challenges in the ability of 
the PPG to inactivate the therapeutic until illumination. Only 2.5 mg of vitamin B12 can be 
absorbed by the adult body per day, further limiting oral administration methods. These carriers, 
such as RBCs, can introduce another level of complexity in design and will require addressing 





the patentability of vitamin B12 as complex nuances surround patenting natural products. Still, 
patents can be attained for unique use, new materials produced from a natural product, or for the 
synthetic methods of producing the natural product.110 Since, as previously described, the Cbl 
scaffold needs to be modified to achieve NIR photoresponsivity, these modified structures and 
their synthesis can potentially be easily patented. However, care should be taken when publishing 



















Figure 1.7 Schematics of Cbl RBC therapeutic DDSs. a) Cyanine-Cbl therapeutics sheltered 
within RBCs. b) Cbl therapeutics and long-wavelength antennas externally loaded on RBCs. 























Phthalocyanine (Pc) Scaffolds 
Pcs have been under development as PSs for PDT since the 1980s. With NIR wavelength 
responsiveness and a variety of core metals, these synthetic dyes demonstrate high Φs of ~0.4. 
Photosens, a complex mixture of aluminum Pc derivatives, has been approved in Russia for the 
treatment of skin, breast, gastrointestinal, and lung cancer demonstrating a high e, high tumor 
accumulation, and fast clearance.74, 75, 112, 113 Under hypoxic conditions, silicon Pcs (SiPcs) have 
been discovered to convert photon energy into the release of small molecules, as the Φ for singlet 
oxygen production decreases dramatically with limited O2 in the environment. Applications for 
PPG SiPcs include cancer, myocardial ischemia, metabolic diseases, chronic heart and kidney 
diseases, and reproductive diseases in which hypoxia plays critical roles.114 SiPcs have only been 
tested in vitro for small molecule release. However, as previously referenced, Pcs in general have 
been clinically tested and even approved in some regions. SiPcs, specifically, have been tested 
in vitro, in vivo, and through Phase I clinical trials as PDT PSs, with Pc 4 as a current prominent 
SiPc that has exhibited potential in breast, colon, and ovarian cancers.113 
Modification of Pcs as PPGs shows promise due to the established clinical safety of Pcs, 
long wavelength responsivity, and potential for dual PDT/ small molecule cancer therapy. 
However, small molecules appended to the axial bond of Si were observed to decrease the Φ of 
singlet oxygen to an unsatisfactory 0.1 depending on the appended therapy’s structure. This 
sensitivity limits the dual application to certain therapeutics and requires further synthetic 
investigation to optimize Φs of both therapeutic release and singlet oxygen production. It is 
important to note an electron donor (such as glutathione) is also required for the therapeutic 
release which may limit in vivo efficacy further depending on the hypoxic environment. Many Pc 
dyes originally demonstrated low water solubility but their biomedical development over the last 





The dual-modality PS/ PPG of SiPcs provides a novel way of introducing PPGs to the 
clinic as PSs have minimal therapeutic effect when not illuminated and the Pc may also act to 
shelter the cytotoxic small molecule therapeutic from systematic cellular uptake. This ability was 
validated during in vitro therapeutic release and cytotoxicity tests on HeLa cells with minimal dark 
activity and toxicity observed.75 NP-appended Pcs have already been explored to improve the 
photodegradation of Pcs, which could also be applied to dual PDT/ photoactivatable DDSs to 
further enhance sheltering of small molecules.113  Further in vitro and in vivo testing is required to 
fully establish SiPcs for dual photoresponsive therapies. 
 
Ruthenium (II) Scaffolds 
Similar to Pcs, Ruthenium (Ru) scaffolds have been investigated for applications in PDT 
as well as PPGs for therapeutic release.112 These compounds have been tested alone as 
cytotoxic therapeutics similar to cisplatin. Interestingly, NAMI-A and KP1019 (the Ru 
investigational products tested up through Phase II clinical trials) display a low degree of systemic 
toxicity with KP1019 producing a cytotoxic effect and NAMI-A producing anti-metastatic effects.115 
With very different mechanisms of action, the complexes demonstrate the variety of geometries, 
oxidation states, and consequently applications of Ru scaffolds. Octahedral Ru(II) complexes 
specifically have been found to undergo ligand dissociation in response to illumination by long 
wavelength light, although these complexes do require insertion of a cyclo-metalating ligand to 
shift photoresponsiveness toward the optimal window of tissue.116 These complexes have been 
tested in vitro for the delivery of abiraterone, a P450  inhibitor used in metastatic prostate cancer, 
a nicotinamide phosphoribosyl transferase (NAMPT) inhibitor, and the cytotoxic natural product 
rigidin. In vivo studies of rigidin were conducted in xenografted human lung cancer tumors 
implanted on both flanks of nude mice. Illumination exhibited a localized effect on tumor growth 





however intravenous therapeutic doses of 2 mg/kg presented severe adverse effects including 
mouse death.117   
Ru(II) scaffolds are promising PPGs as they are clinically established, have the potential 
to deliver up to 2 ligands per PPG, and have extensive synthetic malleability providing a variety 
of properties for optimal PPG production. Limitations arise from the required synthetic optimization 
per therapeutic cargo, as the cargo attached can significantly affect the rate of release due to 
changes in the Ru-Ligand bond strength and tuning of the metal to ligand charge transfer band.  
Thus, optimization of the remaining ligands is required to improve physiochemical states and Φs: 
for example, addition of a triphenylphosphine ligand improved Φ of a g-aminobutyric acid therapy 
by seven-fold to 0.21.118 These modifications are crucial as the inherent responsivity of the metal 
to ligand charge transfer band of octahedral Ru(II) lies between 400 - 500 nm. Ru complexes 
attached to rhodamine B antennas, similar to the previously discussed Cbl scaffolds, as well as 
terpyridine ligands, have achieved long wavelength light responsivity.118-120  Further, the dual 
nature of Ru structures to act as potential PSs and PPGs with nearly equivalent Φ values (0.036 
and 0.013 respectively) may be both beneficial and add further complexity to pharmacological 
testing.77 Though Ru complexes have a precedent of low toxicity and clinical investigation as well 
as promising initial in vivo results, further synthetic exploration and optimization is required to 
produce a photoactivatable DDS with a sufficiently high Φ, NIR responsivity, and low toxicity.121  
 
1.4.2 Long-wavelength Photoswitches and Photogates 
Photoswitches are classically considered small molecules that undergo a reversible 
isomerization in response to light and have been predominantly developed in the field of 
optogenetics and photopharmacology to target enzymes, G-protein coupled receptors, the 
cytoskeleton, and ion channels, transports, and pumps with a variety of light dependent and 





integrated with the structure of a targeting ligand for a specific biologic. The photoswitch then 
provides a light-dependent modification of the affinity of the ligand: i.e., by “flicking the switch” the 
drug can become therapeutically active. The majority of photoswitch development is still focusing 
on in vitro discovery and optimization and still relies on responsivity to short wavelengths (300 - 
500 nm).122 One of the most developed therapeutic photoswitches is the azobenzene DENAQ 
(responsive to 450 - 550 nm) that has demonstrated in vivo promise for treatment of AMD and 
retinitis pigmentosa.78, 123 Therapeutic photoswitches that are responsive to red-shifted 
wavelengths will be focused on below. 
A variety of photoswitches, PPGs, and photopolymerizable phospholipids have been 
developed to act as photoresponsive “gates” (photogates) for nanocarriers that release drugs 
from within the carrier upon irradiation. Photoswitches, as previously described, undergo an 
isomeric change that often shifts their conformation or polarity. By integrating photoswitches with 
carriers, the light triggered change can cause the release of therapeutic by shifts in polarity or 
removal of physical capping agents (Figure 1.5). Photochemically activated systems, such as 
PPG based nanomaterials and photopolymerizable phospholipids, often undergo crosslinking 
changes to induce nanocarrier breakdown. Carriers and their considerations as photoactivatable 
DDSs will be further discussed in section 1.5.5.  
 
1.4.2.1 Photoswitches that Reversibly Isomerize 
Azobenzenes (azo) 
Since their discovery in 1937, azobenzenes are the most developed photoswitch as both 
a molecular and gated photoactivatable DDS.124. Azobenzenes have prevailed outside of 
photoresponsive investigations as artificial food dyes and the anti-bacterial Protonsil. 
Azobenzenes undergo trans to cis isomerization upon illumination and NIR responsive 





benzene rings.125 Photoresponsive therapies include light activated anti-bacterial photoswitches 
(modified antibiotic trimethoprim) and nanomaterials (MSNs releasing doxorubicin and hydrogels 
releasing protein upon isomerized release of a capping agent, as well as hydrogels that undergo 
gelation in response to red light for biomedical applications) (Figure 1.8). All systems have been 
tested only in vitro thus far.79, 80, 126, 127 
Although azobenzene scaffolds have been extensively researched, multiple challenges 
face these long wavelength photoswitches. The initial investigations with Protonsil, led to the 
discovery that azo dyes can be reduced in the human gut. Glutathione’s high cellular 
concentrations can also lead to a similar reduction of the critical azo structure for therapeutic 
photoswitches. Thus, rigorous investigation of stability is required as it varies significantly with 
structure. Azo food dyes also demonstrate potential for clinical safety, however long-term 
exposure to azo food dye methyl yellow was found to induce cancer in rats and thus safety may 
be derivative specific and also require thorough investigation.128 When considering photoswitches 
in general, and azobenzenes specifically, it is important to ensure that the “on” state of the 
photoswitch is sufficiently long lived to produce the desired effect (nanomaterial breakdown, cargo 
diffusion, or therapeutic activation). This is a challenge as the “off” state of the photoswitch should 
be more thermodynamically stable to ensure that the photoswitch remains inactive without light. 
Further, the low es and Φs of azobenzenes in the long wavelength range requires extensive 
modification to produce optimal NIR responsive systems. These modifications have led to large 
molecules and highly polarized structures with photophysical properties that vary significantly with 
solvent. Although further investigations are underway, the current leading NIR materials are 
azonium salts which have extremely pH-dependent properties.129 Nanomaterial applications may 
be modified to maintain the desired azobenzene properties, however therapeutic applications that 








Figure 1.8 Azobenzene Photoswitch based photogated carriers. a) Azobenzene gated 
MSNs which release the b-CD nanocapping agent upon isomerization. b) Azobenzene gated 
hydrogels which breakdown upon release the b-CD nanocapping agent releasing protein 
















Donor-Acceptor Stenhouse Adducts 
Donor-acceptor Stenhouse adducts (DASAs) undergo a cyclization and dramatic shift in 
polarity in response to light. These photoswitches are responsive up to 750 nm of light by 
appending cyclic substituents and aliphatic amines.82, 132 DASAs have been developed as 
photogates for nanocarriers of paclitaxel,81 as well as incorporated in photoresponsive 
nanoreactor systems.133 These photogated carriers have only been tested in vitro (Figure 1.9).  
DASAs are small molecules with minimal synthetic modifications that can dramatically shift 
photophysical properties. The range of photoresponsive wavelengths have been successfully 
modulated such that specific derivatives respond in a narrow wavelength range allowing for 
development of orthogonal DASA photogates. For example, orthogonal nanoreactors have been 
developed which permeabilize green-responsive DASA nanoreactors upon irradiation with green 
light and red-responsive DASA nanoreactors upon irradiation with red light, allowing for 
sequenced nanoreactor systems.133 It was also noted that DASA micelles demonstrated minimal 
sensitivity to ambient light thus requiring few precautions for storage and administration.81 
However, sensitivity to polar solvents and spontaneous cyclization in the dark has been observed 
for certain derivatives. The extreme shift in physical properties of DASA upon isomerization make 
these photoswitches ideal photoresponsive gates for nanomaterials.57 Further in vivo 
development will truly establish DASA photoswitches and photogated nanocarriers as prime 







   
Figure 1.9 DASA Photoswitch based photogated carriers. a) Photoresponsive micelle that 
breaks down upon photoisomerization of DASA into its hydrophilic form b) Photoresponsive 
DASA polymersome which increases permeability to small molecules upon isomerization and 


















Synthetic Development of Prominent Reversible Photoswitches  
Similar to azobenzenes, many other photoswitches have undergone lengthy synthetic 
development but still continue to face challenges of stability and achieving NIR responsiveness. 
Long wavelength response requires significant synthetic modification that may limit applications 
of therapeutic photoswitches due to large size and unfavorable properties for circulation and cell 
permeation. Further, NIR therapeutic photoswitches and gated nanomaterials have yet to be 
developed for the photoswitches discussed below. These structures may still be under early 
synthetic development and have many more challenges to overcome before translational 
applications.  
Red-shifted spiropyran (up to a lmax of 560 nm) photoswitches that form or cleave rings 
within their structure in response to light have been developed by introducing sulfo groups and 
extending the number of appended rings.134, 135 Spiropyrans do not undergo significant 
conformational change in response to light, making nanomaterial applications more challenging. 
However, applications in UV responsive MSNs and self-assembled nanocarriers are under 
development, though face challenges based on spiropyran’s environmental sensitivity.54, 57 
Diarylethenes are another cyclizing photoswitch. NIR responsivity of the closed ring has 
been developed to 635 nm by extending the conjugation and triplet sensitization of the core 
structure.136, 137 Diarylethenes are plagued by low water solubility, though the ring structure is 
thermally resistant responding solely to long wavelength light. Similar to spiropyrans, a minimal 
conformational change occurs requiring nanomaterial applications to take advantage of stacking 
properties. Though development of such nanomaterials is underway they have not yet 
successfully demonstrated cargo delivery.54, 57  
Hemithioindigos (HTI) have also been under development for the last 100 years. Based 
on a photoswitchable E/Z transition, HTI have extended responsivity up to 545 nm while requiring 





developed yet, HTI’s show promise with the varied photophysical properties achievable by 
minimal modification. No applications in nanomaterials have yet been fully developed though 
lipidated HTI’s have been synthesized.57, 139 
Though under development for only half as long as many of the established photoswitches 
discussed above, hexaarylbiimidazoles (HABI) have shown promise with long wavelength 
responsivity to white light during which they undergo a homolytic cleavage.140 However, due to 
their limited development, multiple challenges still face HABI photoswitches. HABI structures are 
quite large and composed of multiple rings making them very sterically constrained. Since the 
photolytic mechanism produces radicals, these radicals can in turn produce ROS. Conversely, 
certain derivatives have been discovered to be sensitive to oxygen which can oxidize 
photoresponsive C-N bonds easily. Long wavelength photoresponsive derivatives have also been 
found to be thermally sensitive.57 HABI photoswitches have not yet been employed as DDSs but 
may be able to be sufficiently protected by nanomaterials while preserving and taking advantage 
of their photoresponsive properties. 
 
1.4.2.2 PPG Photogates 
Ruthenium (Ru) 
Beyond photoswitch applications, MSNs have been used in coordination with Ru PPGs to 
entrap cargo. These 1.5 nm Ru moieties act as obstacles to therapeutic release. Upon irradiation 
(455 nm), the Ru scaffold no longer caps the MSN although it does remain conjugated to it.141  Ru 
moieties have also been developed as photodegradable crosslinkers in hydrogels (Figure 1.10a). 
These hydrogel systems degrade extremely quickly in response to 520 nm irradiation (lmax= 450 
nm). Sample proteins have been successfully released from Ru crosslinked hydrogels which 





Having only been tested in vitro, further development is required to ensure release of 
therapeutic cargo from Ru photogated carriers. Although these systems are not currently 
responsive to light within the optimal window of tissue, the previous discussion on the synthetic 
opportunities for Ru PPGs can be applied to these already established nanomaterials. 
 
Cobalamin (Cbl) 
Cbl PPGs have recently been developed as gates for the destructive release of protein 
therapeutics from RBCs (Figure 1.10b). The natural RBC hemolytic peptide melittin (derived from 
bee venom) and a natural blocking segment that inhibits melittin activity attached to 
photoresponsive Cbl were associated to the surface of RBCs by lipidation to create a gate that 
inhibits hemolysis in the dark. In the light, the blocking segment is photocleaved and released 
allowing melittin hemolytic activity to resume. Long wavelength responsivity was re-introduced to 
the Cbl PPG via a cyanine antenna attached to the blocking segment and appended to Cbl by 
means of the photoresponsive bond (Cbl-Cy5-Blocking Segment).142 In vivo studies successfully 
demonstrated the localized release of thrombin upon 561 nm irradiation of mouse ears. Due to its 
potency, only topical applications of thrombin for surgical purposes have been approved.143  
Cbl based hydrogels have also been developed to improve hydrogel solidification under 
physiological conditions by introducing photoresponsivity to hydrogel gelation at NIR 
wavelengths. Ethyl Cbl scaffolds with a Cy5 antenna were found to produce alkyl radicals that 
could cross-link polymers with radical sensitive acrylates. Although the Φ of radical production 
was a sub-optimal 7%, the Cbl radical photoinitiators were able to polymerize up to 80% of certain 
polymers. Studies were limited to in vitro assays and thus require further in vivo assessment. 
Hydrogel solidification has applications in bone defects, wound healing, and protein delivery.84 
Cbl gated RBCs and hydrogels have the potential to deliver biomacromolecule 





like thrombin. Challenges associated with the current developed systems include potential toxicity 
issues raised by melittin and acrylate polymers. Although, melittin is under development as a  
biotoxin cancer therapeutic and acrylic polymers are under development as natural polymer 
hydrogels.144, 145 The low Φ of Cbl photoinitiators and lack of in vivo studies on the NIR responsivity 
of the melittin system requires further optimization. Further synthetic development and in vivo 
studies will solidify these novel photoresponsive biologic DDSs. 
 
Amino-1,4-benzoquinone (AQ) 
Amino-1,4-benzoquinones (AQ) release therapeutic cargo upon aromatization in 
exposure to long wavelength light (up to 700 nm). Although this reaction is slowed by polar 
solvents, this PPG was discovered to maintain its therapeutic release efficiency when sheltered 
in hydrophobic NPs. AQ NPs have been tested in vitro releasing paclitaxel upon >590 nm 
irradiation (Figure 1.10c).85   
AQ PPGs show promise with modest Φ and long wavelength photoresponsivity. It appears 
that their greatest challenge of environmental sensitivity has been overcome by using NPs. 











Figure 1.10 PPG based photogated carriers. a) Ru hydrogels that degrade upon exposure 
to green light for protein therapeutic delivery. b) RBC melittin-driven hemolysis triggered by 
photorelease of blocking segment releases peptide therapeutics from within RBCs. c) AQ 
NPs employ a hydrophobic core to shelter AQ photochemistry and allow for photoresponsive 









1.4.2.3 Photopolymerizable Phospholipids 
Beyond PPG and photoswitch based photogates, photogates have also been built from 
photopolymerizable lipid moieties. These moieties undergo photocrosslinking which destabilizes 
the lipid bilayer, leading to the breakdown of the nanomaterial and release of therapeutic cargo 
(Figure 1.11). Though out of scope for this discussion, liposomes that take advantage of ROS 
sensitive phospholipids which undergo photooxidation and consequent photofragmentation can 
also release therapeutic cargo in combination with PSs. These dual PDT/ small molecule 
therapeutic systems currently in clinical trials as cancer treatments have built upon the previously 
discussed long-wavelength PSs to develop novel PDT/ therapy systems.146-149 Such 
nanomaterials are reviewed more comprehensively elsewhere.4, 150-152  
Under development for the last 30 years, 1,2- bis[10-(2′,4′-hexadienoyloxy)decanoyl]-sn-
glycero-3-phosphocholine (bis-SorbPC) has been recently red shifted (up to 550 nm) by addition 
of a cyanine dye into the bilayer of these liposomes.153 Though having undergone limited 
development since their first discovery and preliminary in vitro tests, bis-SorbPC provide promise 
in their red-shifted photoresponsivity. Persistent challenges include their hydrophobicity and 
further extending their photoresponsive range. However, nanomaterials provide extensive 
opportunities for synthetic and physical modification of properties.154 
Finding more success 1,2 bis(tricosa-10,12-diynoyl)-sn-glycero-3-phosphocholine 
(DC8,9PC) based liposomes have demonstrated in vivo efficacy against cancer. Although initial 
work demonstrated DC8,9PC photocrosslinking at 254 nm, encapsulation with PS Photochlor 
adjusted the photoresponsive range to 660 nm by means of an ROS-dependent destabilizing 
mechanism. In vitro studies have also included doxorubicin in liposomes responsive to 514 nm 
by means of ROS-dependent mechanisms.148 Although DC8,9PC crosslinking does occur at 






Figure 1.11 Bis-SorbPC photopolymerizes creating permeabilized gaps in the PEG-













1.5 Considerations of Photoactivatable DDS Development: Designing and 
Developing for Clinical Translation 
With the foundation of currently developed long wavelength PPGs, photoswitches, and 
photogates (section 1.4) as well as the precedent of FDA approved light devices and 
photodynamic therapies (section 1.3), this section will provide crucial considerations in the 
design of photoactivatable therapeutics. Specifically, the design of its unique components 
(Figure 1.2) as well as a path towards the FDA Investigational New Drug (IND) application 
(Figure 1.12) – the first step in translating a novel therapeutic into clinical trials. When 
considering the design of novel photoactivatable therapeutics, it is important to note the 
precedent PDT has set. In general, approved PSs have confirmed that perfection is not required 
for clinical approval. Photofrin does have sub-standard (considering current standards) Φ, e, and 
significant phototoxicity (up to three months), and yet is still relevant after 30 years in the clinic 
in Barrett’s esophagus and endobronchial non-small cell lung cancer. These indications include 
non-resectable tissues that require targeted therapy, for which PDT poses less risks and more 
benefits than ionizing radiation.155, 156 However, applications beyond accessible tissue (e.g., 
esophagus, bladder, pancreas) will require more ideal photophysical properties than even 
currently established PDT systems have been able to provide.157 Many in the field have argued 
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The continued relevance of Photofrin, with its less-than-ideal photophysical properties, 
highlights the most crucial idea in successful clinical translation: unmet medical need.159 Although 
the below discussion includes considerations of which therapeutics and treatments can be refined 
by photoactivatable systems (section 1.5.2), meeting an unmet medical need (potentially multiple 
needs) will determine the degree of benefit the photoactivable therapy provides, the standard of 
care it is compared to, and the overall success of translation. Development should always focus 
on the unmet medical need(s) the photoactivatable DDS can resolve which should guide the 
development process. This approach can enhance efficiency in each step, resolution of 
challenges early on, and with multiple applications the potential to pivot the technology if 
necessary. In his 2018 perspective on photoactivated chemotherapeutics (PACTs), Dr. Sylvestre 
Bonnet noted that “Focusing more on the disease will be of primary importance for developing 
PACTs in the future. Questions such as market size, current prognostics, availability of other 
treatments and unmet clinical needs will determine whether a PACT reaches the patients’ beds 
or not.”159 In tandem with this ideology the below discussion on considerations of the key elements 
of photoactivable therapeutics will refer to the potential approaches for answering unmet medical 
needs throughout the design process (see sections 1.5.2 - 1.5.5). 
The FDA evaluates novel technology developed towards an unmet medical need by 
analyzing the risks and benefits the technology brings to the current treatment for an indication. 
Thus, when the unmet medical need is high or in extreme need of even small benefits, the benefit 
of an additional month of survival may be sufficient for clinical approval (provided it outweighs the 
risks of the treatment, as previously observed in pancreatic adenocarcinoma).160 Likewise, when 
limited therapies are available but the disease is serious and severe, toxic treatments such as 
cisplatin with higher risks are permitted. Thus, the discussions on the photoactivatable 
therapeutic’s components will also present considerations in a risk/ benefit analysis including the 





boundaries on what risks are permissible and what is considered a true benefit. The FDA’s IND 
(section 1.5.1) requires 1) the manufacturing process and 2) the animal pharmacology and 
toxicology information broken into i. Pharmacology, ii. Toxicology, and iii. Pharmacokinetics 
studies which include Absorption, Distribution, Metabolism, and Excretion (ADME) studies.  
 
1.5.1 Preparation of Therapeutics for an FDA IND Application 
One of the first steps when embarking on therapeutic development and clinical translation 
is to be familiar with the regulatory agency requirements and processes (e.g., the FDA in the 
USA). The FDA oversees the majority of investigational studies taking place in humans in the 
USA to ensure safety of the investigational substance. Clinical testing is a multi-year process 
during which a continuous relationship with the FDA will need to be maintained, from before IND 
application to continued safety and efficacy regulation post-marketing approval (Figure 1.12). 
More extensive reviews and resources on the history of, interactions with, and approval processes 
of the FDA are available.161 The following brief synopsis will focus on the FDA’s requirements for 
therapeutics attempting to transition from pre-clinical studies to first in human trials.  
The first milestone for therapeutic translation is opening of the IND, which conveys the 
sponsor’s intent to begin clinical investigations in the USA which, for a typical development 
program, are often first in human Phase I trials. A Phase I trial aims to establish safe dosage 
levels and can also begin to assess PK in a small (typically 20 to 80 patients total), healthy patient 
population. Beyond regulatory forms, the IND is composed of 3 main sections: i. non-clinical 
pharmacology, PK, and toxicology, ii. chemistry, manufacturing, and controls (CMC) information, 
and iii. clinical documents for the Phase I trial including the clinical protocol, investigator’s 
brochure, and any previous clinical findings relevant to the product.162 It is important to note that 
30 calendar days after the submission of an IND, the first in human trial can be initiated unless 





clinical components including the investigational brochure and clinical protocol need to be 
prepared, and for multi-site trials other sites should have been contacted to have already begun 
the lengthy process of contracts and institutional review board approval.  
To support opening an IND, the main sources of information to consider even at the 
beginning of the drug development process are: 1) the CMC/ quality of the product and 2) the 
non-clinical information (Figure 1.12). The non-clinical information can be broken down further 
into i. Pharmacology, ii. PK, and iii. Toxicology studies and contain information from both in vitro 
(cellular studies) and in vivo studies (in animal models) that aim to establish the safety of the 
proposed product for use in first in human trials. 
The quality section requires CMC information for the drug substance (the active 
pharmaceutical ingredient), the drug product (drug substance(s) plus any excipients), and the 
placebo formulation as well as any environmental impacts of manufacturing the therapeutic and 
any associated devices. Each component will require full characterization, a description of the 
manufacturing process which must be compliant with Good Manufacturing Practice (GMP) 
standards, a description and data for the analytical methods established to ensure the purity and 
consistent production of the substances, and assessments of stability.162  
The non-clinical pharmacology section focuses on both safety and potential for efficacy 
by providing information about the intended (mechanism of action/ enzyme targets) and 
unintended pharmacological consequences (such as effects on cardiovascular tissue, respiratory 
tissue, nervous system, etc.) of a proposed product. In addition, when applicable, information 
from animal models of the indication/ disease of interest should also be included. The non-clinical 
PK section provides ADME information and potential drug-drug interaction information that can 
be used to guide minimum and maximum dose selection for the first-in-human Phase I studies. 
Important results of the non-clinical studies include the MTD, dose-response curves, as well as 





dosages as well as the proposed treatment protocol (multiple staggered doses versus a one-time 
treatment). Though efficacy results from animal models of the human disease may be included in 
the non-clinical portion they are not as rigorously critiqued by the FDA for Phase I trials. However, 
it is important for sponsors to validate their potential therapeutic efficacy to justify the financial 
costs to run a clinical trial, as well as to justify the risk-benefit analysis once clinical studies begin.  
The toxicology studies support the safety of the therapeutic before the Phase I trial. Pivotal 
toxicology studies are required to be compliant with Good Laboratory Practice (GLP) standards 
and include acute (single-dose) and subacute (repeat-dose) tests usually in at least one rodent 
and one non-rodent animal model. Acute toxicity is the simplest to measure by assessing the LD50 
(lethal dose to 50% of animals) and monitoring effects on animal health, food consumption, and 
clinical pathology, and are crucial to understand for regulatory approval. Sub-chronic toxicity 
measures the effects of repeated exposure on clinical signs, motor activity, food consumption, 
clinical pathology, and ophthalmology, and at termination how critical organs were affected by 
gross necropsy and histopathology. In vitro toxicity and efficacy are often measured by finding 
the LC50 (lethal concentration that suppresses cellular growth) and EC50 (effective concentration 
that produces the desired biological effect in 50% of the population). These terms commonly 
contribute to dose selection for in vivo studies.163 Toxicology studies will often continue after the 
initiation of clinical trials with long-term (6 month and 2 year) toxicology and genotoxicity being 
completed in tandem with clinical investigation. Eventually chronic toxicity tests, effects on 
reproduction and the developing fetus, and toxicity related to the drugs mode of administration 
will be required for the new drug application (NDA).162 Similarly, eventual in vivo efficacy studies 
will require animals to demonstrate the desired biological outcome (tumor reduction, survival rates, 
remission of inflammation, etc.). 
During photoactivatable DDS design and development, it is crucial to consider how the 





process (Figure 1.12). For example, by targeting cellular and animal studies toward an unmet 
clinical need, vital optimization toward the indication, as well as supportive results for the IND, will 
be attained more efficiently. With knowledge of the unmet clinical need and the current therapeutic 
landscape, even initial in vitro testing can be done on disease relevant cell models contributing to 
both in vitro characterization of the phototherapeutic as well as preliminary pharmacology tests. 
Furthermore, photoactivatable DDSs can be improved at the design stage, by ensuring tissue-
penetrant long-wavelength responsivity as well as considering toxicity of the caging moiety and 
how easily the synthesis can be scaled up to manufacturing requirements. Since photoactivatable 
therapeutics seek to enhance the TI of many novel or existing therapeutics, demonstrating how 
the photoactivatable therapeutic compares to the therapeutic precursor or standard of care may 
be crucial validation required for approval. Though these early considerations may require more 
time to complete development, they will contribute significantly toward ensuring some of the main 
challenges facing photoactivatable therapeutics have been tackled in the pre-clinical stage.  
 
1.5.2 Therapeutic Cargo: Drugs with Room for Improvement 
Therapeutics modifiable for photoactivatable DDSs can include approved FDA drugs, 
therapeutics in clinical trials, or novel agents that require spatiotemporal control provided by 
photoresponsive systems. Photoactivatable therapeutics can improve on existing drugs by 
minimizing toxicity or enhancing efficacy through spatial or temporal control of delivery. Enhanced 
localized therapeutic delivery enables reduction in the therapeutic dose required and further 
diminishes toxicity. A more extensive analysis of the ways photoactivable therapeutics can modify 
the TI will be reviewed in section 1.5.6.2. 
When adopting FDA approved or promising therapeutics in clinical trials for 
photoactivatable DDS, it is crucial to understand how the therapeutic is currently employed in the 





and minimizing the risks, an improved derivative of that therapy can be produced. On the other 
hand, when developing completely novel therapies that have not been approved, understanding 
the current market and therapies that are addressing the clinical need is important. This section 
will discuss current indications for photoactivatable therapeutics focused on minimizing toxicity 
and enhancing efficacy.  
 
1.5.2.1 Minimizing Toxicity 
Photoactivated chemotherapeutics (PACTs) for Cancer 
Although PDT is an approved photoresponsive therapy for the treatment of superficial 
cancers, its further development faces challenges, due to a reliance on oxygen to generate ROS 
and limitations of the mechanism of ROS therapy. PACTs have been proposed as an alternative 
that can overcome these limitations.157 Cancers often create a hypoxic environment which results 
in insufficient oxygen for PDT to be truly effective. Furthermore, ROS cytotoxic therapy requires 
high powered lasers to generate enough ROS to create cytotoxic levels of oxidative stress leading 
to multiple mechanisms by which oxidative stress induces cell death, including by necrosis, 
apoptosis, and autophagy.58, 159 Metronomic illumination has evolved as a means of attempting to 
control the mechanistic pathway of cytotoxicity to diminish negative side effects and improve 
efficacy.28 These negative side effects, include tissue necrosis and pain, have led patients to 
reject further PDT treatments and driven the rise of sunlight based therapy.50  
PACT therapies are expected to minimize pain due to fast-acting cytotoxic mechanisms 
and avoid the challenges of PDT, such as hypoxia and the varied cytotoxic mechanisms, by 
eliminating the reliance on ROS. PACT can deliver highly cytotoxic compounds, such as cisplatin, 
auristatin, and duocarmycin in a highly localized manner. These cytotoxic compounds are FDA 
approved or in clinical trials and result in a powerful cytotoxic effect at low doses (e.g., IC50 of 20 





require ADC targeting in the clinic to minimize systemic toxicity.69 Undeniably, it is the inherent 
cytotoxicity of these therapies that introduces high risk to patients due to non-targeted cytotoxicity. 
Present severe side effects including severe chronic kidney disease, neurotoxicity, as well as 
neutropenia, risk of infections, and other common chemotherapeutic side effects.164 Even with 
ADC targeting, concerning systemic toxicity still occurs.165 
Novel photoactivatable therapeutics under development have the potential to target 
systemically present enzymes in a localized manner and combine PDT with PACT. For example, 
Ru based NAMPT (nicotinamide phosphoribosyl transferase) inhibitors which target NAMPT, an 
enzyme found within many tissues but upregulated in cancer, are under development. Systemic 
administration in rats of NAMPT inhibitors without photoactivatable caging led to severe adverse 
effects including blindness.166 Thus, NAMPT inhibitors are a prime candidate for photoactivated 
release as long as activity can be significantly diminished in the dark. Currently only an 18-fold 
difference between dark and light activity has been attained by Ru PPGs.77 Pc, Ru, and cisplatin 
derivatives are also under development for PDT. These scaffolds have been found to be 
synthetically amenable to dual therapeutic activation and can provide the additional benefit in the 
market of inducing cytotoxic effects via multiple mechanisms which may be necessary to eliminate 
extremely resilient cancers.75, 159 Separate administration of chemotherapeutics (such as cisplatin 
and doxorubicin among others) and PDT in in vivo studies have already demonstrated improved 
tumor growth control and antitumor activity.14 Further, combination therapies are also in pre-
clinical development with nanomaterial carriers and ROS activated therapeutic release which can 
release both therapies at the site of treatment and enhance localization due to enhanced 
permeation and retention (EPR) effects of the tumor environment (discussed further in section 
1.5.5).59, 147, 158 Indeed, finding ways to counteract cancer’s resiliency and ensure eradication of 






Higher staged and metastasized cancers as well as tumors that recur often lead to lower 
prognostic success.167 Cancers that still have extensive unmet clinical needs and thus may be 
ideal for PACT are non-resectable tumors, tumors where surgery dramatically lowers the quality 
of life, and rare diseases where current therapies do not sufficiently treat patients (Table 1-5).157 
As previously discussed, Photofrin is commonly applied to non-resectable tumors and is currently 
approved for non-resectable non-small cell lung cancer.156 Further, surgery in many head, neck, 
and brain tumors drastically lowers the quality of life, which is why PDT therapies are investigated 
in these tumors and have been approved in Europe for these indications (e.g. Foscan and 
Laserphyrin).20, 157 PACT and other novel chemotherapeutics can also begin to address the 
extensive treatment gap for rare cancers. Rare cancers accounted for 22% of all diagnosed 
cancers worldwide in 2017. These cancers face extremely poor prognosis due to limited treatment 
experience and limited treatment options.168 As previously, discussed PACT can improve 
chemotherapeutic therapy predominantly by minimizing off-target toxicity as well as potentially 
improving efficacy from localized delivery.  
 
Table 1-5 Available cancer therapies and situations in which they fail.  
Available cancer therapies Unmet clinical needs where cancer 
therapies can fail 
Surgery Non-resectable tumors 
Chemotherapy Dose-limiting side effects 
Radiation therapy Metastases 
Photodynamic therapy Hypoxia 







Improving the Safety of Endogenous Signaling Molecule Therapies 
There are many natural potent signaling molecules that have been successfully harnessed 
or mimicked for therapeutics. However, due to their potency, these signaling molecules often have 
undesired side effects. Again, photoactivatable DDSs provide the means to locally deliver the 
potent signal and minimize off-target signaling and resulting adverse effects. 
Dex is an anti-inflammatory treatment for rheumatoid arthritis, asthma, and other chronic 
auto-immune illnesses. By mimicking natural corticosteroids, Dex can inhibit immune responses. 
However, long-term usage, which is required for chronic diseases, leads to adverse effects 
including osteoporosis, weight gain, diabetes, and immunosuppression.169 Chronic illnesses are 
also the most in need of patient-driven treatments to resolve symptom flare-ups as chronic pain 
and debilitating symptoms in these illnesses have led to chronic work disability and 
absenteeism.170, 171 By localizing therapeutic release to the lungs or joints by means of simple 
handheld laser, patients may be able to resolve symptoms with minimal adverse effects. Slow-
release nanomaterials for Dex treatment have been previously approved as hydrogels (Dextenza) 
and are currently under clinical development with RBC carriers (EryDex).172, 173 Further 
development of these systems with photoactivated therapies could form drug depots which 
provide patient-controlled remission of symptoms during flare-ups while minimizing the systemic 
adverse effects that arise with chronic Dex usage.    
Potent biologics, such as thrombin, vasopressin, and dopamine are also FDA approved 
but have limited application or require extensive oversight during administration due to the non-
desired effects when injected systemically. Current treatments are either given topically 
(thrombin) or intravenously (vasopressin and dopamine) along with close monitoring of the 
patient’s response. Both vasopressin and dopamine cause erratic effects on cardiac function 
during treatment. Thus, localizing the release of these potent therapies to the desired tissue may 





fast clearance times and in vivo instability, which will require some form of carrier as demonstrated 
by the photoresponsive RBC and hydrogel systems.83, 142, 175 Thus, photoactivatable DDSs could 
improve treatments by not only sheltering these therapeutics from their environment and inhibiting 
their activity until illumination, but also allowing for more rigorous measurement of delivery, 
especially if developed in theranostic systems.  
Other photoactivatable therapeutics in development are the gaseous signaling molecules 
NO, CO, and H2S. These endogenously generated molecules are crucial signaling agents and 
mediators that can provide antioxidative, anti-inflammatory, vasorelaxant, cytoprotective, and 
neurosignaling effects, which may provide benefits in cardiovascular, inflammatory, and 
neurological diseases. Although NO and H2S are not as stable as CO, they have both had clinical 
success. H2S therapies are currently in Phase 2 trials as an abdominal analgesic and NO is 
commonly used to treat infants with pulmonary hypertension and is in trials for myocardial 
infarction.64, 176, 177 Photoactivatable BODIPY-H2S has been developed and tested in vitro, while 
photoactivatable BODIPY-NO has been tested in vivo.63 Further, BODIPY-NO has been 
developed as a theranostic which can be imaged with photoacoustic imaging for more precise 
therapeutic release.62 CO is the most toxic gasotransmitter under development with potent toxic 
effects due to its high affinity for hemoglobin. However, clinical trials have successfully 
demonstrated minimal short-term toxicity at CO-hemoglobin levels of <18%.178 CO therapies may 
face more challenges to achieve FDA approval due to the high potential risk. Beyond these 
regulatory challenges, CO treatments may face market resistance due to the molecule’s history 
of being a “silent killer”. Both aspects may thus require considerable evidence of large benefits. 
In general, further research and understanding on how all of these signaling molecules can 
achieve specialized, desired clinical results will be required before successful clinical translation 






1.5.2.2 Increasing Efficacy 
Although most applications of photoactivatable DDSs seek to minimize toxicity, 
spatiotemporal control of therapeutic release can also impact efficacy by localizing the 
concentration of therapeutic. Efficacy based development of photoresponsive therapy is currently 
limited to anti-bacterial treatments. The efficacy of anti-bacterial therapies has recently diminished 
by the rise of antimicrobial resistance. Photoactivatable anti-microbials propose a new way of 
minimizing resistance by limiting the exposure and localizing the treatment: bacteria exposed to 
the anti-microbial do not have the potential for developing resistance to the drug in its inactive 
dark state, while upon illumination high concentrations of activated drug kill off bacteria.79 Further 
developments are also occurring with PS-based antimicrobials. As previously proposed with dual 
active Ru, platinum, and Pc, these PSs could release both a therapeutic and ROS species to 
induce microbial death by multiple mechanisms decreasing the likelihood of resistance further.24 
Other growing fields such as, optogenetics and photoactivatable systems for chemical 
biology research, may eventually lead to novel classes of targeted photoactivatable therapies 
which will also improve localized efficacy. The growth of gene therapy as well could benefit from 
localized delivery, potentially improving transfection efficiency in the desired tissue.179 Further, 
the continued development of light devices and research in dosimetry may improve the 
understanding of light penetration leading to more specialized and localized therapies requiring 
high localized concentrations for efficacy. This would allow for specialized therapeutic proteins 
(such as vascular endothelial growth factor, VEGF), specialized protein targeting and gene 
activation (for pain treatment among other indications), and temporal delivery of these systems 







1.5.3 The Photoresponsive Moiety: The Foundation for Optimizing Benefit and 
Minimizing Risk  
The photoresponsive moiety (photoswitch, photogate, or PPG) is the foundation of the 
entire light responsive system. Thus, selecting the proper moiety is critical to the development 
process. A risk/ benefit analysis provides opportunities to further develop photoresponsive 
systems into photoresponsive therapeutics based on medical need. Although challenges exist in 
accounting for every potential variable that contributes to the ideal drug, the following proposals 
are suggested to improve the chances of success.  
When selecting a photoresponsive moiety, it is important to balance the risks and benefits 
as the photoresponsive moiety can significantly affect both the safety and efficacy of selected 
cargo by means of spatial and temporal control. Table 1-6 summarizes the PPG/ photoswitch 


















Table 1-6 Pros and Cons of the Photoresponsive Moieties introduced in Section 1.4. 
Photoresponsive 
Moiety 
Pros Cons Stage of Development 
BODIPY Optimal window of tissue 
Safe 
Theranostic applications 
Strong Fluorophore properties 
Hydrophobic 
In vivo 








ICG FDA approved 
In vivo 
Cbl Optimal window of tissue 
Safe 






Optimal window of tissue 
Dual PDT and PPG 
Limited to PPG activity in 
hypoxic environments 
Russia approved for 
PDT 
In vitro 
Ru Potential safety 
Multiple drugs per PPG 
Nanomaterial development 
Not in optimal window of 
tissue 
Properties are therapeutic 
dependent 
Clinical trials as 
cytotoxic drugs 
Synthetic development 





DASA Optimal window of tissue  Unstable Synthetic development 
AQ Optimal window of tissue  Requires nanomaterials In vitro NPs 
 
1.5.3.1 Benefit Analysis: Photophysical Properties, Synthesis, and Kinetics 
Photophysical properties lmax, Φ, e: effects on the depth of tissue penetration 
Although shorter wavelength photoresponsive moieties are numerous, PDT sets the 
precedent that their development and translation may be limited to very superficial dermatological 
applications (such as actinic keratoses), ophthalmology, and imaging applications (Table 1-2). 
Because of limited penetration (<1 cm), short wavelength responsive therapies have limited 
applications even in dermatological cancers.14, 50 Thus, long wavelength photoresponsive 
moieties within the optical window of tissue are required to optimize the potential unmet clinical 
needs the photoactivatable therapeutic can address.  
However, current PDT systems, even within the optimal window of tissue, have been 
limited to more superficial indications that can still be accessed by means of optical fibers without 





insertion of light sources as compared to the risks of other systemic therapeutics. Even the best 
PDT systems currently approved have sub-optimal Φ and e, biodistribution, and require costly 
high-powered laser sources, further limiting penetrance and potential applications. For treatment 
of non-accessible organs, photoactivatable systems will require high Φ, e, and may need to 
incorporate nanomaterials to improve delivery quantities by means of EPR and other passive 
modifications of biodistribution as proposed for PDT (further discussed in section 1.5.5).158 As 
previously mentioned, many scaffolds have been extensively modified to impact and improve the 
Φ depending on the photoresponsive moiety as reviewed in the cited publications.69, 121, 181, 182 
Both synthetic expertise and knowledge of past synthetic development will be crucial to accelerate 
the development process. Potentially developing 2 - 3 photoresponsive moieties in tandem as 
potential scaffolds may improve efficiency depending on resources and expertise available.   
It is important to note the balance required between Φ and e. Photoresponsive moieties 
that have extremely high e tend to be better fluorophores than therapeutic delivery systems. 
Though, these fluorescent properties are important for imaging and theranostic applications, if the 
goal of the system is to release therapeutic the energetic loss by fluorescence will need to balance 
with mechanisms of energetic transformation for cargo release. This challenge is present in both 
PSs and PPGs: PSs undergo an electron transfer to produce ROS and PPGs undergo 
photoinduced electron transfer reactions for therapeutic release.183 Thus, unintended release of 
energy as fluorescence poses a challenge to efficiency in both systems. Furthermore, balancing 
the Φ and e is even more important in PPGs that release inherently cytotoxic therapeutics as too 
sensitive systems will produce cellular damage during administration similar to PSs which have 
demonstrated undesirable phototoxicity. For example, Foscan (Φ = 0.35 and e = 23,000 M-1 cm-
1) did not receive approval in the US although it was approved in Europe, potentially due to high 
phototoxicity side effects including burns at the site of administration.12, 19 Thus, when developing 





challenge and may require lower Φ and e values. Similarly, drug depots may require lower Φ and 
e to ensure limited release from ambient light supporting long-term inertness until illumination. 
The ideal photoresponsive moiety faces a complexity of variables, both known and unknown as 
questions remain about the degree of light penetration and how it relates to phototoxicity. For 
simplicity, aiming for a high Φ balanced with a high e responsive to long wavelength light will help 
tackle variables such as penetration through a variety of skin types and tissues expanding the 
potential applications of the photoresponsive moiety.  
 
Synthetic Modification of Therapeutic Potency and the Resulting Photoproducts 
Another consideration in photoactivatable design is the synthetic modifications required to 
append the therapeutic to the PPG. By appending the PPG to the therapeutic by a crucial site for 
therapeutic efficacy, PPGs can inactivate the therapeutic. Only when the therapeutic is released 
upon illumination is the site revealed and activity regained.55 However, these synthetic 
modifications may diminish the efficacy of the therapeutic or the Φ of the PPG depending on the 
lability of the covalent attachment between the two. Photoswitch systems face greater challenges 
in therapeutic modification as a minor conformational change in response to light is required to 
significantly improve therapeutic efficacy. In general, photogated carriers may be optimal for 
synthetically sensitive cargo, although carriers do require further optimization (discussed further 
in section 1.5.5). 
When selecting a photoresponsive moiety, it is also important to consider the 
photoproducts. Once illuminated and the therapeutic is released, the resulting scaffold should 
ideally no longer absorb light to optimize the photons available for PPGs still carrying their cargo. 
With the previously mentioned challenges facing light tissue penetration, this understated 
consideration may be crucial in deeper tissue therapies. The therapeutic photoproduct should 





less crucial for photoswitch development as the conformationally modified photoswitch does not 
commonly produce multiple photoproducts. Instead, in theory, the photoswitch returns to its 
inactive state by exposure to a different wavelength of light. Further, when the photoswitch returns 
to its “off state”, illumination should re-isomerize the therapeutic to its active state improving 
therapeutic activity.  
 
ADME  
The photoresponsive kinetics and general ADME properties of the photoresponsive 
moiety will contribute significantly to therapeutic efficacy. First, localized efficacy can only be 
achieved if the kinetics of cargo release and delivery outcompete rates of diffusion away from the 
site of illumination. Theoretically, the kinetics of absorption and electronic excitation are nearly 
instantaneous as determined by the Franck-Condon principle. However, absorption is limited by 
the tissue penetrance of light and the moiety’s ability to absorb photons (e). Once absorption does 
occur however, the major limiting step for a successful PPG is the release of the cargo (Φ). It is 
crucial that this rate is kept sufficiently fast to outcompete the rate of diffusion away from the target 
tissue.181, 184 Due to these kinetic concerns, as well as the general slow rate of photolysis from 
cyanine, the ADC Panitumumab was introduced to the cyanine-duocarmycin photoactivatable 
therapeutic to improve the kinetics of diffusion and accumulation.102 As previously discussed, the 
control of spatial and temporal delivery is the main therapeutic advantage of using 
photoresponsive moieties and thus the kinetics of cargo release need to be sufficient to maintain 
these benefits in vivo. For photoswitch and photogate systems the kinetics maintain similar 
constraints. A therapeutic photoswitch needs to isomerize into and maintain the active form for 
enough time that the “on state” can achieve its therapeutic effect. Photoswitches that insufficiently 





photogates need to open and therapeutic cargo diffuse into the illuminated tissue before diffusion 
of the nanomaterial away from the site of treatment.  
Therapeutic potency can be further limited by ADME as demonstrated by the sub-optimal 
biodistribution of some PSs.12, 158 The bioavailability of the photoresponsive therapy is initially 
dictated by its administration, absorption, and solubility. While many PDT systems are delivered 
intravenously, a few are orally available (Table 1-2). Although intravenous administration ensures 
a high bioavailability, oral treatments still provide many benefits that could improve safety and 
feasibility of treatment. Orally available treatments require diminished cost of treatment and allow 
for ease of dosing outside the clinic (crucial for when ideal biodistribution is achieved after 
extended periods of time as demonstrated by Photofrin).12, 185 Oral treatments would also further 
support patient-controlled treatment and delivery.  
Photoresponsive moieties need to also be water soluble to diffuse well in the bloodstream 
and ensure distribution to the treatment site. For orally administered treatments physiochemical 
properties (such as pH, molecular weight, and polarity) are further constrained to ensure optimal 
absorption through the gastrointestinal tract.186 Although, there have been approved and tested 
hydrophobic PDT systems (such as Verteporfin and Tookad) that took advantage of liposomal or 
other nanomaterial preparations to improve their water solubility, these more complex designs 
introduce their own absorption-based challenges (discussed in section 1.5.5).12 Similar to these 
nanomaterial preparations, the photoresponsive moiety may help improve poorly soluble 
therapeutic cargo. The photoresponsive moiety circulates and shelters the therapy until 
illumination and therapeutic release, at which point the more hydrophobic cargo permeates into 
the laser-targeted tissue. Extensively hydrophilic properties of the photoresponsive moiety may 
also minimize PPG uptake by tissue which may help minimize inadvertent activation outside the 
laser-targeted tissue. Again, the desired physiochemical properties of the photoactivatable 





photoactivatable therapeutic is a composition of two unique molecules enhances this complexity. 
In general, however, the system should be water soluble to ensure ideal bioavailability and ideally 
provide multiple methods of administration before illumination. 
The photoresponsive moiety’s stability, or ability to resist metabolism and clearance, will 
affect how long the optimal bioavailability persists. Inherently, PPGs balance the bond strength 
required to bind cargo and the inherent bond weakness required for photolability to absorbed NIR 
energy. To optimize photoactivatable benefits, therapeutic release should not happen until 
illumination. Thus, the photolabile bond must resist enzymatic and filtering processes in the blood 
and in organs such as the liver and kidney. Interestingly, isomerizable photoswitches do not have 
the same concerns regarding photolabile bonds. However, their structures often do have 
desaturated bonds that can be reduced or weak ring structures that are crucial to switching.57 
Thus, in vitro testing of stability throughout the moiety optimization process is crucial for all 
photoresponsive systems. Finally, the rate of clearance or excretion from the body needs to be 
slower than the time required for sufficient uptake, ideal distribution, activation, and therapeutic 
release, but not so slow that phototoxicity persists (discussed further in the risk analysis). 
 
1.5.3.2 Risk Analysis: Dark Activity and Toxicity 
Dark Activity  
Photoactivatable therapies rely on diminishing the activity of the drug until illumination for 
therapeutic improvement. Consequently, the therapeutic activity without illumination (referred to 
as “dark activity”) needs to be minimal. Dark activity can be a result of therapeutic release from 
metabolism (in the blood, the liver, kidney, or other tissues), activation by ambient light (as 
demonstrated by PDT phototoxicity), or persistent therapeutic efficacy while appended to the 
photoresponsive moiety. The photoindex quantifies dark activity by comparing efficacy without 





attained 8-fold improvement between dark and light while PPGs have achieved 2-fold to almost 
4,000-fold improvement in cellular studies.69, 79, 117 The concept of photoindex and examples of its 
calculation are further explored and elaborated on in section 1.5.6.  
Low levels of dark activity do not indicate therapeutic failure as photoactivatable DDSs 
can act to enhance effects of less potent therapies by localizing therapeutic release. Such 
therapies may cause minimal toxicity at lower concentrations in the dark. Thus, the risk imposed 
by dark activity will be significantly defined by the therapeutic cargo selected (section 1.5.2). 
However, in general, a minimized dark activity minimizes off-target effects and preserves the 
available photoresponsive cargo, optimizing localized release of therapeutic at the site of 
illumination. 
 
Toxicity of the Photoresponsive Moiety and Photoproducts 
As noted previously, the FDA’s highest priority is safety. Therefore, establishing the 
toxicity of the photoresponsive agent and photoproducts throughout pre-clinical studies is 
essential for development. This exploration commonly includes off-target pharmacology of the 
photoactivatable system which could be introduced earlier in development. For example, off-
target cellular studies alongside validation cellular studies may begin to indicate potential non-
desired pharmacological targets and inadvertent metabolism which could be expected in vivo and 
later in patients. Previous clinical tests of scaffolds may also indicate their potential safety in other 
novel derivations and applications. For example, although heavy metal NIR-responsive PPGs 
exist, they are more likely to exhibit serious toxicity and were thus predominantly excluded from 
the reviewed photoresponsive moieties in section 1.4.184 However, heavy metal species are not 
always toxic and can induce a therapeutic effect by multiple mechanisms of action, as 
demonstrated by NAMI-A and KP1019. Both Ru therapeutics display a low degree of systemic 





produces anti-metastatic effects.115 Thus, thorough pre-clinical investigation (including off-target 
cellular studies and preliminary assessments of toxicity before GLP studies) may begin to account 
for unexpected effects of novel derivatives of tested scaffolds, begin to provide preliminary 
assessments of toxicity of the scaffold, as well as any synthetic modifications that remain on the 
photoproducts. Certainly, in vivo and patient trials will truly assess the safety of the system as 
demonstrated by the extensive toxicity assessments in GLP in vivo studies and Phase I trials. 
 
ADME’s Impact on Toxicity 
The risks associated with using toxic photoresponsive agents or even toxic therapeutic 
cargo will be influenced by excretion and distribution into vulnerable tissue. For example, one of 
the risks of Photofrin usage is the month of phototoxicity due to its slow clearance. Patients must 
avoid direct sunlight and bright indoor lighting to minimize the risk of burns and other superficial 
lesions. Similarly, Photofrin’s distribution and buildup in collagen and smooth muscle layers has 
led to stenosis and other obstructive structures upon illumination. These adverse effects and the 
development of better therapies have led investigations of Photofrin treatment for bladder cancer 
to be discontinued.12 Thus, second and third generation PSs have begun to be address Photofrin’s 
sub-optimal biodistribution, excretion, and inherent phototoxicity. Similar concerns should be 
investigated and addressed during photoactivatable therapy development. 
Unlike PDT, many PPG and photoswitch systems can modify their therapeutic to be non-
cytotoxic and potentially avoid ADME toxicity concerns, however, the majority are still being 
developed with cytotoxic cargo as reviewed above (Table 1-4) and discussed in section 1.5.2. 
Thus, more rigorous optimization of ADME properties may be required for the successful 
development of inherently toxic therapeutics. For example, ADC-cyanine-duocarmycin was 
developed to optimize the localization of the duocarmycin therapeutic in the tumor. Specifically, 





countering cyanine’s slow photocleavage rates.102 Toxic photoresponsive moieties, on the other 
hand, should ideally be avoided but can also be sheltered within photogated carriers. For example, 
Ru based photogated carriers ensure that Ru is retained within the hydrogel to diminish its 
potential toxic effects.83  In general, thorough GLP studies of in vivo toxicity are required to 
convince the FDA of the safety of novel photoactivatable therapeutics regardless of cargo and 
scaffold, while preliminary pre-clinical studies can help to assess initial toxicity and select between 
multiple photoresponsive moiety candidates. 
 
1.5.3.3 Feasibility Considerations: Ease of Synthesis, Patentability, and 
Theranostic Potential 
Beyond the risks and benefits of photoactivatable therapeutics, feasibility of these complex 
novel systems should be contemplated early in the selection and design of photoresponsive 
moieties to ensure success of achieving marketing status. These considerations include: 1) can 
the photoactivatable therapeutic be easily synthesized (in high quantities), 2) is the 
photoactivatable therapeutic stable during storage and administration, 3) can the system be 
patented, and 4) is there potential for theranostic measurements.  
The ease of synthesis of the photoresponsive moiety and photoactivable therapeutic will 
make development more efficient in both the pre-clinical and clinical stages. Pre-clinically, an 
easier synthesis will allow for more attempts at optimization and minimize the time waiting on 
compound for in vitro and in vivo tests. Eventually, a simpler synthesis can be more easily scaled 
up to provide enough therapeutic for hundreds of patients in clinical trials. The more challenging 
the synthesis, the more challenging it will be to iterate and test the photoactivatable system 
through optimization and pre-clinical development, and eventually the more costly it will be for 
patients to purchase. The cost of the therapy, depending on what competitive drugs are available 





market. Thus, the synthetic methods used to attain the final product should be compared to other 
therapeutics available for the targeted indication. 
Along those lines, general instability and inadvertent photoresponsivity of photoactivable 
therapeutics can also make their development and clinical adoption more challenging. During 
synthesis, special dark facilities and training may be required to produce photoactivatable 
therapeutics which can slow development and potentially increase the likelihood of error or 
inadvertent activation of product. To assess the likelihood of inadvertent activation as well as 
intrinsic instability, initial optimization studies can measure background hydrolysis rates similar to 
assays conducted for optimization of ADC-cyanine-duocarmycin leads.69 Although the ADC 
studies were performed under 37 ºC to assess potential physiological stability, performing similar 
studies under cold storage temperatures or under normally lit settings would indicate general 
stability of storage and photoresponsivity for manufacturing and administration. Fluorescence or 
liquid chromatography mass spectrometry can measure background photolysis, hydrolysis, or 
degradation. Once a potential administration method is selected, performing similar 
measurements of background hydrolysis during in vivo administration would assess the likelihood 
of background photolysis in similar clinical applications. Especially during administration, requiring 
medical personnel to prepare syringes or administer therapeutic in dark or low light conditions 
can increase the likelihood of error. Thus, speaking to clinicians and drug manufacturing 
organizations about these potential obstacles may help further scope feasibility. Unlike PDT, 
PPGs release therapeutic only once after photoactivation. Thus, thoroughly understanding 
limitations of synthetic production, inherent stability, and clinical administration are crucial for 
feasible translation. Once again, having the highest possible Φ and e can increase the risk of 
activation during administration in well-lit clinics diminishing the benefits of the photoactivatable 





Patenting the photoactivatable therapeutic is also crucial for feasible translation and 
successful marketing. Beginning conversations with patenting teams early in the design process 
can help ensure a patent will be attained and even potentially sway selection of photoresponsive 
moiety based on patentability. In industry, many potential drugs from high throughput screens are 
often discarded due to potentially weak patent protection. For academic research, patent 
exploration will also help support cognizance of prior art and how the research team furthers prior 
art by publications throughout the development of the system. Such knowledge will help support 
both research ventures, as well as, ensure the technology is not disqualified from patenting by no 
longer meeting the novelty and non-obviousness requirements.111 Although, somewhat beyond 
the scope of this introduction, a review of current patents as well as patents that reposition drugs 
for novel indications may be useful in further learning the landscape of an unmet clinical need and 
gaining a better grasp of how novel photoactivatable therapeutics can meet requirements for 
successful patenting.187  
Finally, theranostic applications of photoactivatable therapeutics may not only expand the 
application and benefits the system provides to a variety of unmet medical needs, but also can 
help support validation assays by clearly demonstrating spatial and temporal control. Intrinsic 
theranostic capabilities (such as those of BODIPY and cyanine PPGs) require the side products 
to continue to absorb light and the scaffold to have inherent fluorescent properties. However, 
counter to the previous concerns of how these properties diminish photoactivatable efficacy, 
theranostics harness these attributes as a means to monitor distribution and release, which may 









1.5.4 Light and Light Devices 
As reviewed in section 1.3, PDT therapies have been applied to multiple indications. In 
tandem with these developments a variety of light sources and fiber optic devices have also been 
made and approved. Although, the FDA approved PSs require some form of easy external access 
to illuminate the tissue, there are many more PDT systems that have been tested or are currently 
being tested in the clinic in parenchymal tissue alongside novel light sources and delivery devices. 
When addressing unmet clinical need(s) with a photoactivatable therapeutic it is important to 
consider the light devices available and limitations of these devices, as the current devices 
available and their cost will contribute significantly to the feasibility of the therapeutic. This section 
will therefore provide a more generic discussion on the clinical precedent of devices and their 
applications as well as the importance of dosage and dosimetry when considering the role of light 
and selection of a light source in photoactivatable therapeutics. 
 
1.5.4.1 Selecting a Device Based on Indication  
When selecting a device for photoactivatable treatment it is important to consider the 
precedent set by previous PDT devices including the intensity of treatment that may be required, 
the necessity of fiber optics based on the indication, and the costs associated with certain devices 
(Table 1-7).31 Laser devices with optical fibers that are loosely inserted or interstitially incised into 
tissue are ideal for internal applications to the gastrointestinal tract, bladder, lung, prostate, head, 
and neck as they provide high intensity, coherent light efficiently. Conversely, lamps are the 
preferred application for superficial indications such as AMD, breast cancer, skin malignancies, 
actinic keratoses, and other applications as they can provide high intensity, incoherent light that 
can be used for multiple wavelength treatments by filters.36 LEDs provide a cheaper alternative 
to both lasers and lamps and have been applied to both internal and superficial applications as 





require filtering. However, LEDs cannot achieve intensities of lasers as they inefficiently convert 
electrical energy to light often resulting in inadvertent heating.28 The continued development of 
LEDs with improvements in their intensity and maximizing compatibility with fiber optics may 
further minimize the current financial costs of treatment associated with lasers.  
Novel applications of PDT that have not yet achieved approval but have been heavily 
investigated include the brain, liver metastases, liver bile ducts, and pancreatic cancer.12, 36 PDT 
has been tested in high grade glioma treatment to ensure removal of any residual cancerous cells 
that can spread throughout the brain and regrow. In previous clinical trials, the PS was 
administered to the patient before surgery. Then, after tumor resection, the surgical cavity was 
coated with intralipid for uniform light delivery and illuminated with a fiber optically delivered high-
intensity laser.158 PDT has also reached the bile ducts for the treatment of hilar 
cholangiocarcinoma and other unresectable gastroenterological diseases by endoscopic 
illumination.188 In pancreatic and liver cancers, multiple diffuser fibers are applied interstitially to 
the respective organ.158, 189 The challenges with these indications for PDT has been the minimal 
concrete evidence of improved response based on PDT treatment. Further trials, novel PACTs, 
and developments in dosimetry may support conclusive evidence for treatment of these 
parenchymal cancers. 
Table 1-7 Pros and Cons of FDA Approved Light Sources for PDT 
Light Source Pros Cons 
Laser 
Capable of high doses 
Monochromatic 
Highly compatible with fiber optics 
Expensive 
Can be large 
Requires high maintenance 
LED 
Small, adaptable, configurable geometry 
Low cost 
Endoscopic and interstitial applications 
Thermal effects 
Low power 




Ease of transitioning between multiple wavelengths 
Can achieve high power 
Often less efficient with fiber optics 








1.5.4.2 Dosimetry: Optimizing Dosage, Geometry, and Timing  
As previously discussed, the dosage and dosimetry of light is highly dependent on the 
intensity, duration, and geometry of light exposure and the distribution of the photoresponsive 
agent. These crucial variables led to the failure of motivating lutetium as Phase I dosimetry 
analysis of prostate cancer treatment was found to be substantially heterogeneous both between 
patients and individually in the patients themselves.12 Thus, beginning dosimetry studies and 
understanding potential efficacious dosages as well as optical properties of the target organs in 
pre-clinical in vivo studies may help reveal such challenges before clinical trials. Initial results can 
be further validated in Phase I clinical trials measuring dosimetry and PK (Figure 1.12). 
The range of intensities under consideration will be limited by the device itself as 
referenced in section 1.5.4.1 with lasers providing up to 8 W, LEDs up to hundreds of mW, and 
lamps up to tens of W.28, 31 The total dosage of light, which correlates to the total therapeutic 
released, is calculated by multiplying the intensity of exposure by the duration of the exposure. 
For PDT, intensities of 1-5 W are required at longer wavelengths of light for successful treatment 
in tens of minutes.28 Similarly scoping the required intensity for photoactivatable therapeutics is 
important to minimize potential photothermal toxicity effects as well as develop feasible treatment 
times. Photothermal toxicity is governed by the Planck-Einstein relationship and occurs when the 
rate of energy delivery to tissue from irradiation exceeds the rate of energy dissipation. Although 
longer wavelength light is, in general, less likely to induce phototoxicity as it is lower energy, if the 
intensity of irradiation is too high ablative effects can still occur.32 Further guidance is offered by 
the American National Standards Institute in the form of maximum permissible exposure.190 
Ensuring that such photothermal toxicity does not result from required light doses during 
toxicology studies will be important for ensuring safety and required in the FDA IND.   
The other components of dosage, the duration and sequence of irradiation, needs to also 





photoresponsive therapies aim for the highest intensity in the shortest duration to optimize local 
therapeutic concentrations and ensure efficacy. However, novel sequences of illumination have 
recently developed in PDT such as metronomic irradiation. Metronomic illumination employs a 
lower rate of light delivery as well as a lower dose of PS for a longer period of time to shift a PS’s 
mechanisms of cytotoxicity from necrosis to apoptosis as the rate of energy delivery is lowered.28 
Although, such mechanistic changes are not expected in photoactivatable therapeutics, they are 
beneficial to understand when considering combinatorial treatments with PDT. Further, the 
illumination duration and sequence of photoactivatable therapeutics may significantly affect the 
kinetics of release as well as the kinetics of diffusion to the therapeutic site. For photoswitches 
especially, the sequence of light delivery may be crucial. Multiple scenarios of irradiation were 
recently proposed for photoswitches with different properties including illumination before 
injection, illumination at the site for short periods of time, and a sequence of illumination to turn 
on and off photoswitches.191 As previously mentioned, photoswitches that quickly return to their 
“off state” may also require extended periods of illumination. These scenarios begin to provide an 
understanding of the potential opportunities of photoactivatable therapeutics as well as the 
complexities of irradiation to make these opportunities feasible. Understanding the ideal 
illumination sequence and duration of dosing will require expertise in dosimetry and can benefit 
from theranostic measurements. 
Dosimetry studies can also elucidate the geometry of illumination to determine the ideal 
spatial boundaries. Indeed, the field of dosimetry seeks to optimize the distribution of light dose 
to ensure efficacious and homogeneous treatment in the desired tissue for both the indication 
generally but also specifically per patient, presenting another way to achieve personalized 
medicine. In 1986, a method for “light therapy planning” was developed based on modeling data, 
data on the optical properties of the target tissue, the patient’s specific treatment requirements, 





undergoing in vitro, in vivo, and clinical trial development, the multitude of fiber optics available 
with both non-contact, contact, and interstitial applications do require planning especially when 
moving into completely interstitial tissues such as the pancreas and liver (Figure 1.4).31 For 
interstitial applications sequential illumination of multiple areas, as well as, simultaneous 
illumination using multiple diffusing fibers have been employed clinically to irradiate a greater 
expanse of tissue and deeper tissue volumes.28 Since photoactivatable therapeutics rely on 
spatial control for their efficacy ensuring that the light reaches the desired treatment area in a 
uniform manner is paramount to achieving this control and consistent efficacy between patients. 
For this reason, theranostics may also be crucial to furthering the development of both dosimetry 
and photoactivatable therapeutics as these substances provide a method of monitoring the 
therapeutic release based on illumination.  
Beyond the considerations of dosage, another consideration is when to begin illumination 
which relies on the administered dose of the photoactivatable therapeutic and its bioavailability in 
the targeted tissue. As previously mentioned in section 1.5.3, Photofrin requires 48 h of circulation 
before ideal concentrations for treatment are attained at the target tissue.12 Similarly, ADC-
cyanine-duocarmycin demonstrated ideal biodistribution in in vivo cancer tissue after 3 - 4 days 
post-dosing. Such studies ensured an optimal localized dose before illumination. Undeniably, 
temporal control is one of the unique benefits of photoresponsive therapies and may require 
extensive investigation especially when paired with other targeting methods (such as ADCs). 
Investigation should be conducted during pre-clinical development to take full advantage of this 
benefit of photoresponsive therapeutics and maximize the localized delivery promised by 








1.5.5 Carriers: Modifying Stability and Distribution 
In section 1.4, photogated systems made from hydrogels, RBCs, NPs, and liposomes 
were introduced. This section will further elaborate on these carriers, beyond photogated 
applications, and consider the benefits a carrier can provide photoactivatable therapeutics. The 
discussion will be limited to more generic classes of DDSs presented in 1.4 as the field of 
nanomaterials is quite expansive and under great development (Figure 1.13). DDSs that respond 
to other stimuli will also be briefly mentioned in relation to developing multi-responsive systems. 
Many carriers have required camouflaging to improve their biocompatibility, which has been 
clinically achieved by PEGylation. Although RBC membranes and other innovative camouflaging 
techniques have demonstrated pre-clinical success in diminishing recognition and clearance of 
foreign nanomaterials, these techniques have not yet been translated into the clinic and thus are 
considered beyond the scope of this introduction.192, 193 Many expansive reviews have been 
written to discuss the diverse and growing field of carriers, which are recommended to assist in 
selecting the ideal carrier for the photoactivatable therapeutic and the indication to be 














Figure 1.13 Reviewed potential carriers for photoactivatable therapeutics that have 
achieved clinical success. Inorganic NPs include gold NPs and superparamagnetic iron oxide 
NPs. Polymeric drug carriers include micelles, polymeric NPs, mesoporous NPs, dendrimers 




























1.5.5.1 An Introduction to Carriers in the Clinic and their Potential Indications 
Inorganic Nanoparticles (NPs) 
Although inorganic NPs, in general, display higher cytotoxicity and less biocompatibility 
than other nanomaterials there have been successful applications of these NPs that harness their 
mechanisms of clearance or are modified to improve biocompatibility by cellular masking. Many 
inorganic NP systems are covered in the next few paragraphs as well as their clinical applications. 
The unique distribution and imaging properties of these systems can be harnessed for 
applications in pre-clinical validation, theranostics, as well as targeting therapeutics to specific 
tissues as will be discussed in section 1.5.5.2. 
Although gold NPs were first discovered in the 1850’s, they have only recently achieved 
clinical translation as a photothermal method to ablate cancer tumors with the clinical studies of 
AuroLase. AuroLase is undergoing testing for the thermal ablation of metastatic lung tumors. The 
PEGylated gold-silica nanoshell displays NIR photoresponsivity which it converts into 
photothermal energy.194 Gold NPs have also been tested pre-clinically as radiation dose 
enhancers and chemotherapeutic carriers.197 Although having achieved limited clinical success in 
these other therapeutic techniques, gold NPs demonstrate a multi-functionality that may be useful 
for certain indications and photoactivatable DDSs. 
Superparamagnetic iron oxide NPs (SPIONs) have had more success with clinical 
translation as they have been applied in both therapeutic and imaging applications (predominantly 
magnetic resonance imaging - MRI). Iron NPs, such as Faraheme, take advantage of clearance 
mechanisms to act as a slow-release system for iron supplementation in anemic patients, while 
Feridex and Resovist are used in MRI liver imaging and GastroMARK is a contrast agent for 
darkening of bowel loops.198 Pre-clinically, SPIONs have also been tested as magnetically guided 
NPs, as another means of thermal ablation excited by an alternating electric field, and as a means 





Electromagnetically excited photothermal effects of SPIONs are also under development in early 
clinical trials with Hafnium oxide NPs (NBTXR3) for squamous cell carcinoma and NanoTherm 
which has been approved in Europe for brain cancer.194  It is important to note, however, that in 
2008, 2012, and 2009 the FDA-approved MRI contrast enhancers Feridex, GastroMARK, and 
European approved Resovist respectively were withdrawn due to a lack of users. Feridex, which 
cannot be injected as a fast bolus due to adverse effects, may have been unable to compete with 
Resovist (injectable as a fast bolus).198 The reasons for the withdrawal of Resovist and 
GastroMARK were not clarified.199 However, the continued withdrawal of the majority of clinically 
approved SPIONs may require further investigation before selecting this carrier above others. 
Silica NPs and MSNs are under investigation as photogated systems, although no 
clinically approved MSNs yet exist. MSNs contain nanopores on their surface that can be used to 
encapsulate hydrophobic drugs or biomacromolecules as previously presented in section 1.4.4 
However, observed cytotoxicity has led to applying previously discussed cell membranes as well 
as PEGylation to their surface to enhance biocompatibility. Antibodies have also been applied to 
MSN surfaces for active targeting.194 Using MSNs for photogated applications may be ideal for 
this unique NP as therapeutics can easily diffuse out of the MSN interior. However, MSNs may 
also be useful in developing multi-responsive DDSs (discussed in 1.5.5.2). 
 
Potential Indications 
Inorganic NPs have demonstrated a variety of safety and success in the clinic. However, 
inorganic NPs pose unique opportunities as carriers that should be noted when considering unmet 
clinical needs. Both gold and iron oxide NPs have demonstrated photothermal and imaging 
properties in the clinic. These unique inherent qualities may be beneficial for multi-responsive 
systems as well as in the development of theranostic applications. SPIONs can additionally add 





metabolized into iron, they have successfully been used to treat chronic kidney disease, 
myocardial infarction, and other cardiovascular diseases.198 Although, SPIONs and gold NPs 
provide unique opportunities for photoactivatable therapeutics they are limited systems in their 
current development. The surface of gold NPs cannot be easily modified and they are often 
produced as mixtures, while as previously mentioned approved SPIONs have been unexpectedly 
withdrawn from clinic.199 Before undertaking the complexity of bringing a multi-layered novel DDS 
to clinic, ensuring that the benefits will outweigh the risks is paramount with inorganic NPs.  
 
Intravenous Polymeric Carriers 
Polymeric NPs and Polymer-Drug Conjugates  
Polymeric NPs and polymer-drug conjugates have been cited to make up 30% of all FDA 
approved nanomedicines from 1995 to 2016. This widespread approval is partially due to the high 
synthetic versatility and ease of modifications of these NPs.200 These NPs are commonly prepared 
as nanocapsules or nanospheres that are composed of poly(glycolic acid), poly(lactic acid), 
poly(lactic-co-glycolic acid), and other synthetic polymers as well as natural polymers, including 
chitosan, gelatin, collagen, dextran, etc. Polymeric NPs are one of the most common carriers due 
to their biocompatibility as well as drug release tunability which is adjusted by manipulating the 
lactide to glycolide ratio and molecular weight. Further, each of the compositional synthetic and 
natural polymers, as well as their modifications, attribute unique properties to the carrier and can 
affect the circulation and distribution of many different therapeutics. Notably, PEG external 
modifications can significantly improve biocompatibility and circulation half-life. Thus, many 
polymer-biologic conjugates are clinically approved including adenosine deaminase enzyme, 
granulocyte-stimulating factor, interferon beta-1a, and antihemophilic factor for the treatment of 
combined immunodeficiency, febrile neutropenia, multiple sclerosis, and hemophilia, respectively. 





including albumin-paclitaxel among other albumin conjugates, and a polymerized leuprolide 
acetate.194 Polymeric NPs and conjugates are ideal for improving biocompatibility and circulation 
time and may be useful in sheltering photoactivatable therapeutics. 
 
Polymeric Micelles 
Resembling monolayer vesicles, polymeric micelles are composed of amphiphilic 
copolymers. The core is commonly hydrophobic with a hydrophilic outer shell. However, inverted 
micelles also exist. Clinical applications of micelles have been limited due to their non-specific 
drug release, instability, and synthesis as mixtures, but micelles have been successful in 
solubilizing poorly soluble drugs and have gained traction for stimuli-responsive and targeted 
therapies including PDT.194 Although no micelle therapeutics have been approved by the FDA, 
micelles carrying paclitaxel and docetaxel are approved in South Korea. Other trials underway 
include improving the safety profiles of chemotherapeutics such as cisplatin and doxorubicin.201 
Silicon phthalocyanine PC4 is also undergoing development in PEG-polycaprolactone micelles.12 
The micellar mixture Cremophore EL has been more widely accepted and has been clinically 
employed for the original hydrophilic form of PDT Tookad, as well as Redaporfin, currently under 
clinical trials.12 However, the biological effects of Cremophore EL are not completely understood 
and may be a potential source of adverse events.202 Micelle based DDSs are ideal for systems 
where the therapeutic can escape the micelle on its own. As demonstrated with photogated 
micelles, photoactivatable therapeutics that take advantage of polarity differences or require 










Dendrimers are highly branched polymeric macromolecules which incorporate 
therapeutics by encapsulation in void spaces or covalent bonding. Dendrimers have achieved 
minimal clinical success due to challenges of therapeutic release as well as complex synthesis 
and resulting issues with mass production.194 A limited number of clinical tests with dendrimers 
have been completed with the most prominent treatment being OP-101. OP-101 is a N-acetyl 
cysteine covalently coupled to a dendrimer that has been found to localize to neuroinflamed 
regions of the brain for the treatment of X-linked adrenoleukodystrophy.203 OP-101 has completed 
Phase I tests and there is now an active Phase II study in COVID-19 patients.204 The feasibility of 
mass-producing photoactivatable dendrimers should be considered before selecting this carrier. 
Further, since products are commonly a mixture of branched species, the FDA may require more 
extensive safety analysis. 
 
 Potential Indications  
Of the discussed polymeric carriers only polymeric NPs and polymer-drug conjugates 
have achieved FDA approval by improving the circulation, drug delivery, and clearance of 
biomacromolecules and cytotoxic therapeutics.194 NPs gather in the vasculature of tumors due to 
the EPR effect, which causes smaller nanomaterials to accumulate in the leaky tumor 
vasculature.32 This passive targeting initially catapulted NPs into the clinic as potential 
chemotherapeutic DDSs with improved PK in cancer tissue. Since then, NPs conjugated with 
antibodies or coated with targeting ligands have been developed and tested in the clinic as a 
means of active targeting and further improving biodistribution and PK.205 NPs can be extensively 
modified and have been conjugated successfully with a multitude of drugs and peptides. Thus, 
NPs are employed for indications ranging from rare diseases to cancer and have thus far been 





clearance which may have contributed to the greater success of liposomes (discussed below).206, 
207 However, NPs still offer an opportunity to manipulate the PK for therapeutic targeting and 
delivery, while avoiding challenges in therapeutic release that other carriers may face. Although 
many micelles have been clinically tested none have yet to receive FDA approval due to the 
instability previously mentioned. Similarly, dendrimers face challenges with their complex 
synthesis and variability. 
 
Hydrogels  
Hydrogels are hydrophilic or amphiphilic polymers that swell upon absorbing water, have 
high loading capacities, enhanced stability, and mimic tissue in water content and malleability. 
The FDA has approved over 30 injectable hydrogels products and there are over 400 clinical trials 
involving hydrogel materials. Hydrogels are available as topical applications, coils, or bulk 
materials. Examples include topical application to burn wounds, coils in the treatment of 
aneurisms, and bulk materials for tissue augmentation or regeneration. Hydrogels are commonly 
composed of natural polypeptides and saccharides or synthetic polymer chains. In general, there 
are more FDA approved naturally derived hydrogels than synthetic hydrogels, likely due to 
differences in biocompatibility. Although, the current clinical landscape is more thoroughly 
reviewed elsewhere some prime examples of successful hydrogels include: dermal fillers in facial 
correction aesthetics with delivery of lidocaine, subcutaneous hormonal therapy for testosterone 
dependent prostate cancer that relies on an implantable diffusion controlled reservoir, spinal 
applications as scaffolds for bone growth, advanced heart failure treatments, treatments for 
urinary disorders, and PEG-based hydrogels for image-guided soft tissue alignment.208 Hydrogels 
are ideal delivery vehicles for proteins and other fragile biological cargo.83, 209 Challenges 





and regulatory approval due to their classification as devices.208 Photoactivatable therapeutics 
that require localized delivery may benefit from hydrogel carriers. 
 
Potential Indications 
PEGylated NPs and hydrogels are a prime choice for protein therapeutic delivery. Many 
stimuli-responsive protein DDSs are under development to enhance both the PK/ PD of proteins 
and enable spatiotemporal delivery. These systems have been tested with vasopressin, VEGF, 
and insulin for applications in cardiovascular indications and in diabetes. Undeniably, diabetes 
affects a widespread and growing population of patients that require continuous insulin injections. 
Development of stimulated, such as light or glucose-responsive, long-term insulin reservoirs may 
begin to address the unmet and growing medical need of insulin administration.175 Although, many 
systems are in early stages of development, the expansive clinical approval of both hydrogels 
and PEGylated NPs may be a positive indicator for photoactivatable protein therapeutics.  
Since there are many clinically approved hydrogels, further harnessing the already 
existing applications of hydrogels for improving therapeutic delivery with spatiotemporal control 
may be a promising method to translate photoactivatable therapies into the clinic. For example, 
the process of tissue regeneration is extremely complex and may be suited for temporally 
controlled, orthogonally delivered photoactivatable therapies. Further, hydrogels can be topically 
applied to joints and injected into subdermal tissue which may improve dermatological therapies 










Red Blood Cells (RBCs) 
Although RBC therapeutics, outside of transfusions, have not yet gained FDA approval, 
they have been successfully tested up to Phase III clinical trials by multiple companies for the 
delivery of Dex 21-phosphate, asparaginase, thymidine phosphorylase, and RTX-134. 
Specifically, Dex 21-phosphate is a pro-drug that undergoes dephosphorylation by RBC enzymes, 
which then allows the parent drug Dex to escape the RBC over a period of a month. This slow-
release system has been tested in multiple indications including irritable bowel disease, Crohn’s 
disease, cystic fibrosis, chronic obstructive pulmonary disorder, and ulcerative colitis, but has 
found significant success in ataxia telangiectasia. RBCs have also been employed as bioreactors 
for enzyme replacement therapy. Specifically, RBCs have successfully delivered thymidine 
phosphorylase for the rare mitochondrial neurogastrointestinal encephalomyopathy and 
phenylalanine ammonia lyase (PAL) for the treatment of phenylketonuria. Initial treatments with 
PAL in a PEGylated form resulted in adverse reactions and anaphylaxis, which were overcome 
by RBC delivery and sheltering of the enzyme. RBCs that can express PAL are now undergoing 
Phase I clinical trials.210 Surface loaded RBC therapeutics have also been under development for 
an extended amount of time but have yet to reach clinical trials.211, 212 
RBCs have many desirable characteristics as carriers. They have an extremely high 
loading capacity (RBCs have a volume of 85 - 91 mm3), they are easily obtained from patients 
with minimal negative impact, and transfusion of blood is a clinically established protocol.213 
Internally loaded RBCs that meet transfusion standards have been prepared by using the EryDex 
System and have gained FDA approval.210, 214 RBCs are ideal for targeting the reticuloendothelial 
system (RES) which clears damaged RBCs or any tissues that are heavily vascularized. RBCs 
are also ideal carriers as long-term drug depots, demonstrated by the slow-release therapeutics 






Potential Indications  
Since RBCs circulate in the blood stream and thus have been proposed to reach the 
central nervous system during a stroke or traumatic brain injury, penumbra of the myocardial 
infarction zone post ischemia, alveolar and airway compartments in pulmonary hypertension or 
acute lung injury, and other locations of vessel damage such as post-surgery as blood pools in 
these locations.192 Other ideal applications of RBCs are in blood related diseases, such as chronic 
anemia, sickle cell, blood-derived cancers, or cardiovascular diseases as these are most 
accessible to RBC carriers. Applications that already require common transfusions, including 
sickle cell anemia and beta-thalassemia, can overcome the feasibility challenges of asking 
patients to receive therapeutics via transfusion. RBCs are regularly captured and cleared by 
means of the RES, thus any therapeutic targets in this space may be ideal. Indications in these 
organs may include enzyme deficiencies, hepatic tumors, parasitic diseases, iron overload in 
thalassemic patients, and toxic agents.213 Dex RBCs and cytokine IL-1B with ceftriaxone in RBCs, 
reduced glutathione with antiretroviral drugs combined into RBCs, and RBCs modified with an 
insulin derived peptide are currently under in vivo development for rheumatoid arthritis, AIDS 
treatment, and Type I diabetes respectively.212 
Slow release RBC therapeutics are also under development that take advantage of 
passive diffusion, such as Dex 21-phosphate RBCs, and include antineoplastics, antiparasitics, 
vitamins, steroids, antibiotics, and cardiovascular drugs.213 While Dex 21-phosphate RBCs have 
improved outcomes in cystic fibrosis patients, bioreactor RBCs with L-asparaginase have also 
been tested in Phase I and II clinical trials for metabolic deprivation of acute lymphoblastic 
leukemia and pancreatic adenocarcinoma patients with minimal adverse effects.212 RBC 
bioreactors are commonly applied as replacement therapies for enzyme deficiencies, which can 
gather in the RES, circulate in the blood stream, or release enzymes upon hemolysis.213  RBC 





bioreactors in the blood, can affect blood clotting, require delivery to the endothelium, improve 
efficacy by long-term circulation and slow release, or affect the immune system.192  
 
Liposomes  
Liposomes are bilayer phospholipid carriers made up of native phosphatidylethanolamine, 
phosphatidylserine, phosphatidylcholine, phosphatidylglycerol lipids, and cholesterol which acts 
as a stabilizer. The type of lipids used, ratio of lipids, surface modifications, and cholesterol 
content affects the size, lamellarity, and surface properties of liposomes and allows for tuning the 
targeting ability and drug release rates. Liposomes can deliver both hydrophilic and hydrophobic 
drugs carried in the aqueous core and lipid bilayer respectively. However, loading of therapeutics 
into liposomes can be challenging. Newly developed methods improve loading, including 
ammonium sulfate gradients that cause weak base drugs to precipitate within the core of the 
liposome. Liposomes are quickly cleared due to plasma proteins opsonization and resulting 
recognition and clearance by the liver and spleen. However, PEGylation of liposomes has 
dramatically increased their circulation times. Further, the extent of PEGylation allows for tuning 
the circulatory half-life.194 
Liposomes have been extremely successful in reaching the clinic and attaining FDA 
approval due to their ability to carry hydrophobic therapeutics and shelter cytotoxic drugs. 
Liposomes have found the most success with cytotoxic therapies by diminishing toxicity to 
improve the TI.215 Thus, the majority of clinical liposomes are cancer treatments as well as 
treatments for infectious diseases, with a few liposomes achieving approval as analgesics. Doxil 
was the first liposome (carrying Doxorubicin) to achieve FDA approval in 1995. Since then, 
AmBisome (carrying Amphotericin B), DaunoXome (liposomal daunorubicin), DepoCyt (liposomal 
cytarabine/ Ara-C), Mariqibo (liposomal vincristine sulfate), Onivyde (carrying irinotecan), 





daunorubicin and cytarabine) among others have all achieved FDA approval.150, 200, 215, 216 
Liposomal systems have been also employed as carriers of hydrophilic PDT therapeutic Visudyne 
for AMD and tested with zinc Pc clinically before being abandoned.12 Examples of liposome 
systems still under development include Arikace (encapsulated Amikacin), and actively targeted 
MM-302, MBP-426, and SGT53 therapy for the targeted delivery of Oxaliplatin. ThermoDox is 
one of the first thermosensitive liposomes to reach Phase III trials for cancer treatment.194 
ThermoDox’s initial clinical success sets a precedent for photoactivatable liposomes. Further, the 
general improvement to safety liposomes provide may be useful for multi-layered improvements 
of safety in conjunction with photoactivatable therapeutics. Liposomes may also be a means of 
sheltering photoactivatable therapeutics from dark activation and be a means of combinatorial 
therapeutic release as demonstrated by Vyxeos. 
 
Potential Indications 
Similar to PEGylated NPs, liposomes can improve the circulation, drug delivery, and 
clearance of biomacromolecules and cytotoxic therapeutics.194 Liposomes also collect near 
tumors due to the EPR effect.32 Although, this may improve therapeutic delivery to tumors 
surrounded by vasculature it may have minimal effect on hypoxic tumors. Thus, liposomes may 
be ideal for PACT applications as demonstrated by the multitude of cancer liposomal therapies 
currently approved. Other applications include enhancing the safety of antifungals and antibiotics.  
Beyond re-purposing suboptimal therapeutics, novel applications of liposomes include 
improving the distribution of PSs, localizing release of PDT by means of ROS sensitive 
unsaturated phospholipids incorporated within liposomes, and combination treatments of PDT 
and immunotherapy. Similarly, liposomes can improve the biodistribution of photoactivatable 
therapeutics, target release in a multi-layered manner (especially with cyanine PPGs that produce 





research for CRISPR delivery by combining liposomes with gold NPs for targeted gene therapy. 
The gold NPs induce photothermal effects which subsequently cause breakdown of the liposome 
and release of internal contents.150 Photoactivatable therapeutics may be another means by which 
gene therapies could be locally targeted from within liposomes. 
 
1.5.5.2 Considering Carriers for Photoactivatable Therapeutics 
With the precedent of stimuli responsive carriers, including micellar and liposomal PDT 
and thermally responsive liposomes and inorganic NPs now in clinical trials, carriers offer 
immense potential to support the translation of photoactivatable DDSs. Carriers can shelter 
photoactivatable therapeutics from dark activation, modify their ADME, as well as provide other 
novel benefits discussed in 1.5.5.3. Carriers may be the perfect solution to avoid dark activation 
as liposomal carriers have already proven to improve the PK and PD of cytotoxic systems and 
hydrophobic photoresponsive moieties (as demonstrated with PDT hydrophobic systems).12, 215 
Carriers, however, can not only shelter the photoactivatable system, but also improve its 
circulation and clearance half-lives and localization by providing an additional layer of tunability 
with surfaces that can be PEGylated to improve circulation and to which targeting agents can be 
appended to.32, 192 Carriers can also deliver high quantities of therapeutic.10 These considerations 
will be discussed in greater depth below. 
Both photogated DDSs as well as PPGs and photoswitches encapsulated within non-
stimuli responsive carriers exist. Because photogated DDSs have not yet achieved clinical 
approval and face similar challenges as their foundational carrier, the discussion below will focus 
on carriers that photoactivatable therapeutics can be encapsulated within that have achieved 
clinical approval. These considerations can then be expanded to the photogated systems which 








Most carriers, including liposomes, micelles, polymeric NPs and internally loaded RBCs, 
are injected intravenously as these carriers inefficiently permeate across the gastrointestinal wall 
during oral delivery.186 Hydrogels, on the other hand, are usually injected into the targeted tissue, 
but require the appropriate viscosity for successful injection.208 Other DDSs can also be directly 
injected, but are expected to be quickly cleared.186 Thus, intravenous injection remains the 
mainstay of all systems (except for hydrogels). The administration method should be considered 
in the benefits and risks analysis of selecting a carrier. As previously discussed, orally available 
therapeutics improve opportunities for personalized medicine and decrease costs among other 
benefits.185  
 
Distribution and Targeting 
Passive and active targeting dictates carrier distribution. In general, most carriers are 
retained within the vascular space, clearance organs, and tumors due to their inability to pass 
between endothelial pores of other tissue. Specifically, carrier sizes over 200 nm concentrate in 
the liver, sizes over 400 nm in the spleen, while those less than 10 nm are cleared by the kidney. 
Polymeric micelles of sizes 50 - 100 nm and liposomes of sizes 100 - 200 nm are considered 
ideal for maximal blood concentrations and minimal RES clearance.186, 201, 218 Tumors often have 
enhanced permeability due to immature chaotically branched vasculature which causes the EPR 
effect and passively targets liposomes and NPs to this tissue. Thus, the manipulation of 
nanomaterial size is crucial to manipulate biodistribution via passive targeting.  
However, distribution is dependent on more than just size. For micelles, liposomes, and 
NPs the distribution also depends on morphology, composition, and mechanical properties. NPs, 





longer periods of time. Similarly, NPs covered in hydrogels to improve flexibility circulated for 
longer periods of time while “hard” NPs concentrate in macrophages, endothelia, and tumors.186  
It is important to note, the majority of carriers are produced as mixtures and these properties 
(including size) vary within that mixture.201 This variability is partially why the FDA is so resistant 
against mixtures, as uncertainty surrounds whether the mixture can produce consistent, 
reproducible safety and efficacy.  
The accumulation of nanomaterials by passive targeting can improve the PK of therapeutic 
release as the high quantity of concentrated drug within the nanomaterial passively accumulates 
in the target location. Active targeting by a light source can then further improve the PK as a large 
burst of therapeutic is released during localized illumination. Layering other active targeting 
agents, such as antibodies, peptides, and small molecules, on these DDSs can further improve 
distribution within tissue.10, 186 Although maximizing the coating density of the targeting agent is 
generally ideal, caveats include how the density affects extravasation through the endothelium 
and how widely the target is expressed throughout tissue. A phenomenon known as the “binding 
site barrier” affects uniform diffusion of high affinity ADCs through targeted tissue and can be 
overcome by optimal dosing and lowering antibody affinity.219 Other nuances of targeting agents 
include the potential of immunogenicity as full antibodies are known to generate an immune 
response. Employing antibody fragments instead can minimize the immune response and 
immune mediated clearance.186 There are many more caveats to active targeting agents not 
covered in this paragraph that should be considered when developing these multi-layered 
targeted DDSs.219 
RBCs and hydrogels pose more limited means of targeting distribution. Unless focusing 
on clearance organs, RBCs are retained within the vasculature for extended circulatory periods. 
However, this systemic distribution may be ideal for reaching tissues and organs that are less 





are targeted during administration, but as the hydrogel is cleared any attached therapeutics will 
also be systemically cleared. 
 
Metabolism and Therapeutic Release 
One of the main advantages of a carrier is their ability to shelter the photoactivatable 
therapeutic until activation by light. The main concern, however, is to ensure the photoreleased 
therapeutic can still exit the carrier and affect the targeted site. Thus, it is important to consider 
and design means of therapeutic escape with appropriate kinetics of release from the carrier to 
the targeted tissue.200, 217  For example, Doxil has enhanced tumor accumulation, but doxorubicin 
release from the liposomes is less than ideal and diminishes the potential efficacy.218 Out of the 
discussed classes of photoresponsive moieties, PPG’s may face the least therapeutic release 
issues as they can modify therapeutic polarity to anchor therapeutics within the carrier, as 
demonstrated by internally loaded Cbl RBCs.72 Photoswitches, on the other hand, may need to 
rely on cellular uptake and breakdown of carriers. This approach would still be feasible if the 
photoswitch is minimally active in its “off state” and would consequently have a minimal effect on 
non-target cells that uptake the photoswitch.  
Liposomes and micelles release therapeutic by drug leakage over time or carrier 
breakdown during RES clearance. Further, micelles require a specific concentration to maintain 
their assembly, otherwise they entirely disassemble or undergo changes in size and morphology 
at lower concentrations.201 The PK of therapeutic within these carriers is therefore affected by 
multiple states: free therapeutic in the plasma and therapeutic still within carriers. Current 
liposomal therapeutics take advantage of the breakdown of liposomes as well as endocytosis into 
cells to generate a unique drug specific release profile.150 4, 194 This release profile is dependent 
on many factors including the stability of the lipid bilayer and the encapsulated therapeutic. 





profile from metabolism and breakdown of the liposome does not inhibit the targeting potential of 
the photoresponsive therapy. For this reason, photogated systems that induce the breakdown of 
liposomes by affecting the hydrophilic and hydrophobic balance may be beneficial.4  
NPs, on the other hand, must either interstitially release drug or be internalized by cellular 
phagocytosis or pinocytosis to induce pharmacological effects.218 Although there are many 
complexities to NP uptake, including what organelles (such as lysosomes) the NP encounters, 
surface modifications (such as folate acid) can improve cellular uptake to tumor cells.221 Similar 
to liposomes and micelles, photogated systems that release therapeutic from NP carriers upon 
illumination may minimize the necessity for cellular uptake. 
While cellular uptake of liposomes and polymeric NPs is based on passive and active 
targeting, RBC targeting will require careful PK consideration to ensure therapeutic quickly 
reaches the targeted tissue before not only diffusing away, but also being carried away by 
circulation. Although more resolution is required, initial in vivo tests have demonstrated localized 
therapeutic release at the target tissue after illumination.72 
 
Excretion/ Clearance 
Not only can carriers protect photoactivatable therapeutics from dark activation, but they 
can also protect biological macromolecules from early clearance.175 The majority of carriers, 
including liposomes and NPs, are cleared by the liver and spleen. Other components of the RES 
can also support clearance including bone marrow and lungs. Opsonization of carriers by serum 
proteins can help enhance recognition by these tissues. For this reason, PEGylation and other 
surface modifications can help carriers be “stealthier” as confirmed with liposomal carriers.186  
Initially, liposomes were found to localize extensively to the spleen and liver due to their extremely 
fast clearance. However, PEGylation helped diminish the clearance rates of liposomes.194 





However, PEGylation has been noted to induce an immune reaction after chronic injections and 
to affect carrier stability, cellular uptake, and drug release. Thus, PEGylation must be optimized 
in both molecular weight and amount used.218  
Previously mentioned carrier properties, including size and shape, influence their 
distribution as well as their clearance. Neutral to cationic surface charges improve circulation and 
minimize clearance for NPs and liposomes respectively.194, 215 However, extended circulation is 
not always beneficial for photoactivatable therapeutics. Depending on the therapeutic cargo, long 
term circulation of a highly photoresponsive cytotoxic phototherapeutic may induce phototoxicity 
similar to the PSs Photofrin and Tookad.12, 212 Fortunately, the degree of PEGylation can be tuned 
to modify the rate of clearance.194, 215 Different clearance rates may need to be tested in animal 
models to assess the ideal treatment efficacy.  
As previously discussed, inorganic NPs can be minimally biocompatible and thus very 
quickly cleared, which PEGylation can counter to a degree.194 However, clearance rates can vary 
based on the patient’s RES activity. Thus, personalized treatment taking into account patient RES 




Whenever incorporating a new component to any therapeutic system, ensuring safety is 
paramount. As mentioned throughout the considerations above, many nanomaterials have 
demonstrated safety concerns. Inorganic NPs most prominently have demonstrated the potential 
for inherent toxicity due to their composition of heavy metals. Antibody targeting techniques as 
well as PEGylation have demonstrated potential concerns for immunogenicity.218 Similarly, 
liposomes composed of synthetic lipids with high cationic charges have also demonstrated risk of 





polymers have been preferred and approved for polymeric NPs and hydrogels due to potential 
biocompatibility and safety.208 In general, carriers are cleared by the RES in high quantities, which 
could pose a risk for liver and spleen toxicity due to high concentrations. Further, as previously 
noted when selecting a therapeutic (section 1.5.2), the therapeutic carried by the photoactivatable 
DDS will modify the risk posed by these inherent clearance mechanisms.  
 
Feasibility Considerations: Manufacturing, Storage, and FDA Approval 
Synthetic Nanomaterials 
During early development, synthetic materials (including liposomes, micelles, hydrogels, 
and polymeric NPs) faced challenges with synthesis and therapeutic preparation. However, 
advancements in synthetic processes, loading processes, and growth of FDA approved carriers 
have improved ease of synthesis and the compatibility of carriers with a variety of drugs.194 
Although hydrogels have wide-spread clinical applications and approval, manufacturing and 
storage of hydrogels still remains very costly as they face challenges with sterilization due to their 
high water content.208 Liposomes and micelles also face challenges with long-term storage 
stability as both are known to leak as their membranes permeabilize over time.150 Cryoprotectants, 
such as dextrose, sucrose, and trehalose, have been incorporated into the storage solutions as 
stabilizers.150 However, these stabilizers provide another product that requires manufacturing, 
optimization, and safety testing.  
Although liposomes, polymeric NPs, and hydrogels have achieved FDA approval with 
multiple therapeutics, micelles have yet to achieve regulatory approval. In general, the FDA 
maintains strict regulation over the pharmaceutically active species and excipients, which need 
to be thoroughly characterized and uniformly produced to ensure reproducible safety. Synthetic 
nanomaterials have faced challenges in uniformizing carrier production and thus have required 





that although properties of individual batches may vary, products are in general the same and will 
produce the same in vivo effect. Micelles still face further challenges due to their varied properties 
and inherent instability both ex vivo and within physiological environments, making consistent 
results more challenging to achieve. Conversely, inorganic NPs can be more easily prepared. 
However, long-term circulation of metal-containing NPs is considered a high risk of potential 
toxicity.195 Thus, clearance of these systems needs to occur within a reasonable time frame for 
FDA approval. Table 1-8 provides an overview of the preclinical considerations specific to NPs, 
but these considerations can be expanded to all synthetic nanomaterials.  
The regulatory classification of carriers can also affect their development requirements 
and delay clinical translation. Carriers are commonly considered new medicinal products, even if 
they incorporate existing drugs, as was the case for Doxil, Abraxane, and Vyxeos.201 Thus, 
introducing a carrier requires the same degree of development as any other novel therapeutic, 
regardless of the therapeutic cargo. Uniquely, hydrogels are considered devices as they do not 
achieve an effect by chemical action. Thus, hydrogels that carry therapeutics have been termed 
combination products which typically require 7 - 10 years of negotiations and compliance testing 
before approval.208 Thoroughly understanding the limitations and scope of development required 
for introducing a carrier to a photoactivatable therapeutic will help weigh benefits and risks 






















Red Blood Cells (RBCs) 
Internally loaded RBCs are currently being tested by autologous administration in patients 
using the ERYcaps and Red Cell Loader devices. These autologously administered RBCs have 
exhibited a 24 h survival of at least 75% of loaded RBCs in patients, a half-life of ~28 days which 
is comparable to non-modified RBCs, and an encapsulation rate of ~30%.222 In general, RBCs 
have to be transfused pretty quickly upon preparation due to the quick rise in storage lesions, 
unless targeting the RES.212, 220 The complex process of loading RBCs and the exacerbation of 
storage lesions pose challenges to adopting stored RBCs as a treatment method. Internally 
loading therapeutics into RBCs also can face challenges as certain therapeutics have been found 
to make RBCs undergo eryptosis.220  
Fortunately, RBCs are easily accessed from patients with minimal negative impact.212 
However, the unique, complex loading process that requires blood collection, loading, and 
transfusion will be expensive which may slow widespread adoption.212 These modified RBCs also 
need to be thoroughly characterized throughout the development process further increasing costs. 
The final manufacturing process should change RBC in vitro properties (including membrane 
plasticity, mean cell volume, percent cell recovery, percent hemoglobin content, etc.) by less than 
20%.213, 222 In vivo tests of transfusion can be conducted on mice, cattle, pigs, dogs, sheep, goats, 
and monkeys.213 However, by ensuring comparable qualities of internally loaded RBCs to 
transfused RBCs, the regulatory testing required can be minimized. For example, FDA regulation 
has allowed the ERYcaps system to classify their internally loaded RBCs as comparable to 
transfusable RBCs.212  
RBCs are regulated by the Center for Biologics Evaluation and Research and blood banks 
are considered “manufacturers” of drugs as they process RBCs for transfusions.192 Adoption of 
the ERYcaps or other loading systems into hospital blood banks may help expedite application of 





met by blood banks. However, costs associated with maintaining the sterility of the loading 
environment and process, required immediacy of the loading and administration process, and 
additional costs of the loading devices may be inhibitory to the feasible application of loaded RBC 
therapeutics. 
 
1.5.5.3 Novel Benefits of Carrier-Based Photoactivatable DDSs 
Photoactivatable therapeutics are poised to provide a novel method of therapeutic delivery 
and personalized medicine. Specifically, long-term circulation of therapeutics may provide a 
photoresponsive therapeutic depot that could be released by NIR handheld patient-owned 
devices.8 RBCs and liposomes provide the potential for long-term circulation and accessibility at 
superficial tissue for treatment of dermatological and joint-based problems. Hydrogels also 
provide a means for long-term slow release with bursts of light-directed release. As has been 
demonstrated with facial applications of hydrogels, hydrogels can take 1 - 2 years to be completely 
absorbed.208 Applications of such long-term hydrogels may include light-directed analgesics for 
post-surgical or spinal applications. Longer circulating carriers are also being developed with 
enzyme cargo to act as bioreactors, such as RBCs carrying L-asparignase.222 In general, carrier-
based bioreactors are ideal for acting within the blood. Although potentially facing clearance 
issues, photogated DASA polymersomes are also under development as photogated bioreactors 
that can be turned on and off.133 The unique combination of photoresponsive therapy with drug or 
bioreactor depots can be an innovative solution to chronic unmet clinical needs and support 
patient-directed treatment. 
As mentioned previously, multiple layers of targeting may be required to maximize the TI, 
especially of cytotoxic therapeutics as each targeting method incorporates its own limitations. For 
example, the development of ThermoDox which both passively targets the tumor by EPR and 





doxorubicin delivery to tumors. Inorganic NPs also passively target different tissues, such as 
SPIONs which localize to the pancreas  during the onset of type 1 diabetes and are thus under 
investigation for imaging and diagnosis applications.199 Thus, carriers can enhance targeting by 
contributing their inherent passive targeting to photoactivatable therapeutics which rely on light-
activated targeting. 
Similarly, carriers that are both photoactivatable as well as have other methods of active 
targeting, such as heat as previously established by ThermoDox or magnetism by incorporation 
of SPIONs, may further tune targeting and therapeutic release. Magnetic targeting by 
incorporating SPIONs into liposomes or carbon particles has also reached clinical testing for 
cancer applications.217, 223 Other stimuli-responsive systems under pre-clinical development 
include pH, electrical, and ultrasound as presented in Table 1-1.4, 10, 175 Specifically, 
photoactivatable cyanine pH-responsive micelles have demonstrated promising enhanced 
localization in vivo.86 Although, it may be some time before multi-stimuli responsive carriers are 
ready for development and translation, the potential enhancements they could provide to the TI 
may be worth the wait.  
Magnetically targeted systems have the additional benefit of theranostic drug delivery as 
SPIONS can be detected by MRI.217 Providing theranostic capabilities may accelerate translation 
with strong proof of concept results as well as develop another opportunity for personalized 
medicine. Theranostic systems currently under pre-clinical development that could take 
advantage of multi-stimuli systems and photoresponsive moieties include photoacoustic imaging, 
surface enhanced Raman scattering, optical coherence tomography, luminescence imaging, and 
Cerenkov radiation techniques.209 Other more clinically accepted imaging techniques include 
fluorescent imaging, computed tomography, MRI, and positron emission tomography.209, 224 
As previously discussed, carriers provide a means of delivering not only high quantities of 





orthogonal wavelengths. As more photoresponsive moieties are developed, therapeutic delivery 
may become so finely tunable that specific therapeutics could be delivered from carriers by 
activation with unique wavelengths. Vyxeos liposomes have already demonstrated the potential 
for combinatorial therapeutic delivery.150 Orthogonally responsive Cbl photoactivatable 
therapeutics and DASA photogated carriers are also under development.105, 133 Delivering multiple 
drugs orthogonally (dependent on the wavelength of excitation) may be useful for diseases which 
already require combinatorial treatments, including cancer and cardiovascular diseases, among 
others. 
 
1.5.6 The Photoactivatable Therapeutic: Developing New Treatments and 
Improving Existing Therapeutics 
As referenced throughout this Chapter, photoactivatable therapeutics provide an 
opportunity for active targeting of therapeutic delivery with improved spatial and temporal control. 
Since photon absorption can lead to both therapeutic release and fluorescence, photoactivatable 
therapeutics can also improve personalized medicine by monitoring therapeutic delivery location 
and dosage with theranostic applications. Further, photoactivatable therapeutics encased in long-
term drug depots create opportunities for patient-controlled therapeutic release. Due to the 
multitude of applications and potential unmet needs photoactivatable therapeutics can address, 
section 1.5.6.1 will describe the path that has been developed thus far to successfully translate 
photoactivatable therapeutics and what steps remain. Section 1.5.6.2 will then clearly define the 






1.5.6.1 Illuminating the Path to Clinical Trials for Photoactivatable Therapeutics: 
Current Progress and Future Steps 
Many photoactivatable therapeutics have progressed into in vivo studies. However, as 
compared to other established fields of therapeutic development, the number of in vivo studies 
underway are still limited. As photoactivatable DDSs begin to prepare to transition into the clinic, 
the approach needs to transition from development of novel photoresponsive moieties toward 
assessing and optimizing a photoactivatable therapeutic’s ability to address the unmet clinical 
need.157 This section aims to provide a path by which researchers have begun to prepare 
photoactivatable therapies for clinical trials and targeting unmet clinical needs (Figure 1.12). 
 
Stage 1: In vitro Characterization and Optimization 
Photophysical Properties and Stability 
As introduced in section 1.3.1 and further emphasized in 1.5.3, ideal photophysical 
properties (Φ, lmax, and e) are crucial for the success of photoactivatable therapeutics. Specifically, 
these properties support enhancing therapeutic release in response to potentially limited light 
penetration. Many groups have approached optimization of these properties by high throughput 
or rational design methods.182 Photoresponsive moieties that have been thoroughly investigated 
and optimized provide structure-function understanding to accelerate adaptation of 
photoresponsive moieties to novel therapeutic cargo. Taking advantage of such precedent may 
then accelerate clinical translation.  
Notably, cyanine PPGs have been thoroughly investigated as photoresponsive moieties 
and successfully optimized for efficient and fast photorelease.69, 98 Lead ADC-cyanine-
duocarmycins were initially modified from a first-generation scaffold to adjust the sensitivity of the 
photoresponsive linker in the dark and to improve the photoresponsive wavelength. Synthetic 





Rational design approaches resulted in to two lead compounds for in vivo testing. Similarly, 
rational design techniques were employed to merge CO-releasing flavanol to a heptamethine 
cyanine photoresponsive moiety and to improve solubility.67 Precedent with cyanines may have 
made both approaches easier and more efficient.98   
BODIPY groups have been similarly investigated and derivatized for both PDT and PPG 
applications. BODIPY based photoactivatable CO releasing molecules (photoCORMs) have been 
successfully developed by means of computational screening followed by structure-activity 
relationships of BODIPY with a carboxy substituent for CO release. Optimization included shifting 
toward long wavelength responsivity and improving photophysical properties. Additionally, an 
inactive control was developed to understand the mechanism of release, as well as to provide a 
control for further studies.64 This development process may have also relied on the precedent of 
BODIPY scaffolds for rational design development.19, 92, 93, 182  
By relying on established synthetic methods (such as high throughput testing, rational 
design, and computational methods), as well as literary precedent, improved photophysical 
properties and solubility may be efficiently achieved. Quick, efficient tests for photophysical 
properties such as kinetics, Φ, and dark activation will also help minimize unintended dark activity 
and improve long-term stability.69 Further, development of an inactive control during optimization 
can improve mechanistic understanding as well as accelerate pre-clinical characterization.  
 
Irradiation Dose 
Oftentimes, studies of Φ and other photophysical properties will result in in vitro 
assessment of the required irradiation dose for photorelease. Of course, in vitro assessments will 
not truly mimic in vivo conditions. However, assays have been developed to begin to mimic in 





In vitro development of ADC-cyanine-duocarmycin conjugates included testing a variety 
of irradiation doses in cellular efficacy assays (Figure 1.14). This assay ensures that under ideal 
in vitro conditions a sufficient irradiation and therapeutic dose (100 pM for duocarmycin-ADCs) 
achieves efficacy.69 Undeniably, if ideal therapeutic efficacy is not achieved at irradiation doses 
and therapeutic concentrations under in vitro conditions, then surely in vivo efficacy will be further 






                         
 
Figure 1.14 In vitro optimization of irradiation dose. a) Absorbance spectra of the two lead 
compounds (16, 17) and the two tested irradiation wavelengths (690, 780 nm). b) Cell viability 
under control conditions (vehicle, free duocarmycin, and lead compounds in the dark). c) and 
d) Viability of cells exposed to 100 pM of each lead compound and a range of light doses at the 













In vitro assays can also be conducted that account for light scattering and absorption that 
occurs through tissue. The development of Cy5-Cbl-Dex RBCs included testing of both Cy5-Cbl-
Dex in solution as well as from within RBCs with Fitzpatrick tissue phantoms (Figure 1.15). 
Fitzpatrick tissue phantoms mimic the light absorption and scattering properties of tissue by 
passing light through solutions of mixed lysed RBCs lipids, hemoglobin, and varying amounts of 
melanin to mimic a variety of skin types (pale-dark, types I-VI).84 Cy5-Cbl-Dex was successfully 
photolyzed through all tissue phantoms with a minimal lamp power of 1 mW/cm2 for 3 min.73 Such 
efficient photoresponsivity is promising for in vivo studies as these studies expectedly will require 













Figure 1.15 Photolysis of Cy5-Cbl-Dex in a PBS solution (left) or from within RBCs (right). 

















In vitro assays provide the opportunity to assess light doses for further in vivo studies. 
Similar to how PK studies contribute to selecting Phase I doses, so too can in vitro assessments 
optimize ideal doses of both therapeutic and light for in vivo experiments. Often, animal disease 
models can be costly, time consuming, and logistically challenging, especially with 
photoresponsive species as animal facilities commonly employ extremely bright lights to regulate 
animal sleep cycles. Thus, quick in vitro assays such as cellular efficacy tests and Fitzpatrick 
series of photorelease can help provide minimum light doses required for in vivo studies. 
 
Toxicity and Efficacy 
In general, toxicity and efficacy studies are required for both in vitro and in vivo tests and 
will often be included in the pharmacology and safety sections of the IND. However, not only does 
the photoactivatable DDS need to be tested for toxicity, but also the photoproducts should be 
individually tested for toxicity. The development of the previously discussed cyanine photoCORMs 
included cellular assays to measure toxicity of the CO photoproduct as well as the cyanine 
photoproducts towards a hepatoblastoma cell line.67 Photoproducts were tested by illuminating 
the cyanine photoCORM alone and adding the resulting mixture to hepatoblastoma cells. 
Presumably, CO is not concentrated in the illuminated mixture as it can transition into a gaseous 
state, thus addition of the resulting mixture only tests the remaining photoproducts. Promisingly, 
the photoproducts demonstrated no toxicity up to 200 mM, while the irradiated photoCORM in the 
presence of cells exhibited cytotoxic effects from concentrations of 100 mM.67 Although, the 
presence of CO did improve the intended cytotoxicity by 2-fold, the high concentration required 
may be unfeasible under physiological conditions, especially with the inherent risk high doses of 
CO pose to patients. 
Ideally, toxicity studies should also be conducted on normal cells that surround the desired 





on both cervical cancer cells and normal liver cells in vitro (Figure 1.16). Minimal cytotoxicity was 
observed on both cell lines without irradiation. Nonetheless, illuminated camptothecin was 
cytotoxic to both normal and cancer cells, as is expected of generically cytotoxic therapies. 
Further, the uptake of the PPG by both cell lines was measured using flow cytometry. Although 
uptake did increase as exposure time increased, the rate of endocytosis was slower for normal 
cells than cancer cells, potentially due to the biotin targeting agent. However, the targeted uptake 
(reaching a 6-fold difference after 30 min of exposure) and minimal dark activation does establish 
promise for in vivo studies.68 Of course, in vitro cellular studies have extended exposure to 
therapeutic, which does not always occur physiologically due to additional kinetic rates of 











Figure 1.16 Cytotoxicity of cyanine-camptothecin-biotin PACT to cancer (SMMC-7721) 
and healthy (QSG-7701) cells. a) Cell viability of a range of cyanine-camptothecin-biotin doses 
(mM) with (+) and without (-) 20 mW/cm2 680 nm illumination. b) Flow cytometry quantification 
of cellular endocytosis over time. Cancer cells (left) show increased rates of PACT uptake than 











Another way to ensure that the photoproducts and the photoresponsive moiety have a 
minimal toxic effect is by measuring the toxicity and efficacy of the active photoactivatable 
therapeutic as compared to an inactive scaffold control. Cy5-Cbl-Dex RBCs were tested for both 
efficacy and toxicity towards target primary fibroblast-like synoviocyte (FLS) cells and compared 
to the inactive control Cy5-Cbl-H2O RBCs. FLS cells are one of the most important mediators of 
inflammation in inflammatory arthritis.225 FLSs demonstrate clear localization of glucocorticoid 
receptor a (GRa; a crucial inflammatory mediator within FLS and other cells and a 
pharmacological target of Dex) to the nucleus. Treatment with inactive control Cy5-Cbl-H2O RBCs 
had comparable localization effects to no treatment controls, while treatment with Cy5-Cbl-Dex 
RBCs localized GRa comparably to conventional Dex treatment (Figure 1.17a). Further, Cy5-
Cbl-Dex RBCs displayed similar toxicity as conventional Dex to FLS and Dex-sensitive Sup-B15 
B cells. Specifically, Dex is minimally cytotoxic to FLS cells but is notably cytotoxic to Sup-B15 
cells, properties successfully reproduced with the photoactivatable DDS. Control Cy5-Cbl-H2O 
RBCs had no significant effect on GRa localization or cell viability of FLS or Dex-sensitive B cells 
(Figure 1.17b).73 
The described assays and applications demonstrate the significance of the in vitro 
validation of the photoactivatable system. PhotoCORM testing not only confirmed the safety of 
the photoresponsive moiety, but also highlighted the concerns of high therapeutic doses for 
efficacy. Assessments of uptake in vitro also began to indicate potential dark activity as well as 
targeting efficiency. Comparison to standard of care and inactive controls helps quantify the risks 
and benefits of a photoactivatable DDS. Further assessments on normal cell lines may provide 








Figure 1.17 Assessing safety of photoresponsive moiety and photoproducts with 
inactive controls. a) Immunocytochemical analysis of GRa localization in FLS cells. Inactive 
control Cy5-Cbl-H2O RBCs localize GRa comparably to no treatment. Only illuminated Cy5-
Cbl-Dex RBCs localize GRa comparably to positive control Dex. b) Illuminated Cy5-Cbl-H2O 
RBCs have no toxic effect on inflammatory FLS cells or Dex-sensitive Sup-B15 B cells. Cy5-
Cbl-Dex RBCs are minimally toxic effect to FLS cells and potently toxic to Sup-B15 cells. (*P < 










In vitro Photoindex 
In vitro efficacy studies can also rigorously assess the photoindex of a photoactivatable 
therapeutic. The photoindex quantifies the ratio of dark activity to light activity and assesses the 
metabolic sensitivity of PPGs. For true comparison of light and dark efficacies it is important to 
use comparable light doses and therapeutic concentrations to the clinical standard of care. As 
previously mentioned, the photoswitch antibacterial Azo-Trimethoprim achieves a 7-fold 
photoindex.79 In general, photoswitches face challenges inactivating therapeutics and are thus 
more likely to encounter dark activity. 
More expansive studies of photoindex were completed with the Ru-Rigidin complex 
introduced in section 1.4. The complete complex, rigidin positive control, inactive scaffold control, 
and standard of care were tested in both 2D and 3D spheroid lung cancer models under normoxia 
and hypoxia. Inclusion of hypoxic models further mimicked potential physiological conditions of 
the target tumors. Further, a non-cancer cell line was included as an additional control. Positive, 
scaffold, and standard of care controls achieve photoindices between 0 and 2, while Ru-Rigidin 
attains photoindices from 4 to 29 in different 2D cell lines. Normoxic conditions improve 
photoindices up to 2.5-fold as compared to hypoxic conditions, potentially due to the mechanism 
of therapeutic release from Ru. 3D spheroids demonstrate more minimal photoindices of 1.6 to 
6.1.117 Due to the novelty of photoactivatable DDSs the required photoindex value for clinical 
translation is not yet known and as demonstrated varies significantly with cell line. Significantly, 
ADC-cyanine-duocarmycin successfully reaches photoindices of 580 in target cell lines to more 
than 3,900 in non-targeted cell lines.69 
Although many qualitative demonstrations of differences between light and dark activity 
have been performed, ideally this difference is tested in a quantitative fashion indicating a 
photoindex. The photoindex also should be assessed in the larger context of standard of care and 





dark activity of the photoactivatable therapeutic, the photoactivatable therapeutic may be 
expected to present similar systemic benefits and risks as the standard of care. However, if dark 
activity occurs at concentrations below the standard of care, the results could serve as in vitro 
validation of the potential for more targeted delivery as opposed to the standard of care. 
Photoindex also relates to the TI as the greater the difference between dark efficacy and light 
efficacy the more likely the photoactivatable therapeutic can minimize toxicity of cytotoxic 
therapeutics by localizing therapeutic effect. Of course, the ratio is a simplification as in vitro 
studies are not limited by concentrations tested, thus both 5 pM to 30 pM and 50 mM to 300 mM 
will have a resulting photoindex of 6. In some ways, this value may be an oversimplification of the 
required efficacy and the surrounding context, however demonstrating a difference between light 
and dark activity is crucial to photoactivatable DDSs. Due to the field’s nascency, rigorous 
photoindex tests are not yet widespread but may be crucial proof of principle data for INDs in the 
future. 
 
Stage 2: In vivo Characterization and Validation 
Proof of Principle: “Localized” light dependent release, a qualitative in vivo photoindex 
An in vivo photoindex can be attained by rigorous PK/PD studies. However, before 
completing such intensive studies, many researchers have performed more qualitative proof of 
principle validation with distal sites analyzed for comparison of “localized” therapeutic effect. 
These distal comparisons have included vascular effects measured in mice ears as well as 
xenografted tumors on both mouse flanks. 
Cbl loaded RBCs successfully localize release in irradiated ears as compared to the 
mouse’s non-irradiated “dark” ear. Docetaxel from Cbl-Docetaxel RBCs is successfully locally 
released upon illumination causing endothelial damage, which is not observed in the “dark” ear.72 





thrombin (Figure 1.18). Fibrinogen is only observed in the light activated ear as compared to the 
dark control.142 Of course, the two ears of a mouse are distal to each other, and thrombin effects 
could potentially be observed throughout the entire irradiated ear or further in the vasculature 
rather than only at the site of illumination. For such vasculature therapeutics, PK measures of 
blood concentrations may further quantify the photoindex. BODIPY based photoCORMs have 
employed such PK measures to assess the modest photoindex of 1.4 for CO levels in the blood.226 

















Figure 1.18 Localized in vivo effect of photogated Cbl thrombin RBCs. Mouse RBCs 
externally loaded with the photogating Cbl-blocking segment and melittin system and internally 
loaded with thrombin were injected intravenously into mice. Immediately after injection, the ear 
was illuminated with a 561 nm laser. The left column shows the non-illuminated ear, the center 
column the illuminated ear, and the right column shows the ear of a mouse that received buffer 
loaded RBCs. Hematoxylin and eosin staining on top shows congestion of illuminated 
vasculature (center), while bottom images stained with Martius Scarlet Blue dye (which labels 
collagen blue, RBCs yellow, and fibrin red) show fibrin formation in illuminated ear. Scale bar 







Distally xenografted tumors on mouse flanks have also served as controls for localized 
measures of efficacy in cancer models. For example, Ru-Rigidin treatment requires both 
illumination and the photoactivatable therapeutic to produce a therapeutic effect. Irradiation alone, 
the scaffold alone with and without light, and the photoactivatable therapeutic without light all had 
minimal effects on tumor growth. Only the illuminated flank with active photoactivatable treatment 
furnishes efficacy.117 The “dark” flank is then a control for excess released rigidin that may be 
circulating in the vasculature or dark activated rigidin. The model also provides more efficient use 
of animals, including more controls in the number of animals used. By employing a similar model, 
photoactivated release of therapeutic from BODIPY-NO theranostics was imaged (Figure 1.19). 
Enhanced therapeutic release is observed in the illuminated tumor. This enhanced therapeutic 







Figure 1.19 Photoactivated therapeutic release observed in irradiated tumors by 
photoacoustic imaging of theranostic BODIPY-NO (photoNOD-1). a) Scheme of 
photoNOD-1 injection and irradiation after 4 h of circulation for 5 min. Photoacoustic imaging 
occurred before and after irradiation. b) Photoacoustic images of light tumor and dark tumor 
before (top) and after irradiation (bottom). Higher intensity areas after irradiation signify 














Preliminary proof of principle studies have been crucial in establishing photoactivatable 
therapeutics as feasible DDSs and challenging concerns of limited light penetrance. However, for 
successful translation of therapeutics to the clinic more extensive PK/PD studies that truly begin 
to assess an in vivo photoindex will be required, especially for the IND application. 
 
Biodistribution: Enhancing Temporal Control 
Biodistribution studies serve two crucial roles in photoactivatable therapeutic 
development, due to the inherent ability to temporally control therapeutic release. First, 
biodistribution studies begin to establish the PK of therapeutic treatment which is vital for 
measuring the photoindex as well as providing indications of safety and potential phototoxicity (as 
cytotoxic therapeutics that are not cleared in a reasonable amount of time pose a higher risk of 
phototoxicity). Second, biodistribution studies serve to provide optimal parameters for when 
therapeutic activation and release should occur. For in vivo studies, experiments should 
characterize the ideal time of treatment to optimize chances of achieving the therapeutic potential. 
Depending on the DDS, timing of treatment may vary depending on when the therapeutic 
sufficiently localizes. Photoactivatable therapeutics have yet to cure cancer in mice, thus many 
protocols focus on releasing as much therapeutic as possible initially and continuing illumination 
treatments for multiple days following initial treatment. Such multi-day studies are possible as long 
wavelength light commonly causes few adverse effects but may pose a feasibility risk for 
translation into clinic. 
Biodistribution studies can provide an indication of which tissues are of concern for 
toxicology studies. For instance, biodistribution studies of a fluorescent Cbl derivative discovered 
extensive distribution of Cbl throughout the body, including into the brain. In addition, a high 
concentration of Cbl accumulating in the tumor within 3 h was noted. Although a therapeutic was 





distributing throughout major tissues. Since endogenous Cbl is observed in the liver, kidneys, and 
lungs as well as to some degree in the heart and brain these tissues should be closely monitored 
especially with cytotoxic therapeutics.106 Investigators have also quantified the concentration of 
CO after illumination of cyanine photoCORM in vulnerable tissues such as the blood and heart.67 
Such knowledge provides researchers with forewarning of potential toxicity risks while also 
making the most efficient use of animal studies. 
As previously discussed, carriers and additional targeting moieties on photoactivable 
therapeutics can affect biodistribution. A proof-of-concept study of the potential of targeting agents 
compared the biodistribution of biotin targeted cyanine-camptothecin-biotin to control cyanine-
camptothecin-alkyne. The alkyne is imaged throughout tissue for a full 6 h, while the biotin 
targeted PPG concentrates within 3 h in the liver and tumor (Figure 1.20). Further, theranostic 
images of illuminated cyanine-camptothecin at 820 nm show liver metabolism of the PPG 
emphasizing a need for further toxicology and safety studies.68 Next generation cyanine-
camptothecin micelles also distribute into the liver and tumor, but after 12 - 24 h PPG fluorescence 
are only observed in the tumor. Since the cyanine micelles rely on accumulating in tissue with an 
acidic pH it appears that this accumulation begins after 6 h and concentrates after 12 h.86 Both 
cyanine systems demonstrate the need for liver safety investigations. Further the power of 
theranostic measures highlights how preliminary biodistribution studies can assess both ideal 
localization of photoactivatable therapeutic and potential dark activation by metabolism. The 
comparison of biotin targeting to the control alkyne also highlights how multi-layer targeting can 









Figure 1.20 Improved biodistribution and PK of targeted cyanine-camptothecin-biotin 
(Cy-CPT-Biotin, left) as compared to control alkyne (Cy-CPT-Alkyne, right). Fluorescent 
signal at 820 nm of inactivated cyanine (top) accumulates in the tumor over 6h due to biotin 
targeting as compared to alkyne control (red circle represents tumor site in top and middle 
images). Fluorescent signal at 535 nm of activated cyanine shows localized therapeutic release 
at the irradiated tumor (680 nm, 200 mW/cm2) and potential dark activation in the liver (middle 
and bottom). Internal organs show enhanced liver metabolism of non-targeted Cy-CPT-Alkyne 











Similarly, biodistribution of ADC-cyanine-duocarmycin was assessed before tests of 
therapeutic efficacy. ADC-cyanine-duocarmycin concentrates in the tumor over 3 - 4 days.69 This 
discovery played a key role in developing an ideal in vivo treatment plan during which light 
exposure was implemented 4 days after dosing. Although waiting a significant amount of time 
between dosing and treatment may be sub-optimal due to risk of phototoxicity, if systemic 
concentrations of inactivated drug cause minimal toxicity and a sufficiently localized concentration 
for effective dosing is achieved during the wait period, these benefits may outweigh the risks. As 
mentioned, Photofrin is still used in the clinic even though patients have to wait 48 h between 
dosing and treatment.12 
Biodistribution studies can also indicate the need for a carrier, as photoactivatable 
therapeutics that have short circulation times and non-selectively diffuse into all tissue diminish 
bioavailability and increase the risk of dark activation. For example, non-photoactivatable 
Cbl≡Cy5 was imaged systemically distributing throughout tissue 5 min after injection (Figure 
1.21).106 Addition of an RBC carrier and internalization of Cbl≡Cy5 within RBCs ensures localized 
exposure of the Cbl≡Cy5 to the vasculature for up to 1.5 h.  This localization was further validated 
by comparing to control externally labeled mouse RBCs with lipidated cyanine fluorophore 1,1-
dioctadecyl-3,3,3,3-tetra-methylindodicarbocyanine (DiD).72 Since the highest therapeutic dose 
needs to be released locally for photoactivated efficacy, current studies of vascular-localized 
photoactivatable therapeutics illuminate soon after intravenous injection as vascular based 







Figure 1.21 RBC carrier-based modification of Cyanine-Cbl-Docetaxel (Cy5-Cbl-DTX) 
biodistribution. Control externally loaded DiD mouse RBCs are localized to the vasculature 
for 1.5 h (top). Cy5-Cbl-DTX mouse RBCs also remain localized to the vasculature for 1.5 h 
(middle). Free Cy5-Cbl-DTX permeates throughout tissue within 5 min and persists through 1.5 








































Thus, investigating biodistribution early in development can help optimize 
photoactivatable DDS in multiple ways: 1) results can provide researchers with indications of 
which tissues are at risk of dark activity/ toxicity effects and need to be examined and validated 
for further translation of the photoactivatable therapeutic; 2) studies support optimizing in vivo 
efficacy by providing the time required to achieve an ideally localized distribution; 3) studies can 
indicate whether a carrier or targeting agent may be necessary to improve localization/ minimize 
systemic exposure. Comparing biodistribution of the photoactivatable therapeutic to the parent 
drug or standard of care may help elucidate other potential risks and benefits of the 
photoresponsive DDS. Theranostic photoresponsive moieties are also extremely beneficial for 
biodistribution studies as they can easily image both the inactivated and activated therapeutic. 
Since many photoresponsive moieties generate a fluorescent signal, such signals can potentially 
be imaged during in vivo biodistribution studies. As noted previously, therapeutics are often 
dependent on the pharmacological processing of the body, but photoactivatable therapeutics can 
inactivate therapeutic to allow for optimal biodistribution before delivery to the site of disease.   
 
Achieving Complete Remission: Optimizing Efficacy Studies  
At this point, few photoactivatable therapeutics have achieved complete remission of 
disease in animal models. Thus, optimizing the parameters of treatment to ensure optimal 
localized efficacy is a necessity. Cbl-Dex RBCs and ADC-cyanine-duocarmycin have achieved 
success in animal models by thorough optimization and by including standard of care controls. 
Additional testing can be performed to ensure that the ideal dose is achieved including using 
doses compared to standard of care dosing or established dosing in that model and optimizing 
the irradiation dose treatment. 
After investigating the biodistribution of ADC-cyanine-duocarmycin for ideal treatment 





J/cm2 for 2 min) led to extensive photobleaching which is assumed to indicate complete activation. 
Although, photobleaching may correlate to the degree of therapeutic activation, dosimetry 
provides a better understanding of the degree of light penetrance and subsequent degree of 
activation. Further optimization of the ADC-cyanine-duocarmycin DDS included testing the 
efficacy of multiple photoactivatable therapeutic doses, including 10, 30, and 100 µg. The highest 
and most effective dose of 100 µg included both light and dark conditions (Figure 1.22). The 
results from the range of doses provide insight into the PK and true photoindex of ADC-cyanine-
duocarmycin as 10 µg has no therapeutic effect even with illumination due to potential clearance 
or insufficiently localized concentrations. Illuminated 30 µg treatment achieves similar efficacy to 
100 µg treatments in the dark. Further, biodistribution imaging during treatment shows that 30 
and 100 µg treatments localize to the tumor after 4 days and are fully photobleached after 
illumination. At both doses, the ADC was observed to re-localize in the tumor supporting multiple 
day irradiation treatments. However, high concentrations of photoactivatable therapeutic are 
imaged throughout tissue at the 100 µg dose, which may be sufficient to achieve efficacy even in 
the dark due to metabolic activation.69 For future animal studies with more aggressive irradiation 








Figure 1.22 In vivo dose response efficacy of photoactivated ADC-Cyanine-Duocarmycin 
in breast cancer xenografts. a) Tumor growth as a function of days. Mice were treated with 
and without illumination and with 10, 30, and 100 µg doses as shown in the graph legend. 100 
µg does produce efficacy in the dark, but illuminated treatment diminishes tumor growth by 3-
fold in 20 days (d). b) Survival of treated and untreated mice. Irradiated 100 µg treatment 
improves mouse survival by 2-fold, while 10 µg treatment has no efficacious effect. (*P < 0.05, 












 Cbl-Dex RBC treatments in the acute collagen antibody induced arthritis mouse model 
also ensured an optimal in vivo testing plan.73 Since biodistribution studies confirmed that the 
highest potential concentrations of the photoactivatable DDS are achieved upon initial injection, 
efficacy studies illuminated inflamed mouse paws immediately after injection. Further, in vitro 
irradiation studies confirmed complete therapeutic release after 1 mW irradiation for 3 min. 
Consequently, 3 mW irradiation for 5 min was proposed to sufficiently penetrate through the thin 
tissues of mouse paws. The previously optimized highest dose of photoactivatable therapeutic 
was loaded into mouse RBCs and the highest intravenous injectable dose of loaded mouse RBCs 
was injected into mice. Uniquely, these were the first reviewed in vivo studies to employ a 
standard of care control. Excitingly, the anti-inflammatory efficacy of Cbl-Dex RBCs is comparable 
to standard intraperitoneal Dex (Figure 1.23). Further, the initial dose of photoactivatable DDS is 
more effective than the initial dose of intraperitoneal standard. To further validate the 
phototherapeutic effect, future studies need to elucidate the localized effect by comparing 
illuminated mouse paws to control inflamed dark paws and to “dark” mice treated with the 
photoactivatable DDS but not illuminated. However, the initial results demonstrate the promise of 






Figure 1.23 In vivo efficacy of Cy5-Cbl-Dex RBCs as compared to standard of care 
intraperitoneal Dex (IP Dex). Mice were treated with Cy5-Cbl-Dex RBCs (dotted line, n = 13) 
and IP Dex (solid line, n = 11) until remission of arthritis as measured by the mean arthritis 
severity score (left). After 1 day of treatment only Dex RBCs demonstrated significant 
improvement from inactive control Cy5-Cbl-H2O RBCs treated mice (gray line, n = 12). (P = 
0.01) The average amount of Dex (mg/kg) administered to IP Dex mice (hatched) and total Dex 
to Dex RBC mice (gray) per treatment day to achieve comparable remission shows IP Dex mice 
required daily dosing (of 0.5 mg/kg Dex) to achieve remission (right). Shaded bars represent 
the ratio of mice (out of 11 mice) that required more IP Dex and the cumulative dose 
administered to those mice. After 3 days of dosing, 78% more IP Dex was administered to 









ADC-cyanine-duocarmycin employed biodistribution investigations before and during 
efficacy studies to ensure therapeutic could still be released. Similarly, the ideal Cbl-Dex RBC 
biodistribution was validated and treatment was compared to a standard of care control.  These 
initial in vivo studies demonstrate the power of dark controls, standard of care controls, and dose-
response testing to truly begin to quantify the in vivo photoindex and demonstrate the potential 
benefits of photoactivatable DDSs. Since animal studies can be quite costly and time-consuming, 
ensuring that all potential data is collected, including collecting tissues for initial toxicology studies, 
can support development and further optimization of the treatment system before costly GLP 
studies. Thorough pre-clinical investigations can support IND application by indicating whether 
multiple injections may be required to achieve efficacy as the FDA will then further emphasize 
sub-chronic toxicology tests. In the end, an optimized treatment protocol will not only ensure ideal 
efficacy, but also provide guidance on the required toxicology tests remaining. 
 
Remaining Steps: PK/PD and GLP Toxicology studies 
Although not commonly published in literature, once efficacy and an ideal photoindex are 
achieved in vivo, researchers may begin establishing companies surrounding their technology 
and searching for investor capital to support rigorous PK/ PD and GLP toxicology studies. Mindful 
investigation in earlier pre-clinical work will support such studies with established chemistry and 
manufacturing, as well as ranges of therapeutic and illumination dosing for toxicology studies and 
eventual first in human trials. Further, early investigations can indicate potential pharmacology 
concerns and what tissues may be most at-risk to the therapeutic’s pharmacological effects based 
on biodistribution studies. Investigating patent potential early on can also help ease this transition. 
When the PK/PD and GLP tests are underway may also be an appropriate time to begin pre-IND 





1.5.6.2 The Spatiotemporal Benefits of Photoactivatable Therapeutics 
Spatiotemporal control provided by photoactivatable therapeutics can improve the TI in a 
multitude of ways. As always, the acceptable efficacy, toxicity, risks, and benefits of 
photoactivatable therapeutics need to be compared against the current standard of care for the 
unmet clinical need. Although there may be subacute toxicity, the assessment should consider 
whether the photoactivatable therapeutic improves characteristics of the therapeutic cargo or 
provides greater benefit than the standard of care. This assessment will commonly include the 
strength of spatiotemporal control and can be validated with the TI acting as a guide. In the 
following discussion, the spatiotemporal benefits of photoactivatable therapeutics will be framed 
within the concept of TI. 
 
Modifying TI 
Diminishing Toxicity/ Increasing the MTD 
With the persistence of clinical need in cancer and the cytotoxic nature of therapeutics, 
many targeted methods of drug delivery have been developed, including PACTs and PDT. PACTs 
seek to improve the TI by increasing the MTD of toxic therapies and diminishing systemic side 
effects via spatial control provided by light and lasers.157 PPGs, photoswitches, and photogates 
can diminish toxicity by means of inactivating or sheltering therapeutics until targeted laser 
activation at the site of disease. Thus, highly cytotoxic species such as doxorubicin, duocarmycin, 
rigidin, docetaxel, and camptothecin have reached in vivo studies for targeted therapeutic delivery. 
Indeed, most therapeutics under development in Table 1-4 are cytotoxic therapeutics for the 
treatment of cancer. As previously discussed, the clinical success of both ThermoDox, 
NanoTherm, AuroLase, and PDT establish a regulatory precedent for externally stimulated DDSs 
in the treatment of cancer and validate the potential to minimize toxicity by deactivating cytotoxic 





Beyond cancer, the photogated Cbl, melittin RBC system highlights the potential of 
photoactivatable therapeutics to minimize severe adverse effects by means of external stimulation 
and the resulting release of thrombin in a localized manner (Figure 1.18).142 Thrombin’s extreme 
potency can lead to undesired clotting if administered systemically. Consequently, thrombin is 
only clinically approved for topical applications. Although toxicity studies are still underway, the 
photogated melittin system highlights the potential of photoactivatable therapeutics to improve 
safety by diminishing toxicity for both cancer and non-cancer indications. 
 
Increasing Efficacy 
Photoactivatable therapeutics can also salvage sub-optimal therapeutics by spatially 
enhancing the local concentration of drug and thus improving efficacy. For example, NO is known 
to have a plethora of roles in the body and potential in treatment of a variety of indications.227 NO 
itself is not excessively dangerous or toxic and has recently been employed as an at-home inhaled 
therapy for COVID-19.228 Due to the plethora of its roles within the body and on disease, targeted 
NO delivery systems have been developed for cancer therapy.229 Specifically, BODIPY based 
photoactivatable NO donors (photoNODs) have successfully achieved an localized 
photoactivated on illuminated subcutaneous flank tumors in Balb/c mice. Suppression of tumor 
growth only occurs in illuminated tumors and has no effect in control dark flank tumors in the same 
animal. This result not only provides further validation of NO’s ability to suppress tumor growth, 
but also the photoactivatable therapeutic’s ability to improve desired efficacy by localizing 
therapeutic release and improving local concentrations. Future implications may include 
salvaging therapeutics that do not successfully progress through clinical trials due to insufficient 







Both Improving Efficacy and Diminishing Toxicity 
Therapeutics that are both insufficiently effective and highly toxic can also be salvaged by 
photoactivatable therapeutics because light-activated DDSs can potentially improve efficacy of 
treatment to the extent that lower doses of therapeutic are needed which in turn diminishes 
systemic toxic effects. The most compelling example of this control is the development of BODIPY 
and cyanine based photoCORMs. Similar to NO, CO has prolific roles throughout the body and 
has been implied in the treatment of inflammation, cardiovascular disease, organ transplantation 
and preservation, as well as cancer.178 However, CO binds 220 times more potently to hemoglobin 
than oxygen which has resulted in fatal consequences in the past.230 Photoactivatable 
therapeutics can both minimize the off-target toxic binding to hemoglobin and potentially provide 
localized therapeutic effects similar to photoNODs. Early in vivo investigations have demonstrated 
biocompatibility and irradiation-dependent release of CO.64  
 
Other Benefits: Personalized Medicine and Temporal Control of Multi-Targeted DDSs  
Beyond improving the TI by salvaging cytotoxic and insufficiently effective therapeutics, 
the unique inherent properties of photoactivatable therapeutics provide potential for other novel 
applications. These applications include the development of personalized medical treatments in 
the form of theranostics and drug depots for patient-controlled at-home photoresponsive therapy 
and enhancement of multi-targeted DDSs due to the temporal control photoactivatable 
therapeutics provide. These applications have successfully been tested in vivo. However, other 
unique benefits of photoactivatable therapeutics have undergone in vitro testing, such as SiPcs 
that are dual PDT and photoactivatable therapeutic treatments. The potential for photoactivatable 
therapeutics is only now being illuminated as imaging devices, light devices, and photoresponsive 






Personalized Medicine: Theranostics 
As previously discussed, energy absorbed from photons can be converted to therapeutic 
release or fluorescence. Although fluorescence of photoactivatable therapeutics does decrease 
the Φ of therapeutic release, many research teams have taken advantage of this inherent dual 
modality to both image therapeutic distribution and measure therapeutic release as theranostics. 
The current theranostics under development include the BODIPY photoNOD and the cyanine-
camptothecin therapeutics.62, 68, 86 Although, fluorophores conjugated to Cbl have demonstrated 
potential theranostic capabilities, the imaging process has not yet been separated from 
therapeutic release.105, 106 Ideally theranostic imaging is independent of therapeutic release 
allowing for a cycle of detection, therapeutic delivery, and monitoring personalized to each 
patient.231  
BODIPY photoNOD is successfully imaged with photoacoustic imaging, activated with NIR 
light, and then imaged at another unique wavelength of photoacoustic imaging for ratiometric 
monitoring of therapeutic release.62 Monitoring shows 65-88% therapeutic release in vivo upon 
irradiation. Similarly, cyanine-camptothecin micelles, the next-generation of theranostic cyanine-
camptothecin (Figure 1.16), have been developed that can detect the micellar state with 
photoacoustic imaging and the disrupted micellar state at 810 nm.86 Subsequent therapeutic 
release is triggered with 670 nm and the resulting photoproduct is detectable at 530 nm. In vivo 
studies demonstrate successful therapeutic release at the site of irradiation measurable by 
fluorescence imaging and photoacoustic imaging.  
Both theranostic systems have demonstrated the ability to detect therapeutic distribution, 
excite therapeutic release, and subsequently quantify the degree of release. In general, these 
systems are limited by their need for photoacoustic imaging which has yet to reach the clinic. 
Thus, the cyanine micelles may demonstrate a greater potential for accelerated translation given 





provide both for proof of principle validation of targeted delivery and development of this unique 
form of personalized medicine. 
 
Personalized Medicine: Drug Depots 
As previously discussed, RBCs have been tested as both slow-release systems and 
bioreactor systems with extended circulation. In general, RBCs can circulate for up to 180 days 
which makes them an optimal carrier as a long-term circulating drug depot. Internally loaded L-
asparaginase and Dex 21-phosphate RBCs have been found to circulate for ~25 days in 
patients.222 Although internally loaded RBCs display a reduced half-life compared to native RBCs, 
they experience a loss similar to transfused RBCs which only circulate for 50-60 days.232 It is not 
surprising that internally loaded RBCs do not circulate for as long as their non-permeabilized 
counterparts. The therapeutic loading process requires RBCs undergo a hypotonic dialysis which 
causes membrane disruption and loss of some internal contents, which may lead to a more 
accelerated clearance as compared to native RBCs. However, internally loaded RBCs can still 
provide a notable increase in circulation time for therapeutic cargo, as exemplified by Cbl DDSs.72 
Cbl-Dex internally loaded RBCs are under development to both minimize the toxicity of 
Dex, as well as provide (eventually patient-controlled) localized therapeutic release. Dex has 
negative side effects from chronic usage, including bone-thinning, weight gain, diabetes, and 
immunosuppression.233 Cbl-Dex RBCs will allow for patient-based therapeutic symptom treatment 
for morning pain and flare-ups while minimizing the toxicity of Dex. This system takes advantage 
of the long-term circulation of internally loaded Cbl-Dex RBCs which can be released in response 
to low-power long-wavelength light in the hands and feet by patient-controlled lasers. Though still 
in early development, Cbl-Dex RBCs have successfully induced arthritic remission in a mouse 





and the successful 1-month circulation studies of EryDel RBCs in clinical trials establishes the 
near-future potential of photoactivatable drug depot therapeutics.222 
 
Temporal Targeting of Multi-targeted DDSs 
Photoactivatable therapeutics can also improve efficacy, and thus the TI, by means of 
temporal control. The potential of this control has been most clearly demonstrated by DDSs that 
employ multiple means of targeting including ADC-cyanine-duocarmycin and pH-responsive 
cyanine-camptothecin micelles.69, 86 The scientists introduced the clinically available ADC 
targeting agent Panitumumab (which targets EGFR on cancer cells) and the pH-sensitivity to the 
acidic tumor environment respectively, to enhance the localization benefits of photoactivatable 
therapeutics. Both groups then completed biodistribution studies to optimize the ideal time for 
therapeutic release. The ADC duocarmycin demonstrated an optimal distribution after 3 - 4 days 
while the cyanine micelles demonstrated a localized presence in the tumor environment after 24 
h.69, 86  
The biodistribution results highlight that clearance of excess DDS has occurred and the 
resulting localization is potentially due to the enhanced targeting provided by ADC and pH-
sensitivity respectively. This potential was further confirmed as previously discussed by targeted 
cyanine-camptothecin-biotin, the precursor of the cyanine-camptothecin micelles (Figure 1.20).68 
With these ideal treatment times, the ADC system successfully demonstrated a suppression of 
tumor growth and almost doubling of survival rates.69 The temporal control provided by the 
photoactivatable DDS further enhanced the potential efficacy of the targeted system by allowing 








1.6 Outlook for the Future of Photoactivated Drug Delivery Systems 
Photoactivatable therapeutics provide a completely novel way of salvaging and delivering 
drugs. Altogether the spatial and temporal control of phototherapeutics can improve the TI of the 
therapeutic cargo by multiple strategies: by modifying the systemic exposure, by minimizing the 
dose of therapeutic required, and by enhancing the local concentration. Further, the inherent 
properties of photoactivatable therapeutics can be enhanced to improve personalized medicine 
by theranostic and drug depot applications. However, with the multitude of benefits that 
photoactivatable DDSs present, there are still quite a few challenges systems need to overcome: 
1) Although the depth of light penetration varies dependent on tissue, in general, ensuring 
optimal photophysical properties of photoresponsive moieties will support penetration into 
deeper tissue indications. Fortunately, many light devices for these spaces have already 
been developed (section 1.3). 
2) Current photoresponsive moieties under development may be insufficiently optimized for 
clinical translation (section 1.4). Though no precedent yet exists for the photophysical 
properties of an ideal theranostic or even photoresponsive therapy, photoresponsive 
moieties that have low Φ due to high fluorescence may be modified for theranostic 
applications. Other photoresponsive moieties will have to achieve the minimum Φ and es 
of at least 0.1 and 5,000 respectively that Photofrin has set.19  
3) Though briefly mentioned, generating a reliable and easy synthetic route for mass 
production of the photoactivatable DDS will be crucial for clinical translation. Many clinical 
holds arise from concerns or changes to the chemistry and manufacturing. To ensure 
efficient translation, regulated synthesis and quality control of these complex therapies will 
be of utmost importance. 
4) High spatiotemporally controlled efficacy in vivo with minimal dark activity has yet to be 





thorough validation will be crucial. Once the initial approved system proves efficacy with 
minimal dark activity, the photoactivatable therapeutic field may see a boon of confidence 
and rise of capital to support translation. 
5) Photoactivatable therapeutic need to be designed as simply as possible. Every complexity 
added to the DDS will require optimization and may cause nuanced problems that require 
further troubleshooting and a variety of expertise. For example, adding a carrier may 
further complicate synthesis and regulatory translation.221 Thus, minimizing the complexity 
of the DDS is ideal, as validated by Tookad’s accelerated development once a lipidated 
carrier was no longer required.12 However, early generations of photoactivatable DDSs 
may require carriers to overcome limitations of dark activation until more ideal 
photoresponsive moieties are developed.  
6) Careful planning should go into animal studies. As discussed throughout 1.5.6 a plethora 
of information can be obtained from even preliminary animal tests. Using animal models 
that begin to validate spatiotemporal control (such as double tumor models or comparing 
illuminated to dark tissue) may provide crucial justification of the phototherapeutic benefits. 
These animal studies can also indicate risks of potential dark activation, toxicity, feasibility 
of administration method, as well as insufficient therapeutic effect. Including proper 
controls such as standard of care treatments can also help further the crucial proof of 
principle data required to continue the growth of photoactivatable therapeutics. 
7) Externally controlled DDSs are often called “smart” drugs, originally named thusly because 
these DDS can be controlled to only react in the desired diseased tissue. However, 
although these DDS may in themselves be “smart”, they also require extensive expertise 
(Figure 1.2) and planning (Figure 1.12) to develop successfully. Embarking on developing 
these exciting and novel systems should be taken with great care and thought. Having in 





photoresponsive moieties that can meet the need will tremendously help guide and 
accelerate the journey. Further, understanding the scope of the current standard of care’s 
risk and benefits will provide boundaries and goals for the photoactivatable therapeutic’s 
risks and benefits. 
Only 30 years have passed since the first photoresponsive therapy, Photofrin, was 
approved.12 Since then, the field of PDT has observed both successes and failures. It would be 
naïve to think that photoactivatable therapeutics will not face similar struggles. However, the 
foundation of PDT and established light devices help support the translation of photoactivatable 
therapeutics. The many photoresponsive moieties responsive to long wavelength light, literary 
background on the synthesis and photochemical mechanisms, and success of in vivo validation 
of localized effect and therapeutic efficacy provides hope for many therapeutics approaching clinic. 
The personalized medicine applications of photoactivated drug depots and theranostics may still 
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2 CHAPTER 2: PHOTOACTIVATED CHEMOTHERAPEUTIC COBALAMIN-
DOCETAXEL RED BLOOD CELLS LOCALLY RELEASE DRUG ON 
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the most scientific ideas and experimental effort. Emilia M. Zywot, the author of this 
dissertation, was trained during the described studies and contributed experimental 
efforts involving red blood cell loading, cell culture assays, flow cytometry, and histology 
studies.  
2.1 Introduction to Photoactivated Chemotherapeutics  
Photoactivated chemotherapeutics (PACTs) seek to diminish the inherent off-target 
systemic toxicity of chemotherapeutic treatments.1-4 PACTs are one of many drug delivery 
systems (DDSs) that rely on an external stimulant, specifically light illumination, to localize 
therapeutic release.5-8 Other targeted DDSs in the clinic include liposomes, such as Doxil and 
ThermoDox, photothermal therapies AuroLase and NanoTherm, and many antibody drug 
conjugates (ADCs), such as trastuzumab and bevacizumab among others.4, 9, 10 These systems 
rely on passive and/or active targeting to diminish off-target toxicity and enhance efficacy by 
localization including: passive targeting of nanomaterials due to the enhanced permeation and 
retention effect, active targeting by external stimulation (light or an alternating magnetic field) to 
induce a photothermal effect, and active targeting by inducing strong binding interactions to 
receptors and other biomarkers on the surface of cancer cells. Yet, these systems are limited by 





high intensity stimuli that cause inadvertent damage to treated tissue.7, 11-13 Still, ThermoDox 
improves upon the limited therapeutic release from Doxil by providing a means of externally 
triggering liposomal degradation resulting in targeted therapeutic release which can be controlled 
by intensity, location, and time. Such clinically tested solutions establish the precedent for 
externally controlled DDSs enhancing therapeutic delivery as compared to passively targeted 
systems. Similar to AuroLase, PACTs rely on light as an external stimulant that triggers 
therapeutic release. PACTs may provide another solution to Doxil’s and ADC’s therapeutic 
release issues, while avoiding limitations of photothermal therapeutics and heat-dependent 
DDSs.2, 14, 15 Herein, we assess the localized light-activated therapeutic release from red blood 
cell (RBC) carriers to support the continued development of PACTs and other photoactivated 
therapeutic DDSs.  
We have successfully modified vitamin B12 (also known as cobalamin, Cbl) into a tunable 
PACT scaffold by shifting its inherent light-responsive properties (330 - 575 nm), which trigger 
photolysis of its axial cobalt bond, into the optical window of tissue (600 - 900 nm). Specifically, 
synthetically appended red and far-red fluorophores on the 5’ hydroxyl of Cbl’s ribose act as an 
antenna to shift the photoresponsive wavelengths of Cbl.16 Many therapeutics have also been 
appended successfully via the photoresponsive axial cobalt bond.17, 18 This study, specifically, 
focuses on development of the clinically-approved taxane docetaxel. Docetaxel is an antimitotic 
used in the treatment of a variety of solid tumors, including breast, gastric, prostate, and non-
small cell lung cancers. However, taxanes produce a variety of short- and long-term adverse 
effects in more than 30% of patients.19-21  
RBC carriers should limit the biodistribution and improve the circulation half-life of 
photoresponsive fluorophore-Cbl-Docetaxel, which further minimizes off-target toxicity and 
improves localized efficacy. The Cbl scaffolds are successfully loaded into RBCs by means of a 





clinic and demonstrated the ability to carry large therapeutic payloads and maintain 
biocompatibility up to ~25 days of circulation, making them flexible carriers for many indications.24-
27 Further, RBCs shelter the Cbl PACT as Cbl cannot escape the cell due to its inherent membrane 
impermeability. Thus, therapeutics covalently conjugated to Cbl are retained within the RBC until 
illumination in the optical window of tissue. Fluorophore-Cbl-Docetaxel RBCs provide a method 
of combining externally light-triggered therapy of AuroLase with the sheltering properties of 
ThermoDox ideally enhancing their beneficial properties that have achieved positive clinical 
results thus far.  
 
2.2 Construction of Cobalamin-Docetaxel RBCs 
A cyanine5 (Cy5) fluorophore antenna (responsive to 645 nm) and docetaxel (TAX) were 
appended to the Cbl derivative 1 to yield photoresponsive Cy5-Cbl-TAX (2) (Figure 2.1).28 Briefly, 
the three-step synthesis requires condensation of N-Deboc TAX with the axial carboxylate of 1, 
deprotection of the ribose Fmoc group, and condensation of the resulting deprotected amine with 
activated N-hydroxysuccinimide Cy5.18 The inactive derivative Cy5-Cbl-H2O (3), with no 
appended therapeutic, and non-photocleavable fluorescent analog Cbl≡Cy5 (4) were synthesized 








Figure 2.1 Structures of Cbl therapeutic and controls. Compound 1 (inset) shows the full 
Cbl structure modified with a carboxylate off the axial cobalt bond and Fmoc protection of the 
ethylamine linker off the ribose 5’-OH. The equivalent abbreviated structure is shown on the 
right. Compound 2 is the resulting PACT Cy5-Cbl-TAX synthesized from 1. The photolabile 
axial bond is highlighted. The inactive derivative 3 is both a photoproduct of photolysis of 2 and 
acts as a non-therapeutic control. The non-photolytic analog 4 contains a Co≡C triple bond that 
is photostable and therefore allows Cy5 to be employed as a fluorescent tracker without 








































































































Therapeutic RBCs loaded with 2 or control RBCs loaded with 3 were prepared by 
hypotonic dialysis in PBS containing 6 x 10-3 M glucose, within which RBCs swell due to osmotic 
pressure and a pore(s) forms in the membrane. Cbl species can then freely diffuse into RBCs. 
After dialysis, the loaded RBCs are returned to an isotonic environment, which causes the pore(s) 
to reseal and traps the Cbl conjugates within. The hydrophobic drug can now only escape the 
RBCs when photolytic cleavage of the axial cobalt bond occurs upon excitation of the Cy5 antenna 

















Figure 2.2 Chemotherapeutic release from Fluorophore-Cbl-Drug RBCs. Drug cannot 
escape from RBCs internally loaded with Cbl conjugates until illumination. Upon illumination, 
the photolabile axial bond cleaves releasing hydrophobic drug, which can permeate across the 















































2.3 Characterization of Cy5-Cbl-TAX Mouse Red Blood Cells in vitro 
Widefield microscopy images of loaded mouse RBCs (mRBCs) indicate successful 
loading of Cy5-Cbl conjugates and conservation of the mRBC morphology as compared with 
native (isolated but unmodified) control mRBCs and vehicle-loaded mRBCs (mRBCs that undergo 
the loading process exposed to PBS rather than a Cbl species) (Figure 2.3a). Externally loaded 
1,1-dioctadecyl-3,3,3,3-tetra-methylindodicarbocyanine (DiD) mRBCs verify Cy5 fluorescence, 
when appended to Cbl, is unaffected by the loading procedure and can be used for tracking 
loaded mRBCs. Further, confocal microscopy images taken through z-space can characterize the 
unique biconcave edges and spherical center planes of RBCs and identify distribution (external 
or internal) of fluorescent species. Confocal images of 2 mRBCs confirm internal loading within 
mRBCs as 2 distributes throughout the risen biconcave edges of the edge planes and throughout 
the spherical center plane (Figure 2.3b). Efficiency of loading was assessed by cell recovery and 
by hemocytometer counting of loaded mRBCs followed by ethanol extraction to determine the 
encapsulated concentration of 2 and 3. 53 ± 6% of 2 mRBCs are recovered from the loading 
process and contain 39 ± 4 μM 2, while 63 ± 4% of 3 mRBCs are recovered and contain 32 ± 2 






















Figure 2.3 Microscopy characterization of mRBCs. a) Transmitted (top) and fluorescent 
(bottom) widefield images of internally loaded Cy5-Cbl-TAX (2) and Cy5-Cbl-H2O (3) mRBCs, 
externally loaded (DiD), native mRBCs, and vehicle loaded mRBCs. Scale bar = 20 μm. b) Two 
confocal images (left) in different z-planes of 2 mRBCs demonstrate different fluorescent 
distributions of internally loaded 2 due to the mRBC biconcave shape. Quantitative analysis of 
15 representative cells (right) across straight-line regions as exemplified in sample mRBC 
images of the edge (left image) and center plane (right image) confirm the biconcave distribution 

















































Figure 2.4 Concentration of 2 and 3 loaded into mRBCs. Concentration per mRBC was 
determined by hemocytometry counting of loaded mRBCs followed by ethanol extraction of 
Cy5-Cbl conjugates and calculation of concentration with UV-Visible spectroscopy absorbance 
























mRBCs loaded with 2 and 3 were further characterized with flow cytometry. Resulting 
overlaid histograms of in-focus singlets display the uniform loading of internal 2 and 3 mRBCs 
(Figure 2.5a). A linear region of interest was analyzed at an intensity of 1 x 104 fluorescent units 
to quantify the percentage of cells successfully loaded. 99.4% and 99.7% of 2 and 3 mRBCs are 
loaded respectively. Notably, only 49.3% of DiD mRBCs fall within the loaded gate, which signifies 
a more heterogenous external loading. Analysis of cell morphology using flow cytometry side 
scattering (an indicator of granularity of the cell interior) versus fluorescent intensity demonstrates 
DiD mRBCs have comparable SSC variability to native mRBCs (Figure 2.5b).31 Conversely, 
internally loaded 2, 3, and vehicle mRBCs have comparable SSC variability, but increased 
heterogeneity when compared to the DiD and native controls. This heterogeneity suggests a less 
consistent internal composition which could result from the change in the internal environment of 
RBCs during the hypotonic dialysis process. Since 90% of an RBC’s internal composition is 
hemoglobin and there is an observed loss of this protein during dialysis, variable loss of 
hemoglobin from individual cells may result in the observed SSC heterogeneity.32, 33 Changes of 
the membrane shape upon pore resealing may also factor into this observed heterogeneity.34 The 
flow cytometry findings further support successful internal loading of Cbl species into RBCs and 
validate a uniform loading of 2 and 3 into mRBCs, although the loading process may result in 








Figure 2.5 Flow cytometry characterization of mRBCs. a) Overlaid fluorescent histograms 
of native (magenta), externally loaded DiD (green), and internally loaded 2 (black) and 3 (blue) 
mRBCs. The linear region of interest beginning at 1 x 104 fluorescent intensity signifies loaded 
RBCs. 99.4% and 99.7% of 2 and 3 mRBCs are loaded respectively. Only 49.3% of DiD mRBCs 
fall within the loaded gate. b) Side scatter (SSC) versus fluorescent intensity dot plots of 
internally loaded 2, 3, and vehicle mRBCs compared to control native and externally loaded 
DiD mRBCs. Internally loaded mRBCs display higher variability in SSC values, while DiD 
mRBCs are comparable to native mRBCs in SSC complexity.  
b) 2 mRBCs 3 mRBCs DiD mRBCs 






2.3.1 In vitro Assessment of Cbl-Tax RBC Stability and Photolysis 
Due to the noted internal heterogeneity, the stability of loaded mRBCs was assessed to 
ensure mRBCs retain fluorescent conjugates during in vivo studies. Loaded mRBCs shelter Cbl 
species for at least 5 h in vitro, the length of time required for in vivo studies. Over 24 h at 4 °C in 
vitro, loaded mRBCs containing 2 are less stable than control native mRBCs as both visually 
assessed with widefield microscopy and quantified by measuring the amount of hemoglobin 
detected in the supernatant (indicative of hemolysis) and the amount of mRBC pellet remaining 
(Figure 2.6a,c). This inherent in vitro instability is enhanced in mRBCs as compared to human 
RBCs (hRBCs) as previously reported and experimentally validated (Figure 2.6b,c).35, 36 The 
fragility of loaded mRBCs supports immediate injection upon preparation for in vivo studies. 
Conversely, both native and loaded hRBCs demonstrate significant in vitro and in vivo stability as 
compared to mRBCs, even after undergoing the internal loading process, which has also been 












    
    
Figure 2.6 Stability assessments of internally loaded RBCs. a) Widefield analysis of 2 
loaded hRBCs (left) and mRBCs (right) stability of loaded RBCs assessed by transmitted (top) 
and Cy5 channels (bottom) after incubating for 0, 6, 18, and 25 h in L-15 at 4 °C. Scale bar 
represents 20 μm. b) Widefield analysis of 2 loaded and native hRBCs (left) and mRBCs (right) 
after incubating for 1, 2, 3, and 5 days in DMEM media with 1X GlutaMAX and 1% FBS at 4 °C. 
Scale bar represents 20 μm. c) Quantified % hemolysis over time (left) of RBCs represented in 
b) measured by isolating hemoglobin from the supernatant and comparing to a 100% hemolysis 
control. Estimated quantity of 100 μL mRBC pellet remaining over time (right) validates 




















Upon successful generation and characterization of Cbl loaded mRBCs in preparation for 
in vivo studies, it was important to ensure photolysis and escape of TAX from loaded RBCs. 
Photolysis of 2, as well as 2 contained within hRBCs, was measured. After 30 min of 646 nm 800 
mJ irradiation, free 2 in a solution of PBS is fully photolyzed. This result confirms that Cy5 serves 
as an antenna and extends the natural photoresponsivity of Cbl into the optical window of tissue 
(see section 2.7.3). Similarly, photolysis of hRBCs containing 2 results in release of 98% of loaded 
TAX into the supernatant (Figure 2.7). In addition, no detectable levels of TAX are found in the 
supernatant of hRBC pellets incubated in the dark (data not shown). Given the noted instability of 
mRBCs, photolysis of 2 from within mRBCs and illumination of inactive control 3 within mRBCs 
was validated to have no effect on mRBC stability. Minimal Cy5 fluorescence is observed in the 
supernatant of dark and illuminated mRBCs loaded with 2 or 3, confirming intracellular retention 
of the non-cell permeable Cy5-Cbl (Figure 2.8a). Further, less than 25% of hemoglobin is 
released from both groups regardless of incubation in the light or dark (Figure 2.8b). Thus, 
although mRBCs are inherently less stable, illumination at 660 nm for 10 min, as well as activation 
of 2 or 3, and photocleavage of TAX from 2 has a negligible effect on mRBC hemolysis as 













Figure 2.7 Photolysis of Cy5-Cbl-TAX loaded hRBCs. hRBCs in human platelet rich plasma 
were photolyzed at 646 ± 10 nm using an Oriel Xe flash lamp (800 mJ, 62 Hz) and appropriate 
bandpass filters. Analysis by LC-MS revealed that the overwhelming majority (98 ± 1%) of the 




















5000 Photolyzed product 
in the Supernatant Photolyzed product 








Figure 2.8 Stability of photolyzed mRBCs. a) Fluorescence from Cy5 conjugated to the Cbl 
species was measured from 2 mRBCs (left) and 3 mRBCs (right). Supernatants from treatment 
with 660 nm LED illumination for 10 min or incubated mRBCs in the dark is compared to control 
lysed mRBCs. b) % hemolysis as quantified by absorbance of hemoglobin was measured for 
all treatment groups of 2 and 3 containing mRBCs. Less than 25% hemoglobin is released 















2.3.2 Cellular Assays of Cy5-Cbl-TAX Efficacy  
To validate the pharmacological activity of TAX is preserved upon photoactivation and 
release from Cy5-Cbl hRBCs, photoreleased TAX cytotoxicity and mechanism of action were 
tested in HeLa cells. In general, taxanes, including docetaxel, are cytotoxic by suppressing 
microtubule dynamics and blocking mitosis in cancer cells.21 TAX released from illuminated 
hRBCs containing 2 also affects microtubule dynamics of HeLa cells by polymerizing microtubules 
similarly to free TAX, while 2 hRBCs incubated in the dark and no treatment controls have a 
minimal effect on microtubule polymerization (Figure 2.9a). Similarly, illuminated 2 hRBCs affect 
HeLa cell viability equivalently to 1 µM TAX (Figure 2.9b). Thus, appending TAX to the 
photoactivable Cy5-Cbl scaffold does not eliminate TAX’s inherent pharmacological impacts. In 
general, in vitro tests confirm Cy5-Cbl-TAX RBC stability, successful photolytic release of TAX, 
and preserved therapeutic effect of TAX in preparation for in vivo tests of localized TAX release 














Figure 2.9 TAX photoreleased from Cy5-Cbl hRBCs has a similar effect on HeLa cells to 
conventional TAX. a) HeLa cells exposed to media (no treatment), docetaxel (TAX), and 
hRBCs containing 2 with or without 660-nm illumination for 30 min were fixed and stained for 
a-Tubulin (magenta) and nuclei with Hoechst 33342 (blue). TAX and illuminated mRBCs 
containing 2 polymerize microtubules (arrows). b) Viability of HeLa cells following treatment 
with TAX (10 nM or 1 µM), hRBCs loaded with 2 exposed to 660 nm LED light for 30 min or 
kept in the dark. Treatment with 1 µM TAX or 660 nm-exposed 2 hRBCs results in the same 
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2.4 Biodistribution of Cy5-Cbl-TAX mRBCs in vivo 
Biodistribution of Cy5-Cbl-TAX mRBCs was assessed by intravital imaging vasculature of 
Cbl-treated healthy FVB mouse ears (Figure 2.10a). Non-photoresponsive control Cbl≡Cy5 
served to control for effects of photocleavage of the axial cobalt bond, while DiD mRBCs served 
as a circulatory control as previously reported.37 Mice were intravenously injected with the 
modified mRBC species and Cy5 was subsequently imaged in the lasered ear for 90 min (633 
nm, 30% power, 0.5 mm diameter imaged every 5 s). The mouse’s other ear was not exposed to 
laser illumination and, in general, environmental light was kept as dim as possible during injection 
and imaging. Freely injected 4 rapidly diffuses into surrounding tissue within 5 min, while 
externally loaded DiD and internally loaded 4 mRBCs are retained within the vasculature 
throughout the experimental time course (90 min) (Figure 2.10b). Quantification of fluorescence 
over 90 min from the treatment groups reveals fluorescent signal from freely injected 4 is no longer 
detectable after 20 min (Figure 2.10c). Conversely, DiD mRBCs and 4 mRBCs maintain 69 ± 2% 
and 53 ± 5% of their fluorescence respectively. Although, internally loaded 4 mRBCs are initially 
rapidly cleared, potentially due to incurred damage from the dialysis procedure, they retain 
comparable circulation fluorescence to DiD mRBCs after 40 min throughout the remaining 
imaging period. These preliminary biodistribution results underscore the benefit RBCs provide to 










Figure 2.10 Biodistribution of Cy5-Cbl-TAX mRBCs. a) Intravital imaging of free 4, internally 
loaded mRBCs containing 4, or externally loaded DiD mRBCs was performed. Treatments were 
intravenously injected into anesthetized mice followed by intravital imaging at 10X using a 633 
nm laser. b) Intravital images for the first 0, 0.2, 1, 5 min and an offset image at 90 min of 
treatments. Scale bar represents 100 μm. c) Quantification of the fluorescence intensity of 
treatments for 90 min. The initial DiD fluorescence remains in circulation with a slope of –6, 









2.5 Localized in vivo Effect of Cy5-Cbl-TAX mRBCs  
Having validated that 1) TAX is successfully photolyzed from RBCs in vitro, 2) the 
pharmacological effect of photocleaved TAX is preserved in vitro, and 3) the biodistribution of 4 
mRBCs is predominantly constrained to the vasculature for 90 min, we prepared for in vivo 
evaluation of localized TAX release. Since TAX is a potent cytotoxic agent, it produces adverse 
cytotoxic effects on endothelial cells that line blood vessels, even at subclinical concentrations.38-
41 After intravenous administration, taxanes commonly associate with serum proteins in circulation 
due to their extremely lipophilicity, but do not interact with RBCs.42, 43 Since RBCs do not naturally 
support free taxane circulation, sheltering taxanes within RBCs could help prevent inadvertent 
cytotoxicity to the endothelial wall. To test for a localized effect of TAX after photoactivation, we 
inverted this idea by releasing TAX to purposely identify localized cytotoxic damage to the 
endothelial wall. 100 μL of mRBCs (~8 x 107mRBCs) loaded with 2 were injected intravenously 
into mice. TAX was then photoactivated with the intravital imaging 633 nm laser, which both 
activated and was used to visualize the photoresponsive Cy5-Cbl species. After 90 min, 
significant extravasation of Cy5 fluorescence is observed signifying release of the Cy5-Cbl 
scaffold (Figure 2.11a). Since extravasation was not previously observed with DiD mRBCs or 4 
mRBCs this property is potentially unique to the TAX therapeutic. While TAX release did not 
produce significant hemolysis in vitro as previously described, physiological cytotoxic damage to 
the endothelial wall by TAX may lead to a coagulation cascade that causes the more fragile 
internally loaded mRBCs to rupture as the vessel congests and RBCs, among other circulating 
species, pack.44 Such events are observed during microangiopathic hemolytic anemias and as a 
result of venoms and drugs, including taxol.45-47   
To confirm the suspicion of a cardiovascular damage and clotting, mice were euthanized, 
and ear tissue collected and fixed. Hematoxylin and eosin (H&E) staining of illuminated ears of  





endothelial damage (Figure 2.11b). The non-illuminated (dark) control ear from the same mouse 
shows spacing between the circulating RBCs themselves and between the RBCs and the vessel 
wall indicative of normal vascular circulation (Figure 2.11c). Similar spacing to the dark control 
ear is observed in the stained ears of untreated mice, while extensive cytotoxic effects are 
achieved by topically applying free TAX (20 μM) to a mouse ear (Figure 2.12a,b). To address 
concerns of photoactivation contributing to cardiovascular damage, 3 loaded mRBCs were also 
tested. Cy5-Cbl from 3 mRBCs does not significantly extravasate during activation and imaging 
as opposed to 2 mRBCs. However, a slight disturbance in the microvasculature is noted 
potentially due to generation of reactive oxygen species (ROS) during Cy5 photoactivation 
(Figure 2.12c).48 Correspondingly, the illuminated ear does contain less space between the 
endothelium and RBCs, however the degree of distension of the endothelial wall is more limited 
than the vasculature of illuminated 2 mRBCs (Figure 2.12d). Thus, TAX release does create a 
potent localized effect of cytotoxic endothelial damage as compared to the dark ear, untreated 
mouse ears, and 3 mRBCs. The extent of this localization is further quantified as TAX carried 
within transfused mRBCs that produce this effect sums up to 1 µg, while the maximum tolerated 
dose of TAX is 15 mg/kg in mice, and typical doses in mouse treatments are between 5 to 10 
mg/kg (75 to 250 µg) injected intravenously.49 Therefore, the adverse cardiovascular effect is 
achieved at treatments much lower than the maximum tolerated dose of TAX due to the localized 









Figure 2.11 Localized TAX damage to the endothelial wall upon photoactivation. a) 
Intravital imaging of photoactivated 2 mRBCs led to extravasation of the Cy5 fluorescence over 
90 min in healthy mouse ears. Representative images include 0, 15, 58, and 85 min with a 
scale bar of 100 μm. b) H&E staining of the photoactivated ear reveals a cardiovascular event 
due to minimal spacing between RBCs and distension of the endothelial wall (arrows, left). 
Control non-lasered ear has natural, generous spacing between RBCs and the endothelial wall 

















Figure 2.12 Additional controls of localized TAX release and resulting damage. Scale bar 
of all images represent 100 μm. a) H&E staining of topically applied free TAX (20 μM) to healthy 
mouse ears validates the extensive cytotoxic damage of TAX. b) Untreated left and right mouse 
ears display similar spacing between RBCs and the endothelial wall as the dark ear of the 2 
treated mouse. c) Intravital imaging over 90 min (including 0, 0.2, 5, 30, and 90 min) of 
photoactivated release from 3 mRBCs in vivo. Arrows highlight the fluorescence leak potentially 
due to ROS-driven extravasation. d) H&E staining of 3 mRBC treated mouse including 
photoactivated ear (left) and dark ear (right). Photoactivated ear demonstrates a degree of 









The localized effect of TAX was also analyzed in the tumor vasculature of an SVR 
angiosarcoma in immunodeficient Nu/Nu mice.50 Changes in the microvasculature surrounding 
the tumor were imaged using acoustic angiography with microbubble contrast agents (Figure 
2.13a).51, 52 TAX was photoreleased from 2 mRBCs by illumination with a 100 mW, 655 nm laser 
for 5 min. Imaging with acoustic angiography was done before injection for baseline, and at 0, 25, 
and 45 min post-injection. Images of tumor vasculature after treating with 2 mRBC with and 
without 655 nm illumination, 3 mRBC with 655 nm illumination, and vehicle mRBCs with 655 nm 
illumination were collected (Figure 2.13b,c). The intensity of the images corresponds to the 
localization of the microbubble contrast agents. Qualitatively, treatment with illuminated 3 mRBCs 
caused extravasation of the microbubble contrast agent into the tumor (Figure 2.13b). Images 
were quantified by the ratio of the summated microbubble coverage within the tumor to the 
summated total 3D tumor volume (Figure 2.14). Quantification validated initial qualitative 
observations, finding near doubling of the area microbubbles covered after treatment with 
illuminated 3 mRBCs. By contrast, control dark 2 mRBCs, illuminated 3 mRBCs, and illuminated 
vehicle-loaded mRBCs do not exhibit a significant persistent enhancement of microbubble 
coverage over time. These findings validate previous intravital imaging results, as TAX damage 
to the vessel endothelium results in extravasation of microbubbles into the tumor. Further, since 
controls do not exhibit comparable extravasation, both mRBCs containing 3 and illumination are 













Figure 2.13 Localized TAX effect in SVR-tumor-bearing, female Nu/Nu mice. a) Ultrasound 
acoustic angiography imaging setup. Laser illumination (100 mW, 655 nm) for 5 min at the 
tumor site ensured localized stimulation of treatment mRBCs. Scale bar represents 1 mm. b) 
Ultrasound images of illuminated (655 nm, 100 mW, 5 min) 2 mRBCs within the tumor shows 
a qualitative increase in microbubble coverage from baseline (left) to 45 min (right). c) 
Ultrasound images of control dark 2 mRBCs (n = 7), illuminated 3 mRBCs (n = 4), and vehicle 
mRBCs (n = 4) at baseline (top) and after 45 min (bottom). Scale bar represents 2.5 mm. 
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Figure 2.14 Quantification of localized TAX release as measured by microbubble 
coverage. The normalized microbubble retention was calculated as a ratio of summative 
microbubble coverage in the tumor to the summative 3D tumor size. These calculated values 
over time were then normalized to the baseline. Microbubble retention is significantly enhanced 
and persists over time in illuminated 2 mRBCs as compared to the controls: dark 2 mRBCs, 






Although many taxane carrier systems are under development and incorporate RBC 
membranes commonly for improved biocompatibility and circulation (e.g. nanoparticles coated 
with RBC membranes), no localized RBC delivery system of taxanes yet exist.53-58 The closest 
example, is paclitaxel loaded into RBCs, however no therapeutic release trigger is available in 
this system.59 Thus, we have generated the first taxane PACT delivery system which employs a 
photoresponsive Cbl scaffold and RBC carriers. The RBC carriers preserve the pharmacologic 
effects of the TAX chemotherapeutic, carry high quantities of drug (>30 μM/ mRBC), improve 
biodistribution of Cbl, and shelter TAX until photoactivation. Further, we have successfully 
demonstrated the localized photoactivation, release, and expected pharmacological effect of TAX 
in response to long-wavelength illumination in two in vivo mouse models by two unique imaging 
methodologies.  
RBC-based PACTs offer a biocompatible means of sheltering and localizing high 
quantities of therapeutic delivery to diminish off-target toxicity effects of potent chemotherapeutics. 
Stimulation with an external light device and response to wavelengths within the optimal window 
of tissue provides both spatial and temporal control over drug release at greater in vivo tissue 
depths. The inherent fluorescent properties of Cy5-Cbl PACTs also allow for imaging of 
distribution supporting the potential of theranostic applications. This initial validation of Cy5-Cbl-










2.7 Supporting Information, Figures, and Methods 
Materials  
All chemical reagents were purchased from Sigma-Aldrich or Thermo Fisher Scientific and 
were used as received. Human RBCs were purchased from ZenBio. Mice were purchased from 
Jackson Laboratories.  
 
2.7.1 Synthesis of Cbl Conjugates 
Synthesis of Cy5-Cbl-TAX (Scheme 2-1) 
Precursors N-Deboc docetaxel and FmocAM2-Cbl-AC4 were synthesized according to 
the previously procedures reported.18, 60 To prepare conjugate Cy5-Cbl-TAX, FmocAM2-Cbl-AC4 
(100 mg, 58 µmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU) (22 mg, 55 µmol) and N,N-diisopropylethylamine (DIPEA) (40 µL, 
232 µmol) were reacted in 4 mL anhydrous dimethylformamide (DMF) for 2 h at room temperature 
in the dark. DMF (2 mL) containing N-Deboc TAX (41 mg, 58 µmol) was added and the reaction 
was incubated at room temperature for another 5 h. To remove the Fmoc protecting group, 
piperidine (286 µL, 290 µmol) was added into the reaction mixture and mixed at room temperature 
for additional 30 min. The reaction mixture was precipitated with anhydrous ethyl ether (6 x 40 
mL) to remove piperidine. The crude sample was collected via centrifugation, mixed with Cy5-
NHS ester (30 mg, 52 µmol) and DIPEA (40 µL, 232 µmol) in DMF (2 mL) and allowed to react 
overnight in the dark. The reaction mixture was precipitated by diethyl ether (3 x 40 mL), filtered 
and dried under vacuum for 2 h. The product was purified via reverse phase chromatography (30 
g, RP-C18, Biotage) using a binary solvent system (A: water with 0.1% v/v TFA, B: MeOH with 
0.1% v/v TFA) with a gradient change from 50% B to 70% B over 12 column volumes (Figure 
2.15). Lyophilization yielded the product as a blue solid (60 mg, 41%). 1H NMR (400 MHz, DMSO-





7.57 – 7.06 (m, 17H), 7.05 – 6.76 (m, 5H), 6.71 – 6.45 (m, 3H), 6.32 – 6.23 (m, 4H), 5.80 (t, J = 
8.9 Hz, 1H), 5.72 – 3.81 (m, 34H), 3.74 – 3.46 (m, 6H), 3.45 – 2.57 (m, 9 H), 2.40 – 1.96 (m, 28H), 
1.96 – 1.44 (m, 24H), 1.44 – 0.75 (m, 29H), 0.55 (br.s, 2H), 0.32 (br.s, 2H), 0.04 (br.s, 2H), -0.27 





















































































































Figure 2.15 LC-MS chromatogram of purified Cy5-Cbl-TAX (2) detected by the fluorescent 













Synthesis of non-photocleavable conjugate Cbl≡-NH2, precursor of Cbl≡Cy5 
Cbl≡-NH2 was synthesized following modified procedure from literature.29 The reaction 
was carried by stirring using 1 eq of cyanocobalamin, 1 eq of copper (I) acetate (CuOAc), 2 eq of 
1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and 10 eq of 1,1-dimethylpropargylamine in 
dimethylacetamide (DMA) overnight under N2. The product was purified via reverse phase 
chromatography with water-methanol (containing 0.1% TFA) solvent system (Yield 71%; Figure 
2.16). 1H NMR (400 MHz, DMSO-d6, δ): 7.86 (s, 1H), 7.63 (s, 2H), 7.51 (s, 2H), 7.34 (s, 1H), 7.27 
(s, 1H), 7.17 (s, 1H), 7.06 (d, J = 7.6 Hz, 2H), 6.98 (s, 1H), 6.92 (s, 1H), 6.79 (s, 1H), 6.66 (s, 1H), 
6.54 (s, 1H), 6.47 (s, 1H), 6.36 (s, 1H), 6.24 (d, J = 2.9 Hz, 1H), 6.02 (d, J = 4.3 Hz, 1H), 5.79 (s, 
1H), 4.47 (s, 1H), 4.24 (d, J = 7.4 Hz, 1H), 4.20 (d, J = 11.3 Hz, 1H), 4.11 (d, J = 8.3 Hz, 1H), 3.89 
(s, 2H), 3.70 (dd, J = 10.1, 5.4 Hz, 2H), 3.55 (dd, J = 18.4, 11.5 Hz, 3H), 3.03 (d, J = 10.7 Hz, 1H), 
2.69 (m, 3H), 2.50-2.30 (m, 11H), 2.30 – 2.22 (m, 2H), 2.16 (d, J = 11.5 Hz, 6H),2.10-2.14 (broad 
s, 1H), 2.04 (d, J = 14.3 Hz, 1H), 1.88 (s, 4H), 1.80 (t, J = 14.3 Hz, 3H), 1.72 (s, 2H), 1.67 (s, 3H), 
1.56 (dt, J = 15.3, 7.7 Hz, 3H), 1.34 (s, 3H), 1.21-1.19 (s, 1H), 1.20 (d, J = 6.2 Hz, 6H), 1.07 (d, J 
= 6.11 Hz, 3 H), 0.98 (s, 5H), 0.97(s, 3H), 0.27 (s, 3H); HRMS (ESI) m/z: [M+H]+ calcd for 







Figure 2.16 LC-MS chromatogram of purified non-photocleavable conjugate Cbl≡-NH2 

















Synthesis of non-photocleavable conjugate Cbl≡Cy5 (Scheme 2-2)  
Cbl≡Cy5 was synthesized following procedure for Cy5-Cbl-TAX using Cbl≡-NH2 (1 eq), 
Cy5-COOH (1 eq), HATU (1 eq) and DIPEA (4 eq) in DMF and mixing for 0.5 h. The product was 
purified via reverse phase chromatography with water-methanol (containing 0.1% TFA) solvent 
system (Yield 90%; Figure 2.17). 1H NMR (400 MHz, DMSO-d6, δ): 8.33 (t, J = 13.2 Hz, 2H), 7.85 
(s, 1H), 7.66 – 7.56 (m, 5H), 7.52 (s, 1H), 7.41 (s, 3H),7.38 – 7.32 (m, 1H), 7.34 (s, 3H), 7.32 – 
7.20 (m, 3H), 7.14 (s, 1H), 7.04 (s, 1H), 6.94 (s, 1H), 6.88 (s, 1H), 6.80 (s, 1H), 6.65 (s, 1H), 6.60 
– 6.50 (m, 2H), 6.44 (s, 1H), 6.30 – 6.21 (m, 3H), 6.00 (s, 1H), 5.74 (s, 1H), 4.46 (s, 1H), 4.22 (s, 
1H), 4.07 (s, 5H), 3.88 (s, 2H), 3.61 (s, 3H), 3.55 (s, 5H), 2.55 (s, 92H), 2.38 (d, J = 16.0 Hz, 9H), 
2.27 (s, 1H), 2.15 (d, J = 14.2 Hz, 6H), 2.05 (s, 1H), 1.88 (s, 4H), 1.78 (s, 1H), 1.70 – 1.65 (m, 
25H), 1.56 (s, 2H), 1.42 (s, 2H), 1.31 (s, 2H), 1.23 (s, 8H), 1.15 (s, 4H), 1.10 – 1.02 (m, 10H), 1.01 
- 0.91 (m, 5H), 0.24 (s, 3H); HRMS (ESI) m/z: M+  calculated for (C99H133CoN16O15P)+, 1875.9; 





































































































































Figure 2.17 LC-MS chromatogram of purified non-photocleavable conjugate Cbl≡Cy5 (4) 
detected by the fluorescent detector (top, λex = 645 nm; λem = 675 nm) and by the UV detector 





2.7.2 Loading and Characterization of Cbl RBCs 
Red Blood Cell (RBC) Internal Loading Procedure  
Whole blood was collected from FVB or Nu/Nu mice via cardiac puncture. RBCs were 
isolated from whole blood using Ficoll and washed 3x in isotonic PBS (300 mOsm). RBCs were 
loaded with either Cy5-Cbl-H2O, Cbl≡Cy5, or Cy5-Cbl-TAX using a modified dialysis procedure.22-
24 The phototherapeutic conjugate was suspended in an 8:1 solution of Diluent C:DMSO and 
mixed with washed RBC pellets so that the final hematocrit was 70% and the Cbl conjugate 
concentration was 200 μM. The mixture was placed in a 1 kDa dialysis film and dialyzed against 
hypotonic buffer (80 mOsm/L PBS containing 6 mM glucose) for 20 min to open pores and allow 
influx of the Cbl conjugates. The dialysis film was then transferred to isotonic PBS and incubated 
for 10 min at 37 °C to reseal the cells. The RBCs were washed 3x in isotonic PBS to remove 
unloaded material and released hemoglobin. Quantitative loading efficiencies were obtained by 
extracting the conjugate into ethanol and measuring Cy5 absorbance at 645 nm (Figure 2.18 and 











Figure 2.18 UV-Vis absorbance spectra of Cy5-Cbl-TAX (2) (solid black line) and Cy5-Cbl-
H2O (3) (solid gray line) extracted from mRBCs with ethanol. The Cy5 peak at 649 nm is absent 






Figure 2.19 Quantification of Concentration of Cy5-Cbl-R/ mRBC. Standard curves at 645 
nm for a) Cy5-Cbl-TAX (2) and b) Cy5-Cbl-H2O (3) and cell counts post-loading of c) Cy5-Cbl-













RBC Surface Loading Procedure  
RBCs were prepared from whole blood the same way as in the RBC Internal Loading 
Procedure. RBCs were suspended to 10% hematocrit in PBS containing 0.02% FBS and mixed 
with the membrane staining dye DiD (Thermo Fisher Scientific) at a concentration of 10 µM. The 
mRBCs and dye were incubated at 37 °C with mild vertical rotation for 30 min and then washed 
3x in isotonic PBS to remove unloaded material.  
 
Widefield Microscopy 
RBCs were diluted to 0.05% hematocrit in PBS, plated on 35 mm MatTek glass bottom 
dishes, and incubated at room temperature for 15 min to allow the suspended cells to fall to the 
bottom of the plate. Widefield images were acquired with an inverted Olympus IX81 microscope 
equipped with a Hamamatsu FLASH 4V3, 60X oil objective and a Cy5 filter cube (Semrock). 
Multichannel images were split into their respective single channels.  
 
Confocal Microscopy 
Confocal microscopy images were taken with an Olympus FV1000 scanning confocal 
microscope with an IV81 base. Images were acquired using a 60X oil objective. A 635 nm laser 
was used for excitation of Cy5. All images were acquired at a resolution of 512 x 512 and a pixel 
dwell time of 10 μs pixel-1. All processing was performed using ImageJ software.  
 
Flow Cytometry 
Cbl conjugate loading was evaluated by an imaging flow cytometer (Image Stream, Amnis, 
Seattle, USA) acquiring 2000 - 10000 images of in focus singlets in the bright field channel and 
the fluorescence emission channel at 660 - 740 nm (Cy5) for each sample. First, a gradient root 





ratio/area was used to gate for single cells. The acquired images were analyzed with IDEAS 
software (Amnis). Scatter plots of Cy5 intensity/SSC (side scattering) were used to compare and 
contrast the internal complexity of the cells. For loading quantification, cells with a fluorescent 
intensity of at least 1 x 104 were defined as loaded. 
 
2.7.3 Stability and Photolysis of Cbl RBCs 
Mouse and Human in vitro Fragility Tests 
Whole blood was collected from DBAIJ mice by cardiac puncture and mRBCs were 
isolated via a standard Ficoll procedure. Human RBCs were purchased from Zen-Bio. RBCs were 
internally loaded with Cy5-Cbl-TAX (2) using the RBC Internal Loading Procedure. All the 
procedures involving light-sensitive drug were conducted with a minimal light exposure. After the 
loading procedure, the cells were washed 3x in 1X PBS, the pellet volume was measured, and 
the cells were diluted to 10% hematocrit in clear DMEM media (Gibco) with 1X GlutaMAX (Gibco) 
and 1% FBS. The cells were suspended and divided into four equal aliquots and stored at 4 °C in 
dark. After 1, 2, 3 and 5 days, the cells were centrifuged, and the supernatant absorbance was 
measured at 420 nm to determine hemoglobin leakage. A completely lysed pellet was measured 
at 420 nm to determine the absorbance at 100% lysis. The pellet size was estimated in order to 
determine the rate of cell lysis. hRBCs were treated the same except that washes were conducted 










Characterization of Photolysis Product of Cy5-Cbl-TAX (Scheme 2-3) 
Cy5-Cbl-TAX (25 μM) in phosphate-buffered saline (1x PBS) was illuminated for 30 min 
using an Oriel Xe flash lamp (800 mJ, 62 Hz) as the light source with selective bandpass filters 
for 646 ± 10 nm. Photolyzed samples were analyzed by LC-MS using a linear gradient binary 
solvent system (solvent A: 0.1% formic acid/H2O; solvent B: 0.1% formic acid/methanol) with a 





















































































































Molecular Weight: 1899.14 
Cy5-Cbl-TAX (2) 






Figure 2.20 Complete photolysis of Cy5-Cbl-TAX (2). a) Reverse-phase HPLC trace of Cy5-
Cbl-TAX in PBS (25 μM, pH = 7.4) irradiated at 646 nm for 30 min. The chromatogram was 
recorded at 254 nm where “peak a” = TAX photoproduct (Scheme 2-3) and “peak b” = Cy5-
Cbl-H2O photoproducts. b) ES-MS spectrum of the photolyzed Cy5-Cbl-TAX derivative was 
recorded in positive ion mode (peak a). Characteristic molecular and fragment ions: [M++Na]2+ 
(m/z 816.6), [M++K]2+ (m/z 832.4). c) ES-MS spectrum of photolyzed Cy5-Cbl-TAX recorded in 
positive-ion mode (peak b). Characteristic molecular and fragment ions: [M-H2O]2+ (m/z 940.1), 












Assessment of TAX Photorelease from RBCs 
Cy5-Cbl-TAX loaded hRBCs (100 µL) were added to 1 mL of human platelet rich plasma 
from Zen-Bio, Inc. Photolysis of the samples was performed using an Oriel Xe flash lamp (800 
mJ, 62 Hz) as the light source with selective bandpass filters for 646 ± 10 nm as described above 
in Characterization of Photolysis Product of Cy5-Cbl-TAX. Photolyzed RBC suspensions were 
incubated at 37 ˚C, subsequently centrifuged at 1000 g for 2 min, and the supernatant removed 
from the pellet. Acetonitrile was added to the supernatant in a 1:1 ratio, centrifuged at 21,000 g 
for 10 min, and then analyzed by LCMS (solvent A: 0.1% formic acid/H2O; solvent B: 0.1% formic 
acid/isopropanol). The pellet was lysed with 1 mL of acetonitrile and analyzed by LC-MS. The 
photolyzed TAX product was monitored by its fragment ions 506.8 and 626.8. The percentage of 
photolyzed TAX present in the supernatant was 98 ± 1%. By contrast, no detectable levels of TAX 
were found in the supernatant for samples incubated in the dark. 
 
Sensitivity of mRBCs to Hemolysis Under Light Conditions  
Whole blood was collected from DBA1J mice by cardiac puncture and isolated via a 
standard Ficoll procedure. mRBCs were internally loaded with Cy5-Cbl-TAX (2) or Cy5-Cbl-H2O 
(3) using the RBC Internal Loading Procedure. All the procedures involving light-sensitive drug 
were conducted with a minimal light exposure. The loading procedure was performed 3x for each 
sample to ensure sufficient volume and each sample was pooled and diluted to 5% hematocrit. 
The cells loaded with each compound were then separated into nine 300 µL aliquots. Three 
aliquots were completely lysed by adding Triton X-100 to final concentration of 0.05%. Three other 
aliquots were incubated for 10 min in the dark and the last three aliquots were illuminated for 10 
min under 660 nm LED light. The cells from the dark and light experiments were spun down and 
the supernatant collected. Triton X-100 was added to the recovered supernatants so that the final 





= 645 nm, λem = 675 nm) and hemoglobin absorbance (λmax = 420 nm). Fluorescence was 
measured using SpectraMax Gemini EM (Molecular Devices) while absorbance was measured 
with a DeNovix DS-11 FX+ spectrophotometer/fluorometer, using the microvolume setting.  
 
2.7.4 Cellular Assays Characterizing Cbl-Tax RBC Pharmacological Effects 
Microtubule Polymerization Assay 
HeLa cells (ATCC) at 50,000 cells/well were plated on MatTek 24-well glass bottom plates 
pre-coated with gelatin. hRBCs loaded with Cy5-B12-TAX (2) [see Red Blood Cell (RBC) Internal 
Loading Procedure method above] were added at 10% hematocrit in 500 µL of complete media 
in a Millicell Hanging Cell Culture Insert (1 µm, polyethylene terephthalate, Millipore). Control 
groups include complete media only as well as docetaxel (TAX, 20 nM). Wells for the hRBC + 
light conditions, complete media, and 20 nM TAX in media, were then exposed to a 660 nm LED 
board for 30 min at room temperature. Cells were then allowed to incubate for 24 h. Following 
this treatment time, culture inserts containing HeLa cells were removed from each well, washed 
once with Dulbecco’s PBS (DPBS) and fixed with 4% paraformaldehyde for 10 min at room 
temperature in the dark. Cells were washed twice with 500 µL DPBS and immediately blocked for 
1 h at room temperature in 5% donkey serum (Millipore), 1% BSA, and 0.1% Triton-X 100 in PBS. 
Cells were incubated with mouse anti-a-Tubulin [DM1A] antibody (Sigma Aldrich, T9026) at 
1:1000 in 1% BSA, 0.5% Triton-X 100 in PBS overnight at 4 °C. Cells were washed 3 x 5 min in 
DPBS before application of Alexa546 anti-mouse secondary antibody at 1:2000 in blocking buffer 
for 1 h at room temperature. Cells were then washed 3x with PBS. The second wash contained 
Hoechst 33342 as a nuclear counterstain (1 µL of 5 mg/mL solution per 1 mL PBS). Imaging was 
performed on an inverted Olympus IX81 microscope equipped with a Hamamatsu ORCA-
Flash4.0 camera, 60x oil immersion Plan S-Apo NA 1.35 objective. Images for each condition 





Cell Viability Assay  
HeLa cells (ATCC Cat. CCL-2) were plated 2,500 cells/well in 96-well tissue culture plates 
(Corning Costar Cat. #3595) in full growth media following the supplier’s recommendations. 
Human RBCs (ZenBio Cat. SER-10MLRBC) were loaded with Cy5-Cbl-TAX (2) following the RBC 
Internal Loading Procedure with minimal light exposure. hRBCs were washed with L-15 media 
(Gibco Cat. #21083-027) 3-5x, then a final wash with 0.22 µm filtered FBS (Millipore-Sigma Cat. 
#TMS-013-B). hRBCs were resuspended to 20% hematocrit with full HeLa cell growth media. 
Light treated hRBCs were illuminated with a 660 nm LED light board for 30 min at room 
temperature. Unilluminated hRBCs were wrapped in aluminum foil at room temperature for 30 
min. hRBCs were spun down and the supernatants for the light and dark treatments were 
collected and put on ice. 24 h after HeLa cells were plated, all media was removed from wells and 
exposed to the following different conditions in triplicate at 37 ˚C for 24 h: 100 µL of (i) complete 
media, (ii) 10 nM docetaxel in full media, (iii) 1 µM docetaxel in full media, (iv) supernatant from 
light-exposed, Cy5-Cbl-TAX (2) loaded hRBCs, or (v) supernatant from unilluminated, Cy5-Cbl-
TAX (2) loaded hRBCs. Cells were incubated at 37 °C for 24 h. Cell viability was assessed using 
the Calcein AM kit (BioVision #K305-1000) following the manufacturer’s instructions. 
 
2.7.5 In vivo Biodistribution and Localization Studies 
Intravital Imaging 
Healthy FVB mice were housed in an approved Division of Comparative Medicine facility 
until time of imaging. Intravital imaging microscopy experiments were performed using an 
Olympus IV-100 laser scanning confocal microscope. Images were acquired using a 10x air, 0.4 
numerical aperture, working distance 3.1, 13 mm objective and 1.5 zoom value. Images were 
acquired every 5 s for 90 min at a resolution of 512 x 512 and a pixel dwell time of 10 μs pixel-1. 





two-sided tape on an aluminum block. The mice were anesthetized with 2% isoflurane and placed 
onto a heated stage (37 °C) to maintain their core body temperature throughout the 90 min 
imaging procedure. Blood vessels were located in the left ear by illuminating it with a bright white 
light while imaging in the green fluorescence channel. Tissue autofluorescence appears green, 
while the vessels appear as dark voids. Suspensions of 100 μL containing RBC pellets at 75 - 
90% hematocrit in PBS were injected via tail vein. Prior to injection, RBCs were internally loaded 
with either Cy5-Cbl-H2O or Cy5-Cbl-TAX (n = 3 animals). As controls, groups of mice were also 
injected via tail vein with 100 μL RBCs at 75 - 90% hematocrit internally loaded with Cbl≡Cy5, 
mixed with free Cbl≡Cy5, or externally loaded with DiD (n = 6 vessels). Both Cy5 and DiD 
fluorophores were excited using a 633 nm laser and detected in the 647 nm channel. The image 
files from each scan were exported to ImageJ software for analysis. Once imaging was completed, 
mice were euthanized with CO2 followed by a secondary physical method. All animal imaging 
performed was approved by the Institutional Animal Care and Use Committee at the University of 
North Carolina at Chapel Hill. 
 
Measurement of Circulation Time 
The quantitative fluorescent intensity of a straight-line region of interest containing 
vasculature was measured and background fluorescence of an empty vessel was subtracted from 
each measurement. Selected regions of interest (n = 3) for mice in each category were used to 
calculate the average fluorescence intensity at each time point. Each point in each time series 
was normalized to the highest fluorescent value to account for random variation between animals 









For histological analysis, ears were harvested less than 5 min after euthanasia at room 
temperature and the illuminated blood vessels (as well as the corresponding vessel in the non-
illuminated ear) were marked with tissue staining dye. Ears were immediately immersion-fixed in 
10% neutral buffered formalin in a 1:15 tissue: fixative volume ratio for 48 h at room temperature. 
The tissue was post-fixed in 70% ethanol at a 1:15 tissue: ethanol volume ratio and embedded in 
paraffin. 4 μm cross-sections were subsequently stained with H&E and microscopically evaluated. 
Images were acquired under a 40X objective of a color optical microscope.  
 
Ultrasound Animal Care and Imaging  
Homozygous Nu/Nu mice were housed in an approved Division of Comparative Medicine 
facility until time of imaging. At five weeks old, mice were given a 100 µL subcutaneous injection 
of 7 x 106 SVR angiosarcoma cells/mL. Tumor measurements were recorded 3x a week and mice 
were imaged when tumor size was between 5 - 10 mm in the largest dimension. Mice were placed 
on a heating pad warmed to 37 ˚C and kept under 1.5% isoflurane anesthesia for the duration of 
the imaging experiment. Ultrasound gel applied to the tumor site helped couple tissue with the 
transducer used for imaging. Once imaging was completed, mice were euthanized with an 
overdose of isoflurane followed by a secondary physical method. All animal imaging performed 
was approved by the Institutional Animal Care and Use Committee at the University of North 
Carolina at Chapel Hill.  
 
Ultrasound Contrast Agent and RBC Administration 
Perfluorocarbon microbubbles made in-house were injected in each animal via a 27G tail-
vein catheter. Microbubbles were sized using an AccuSizer 780A (Particle Sizing Systems, Santa 





maintained throughout the course of the study. Microbubbles (MB) were diluted to 5 x 109 MB/ 
mL and were delivered via a 50 µL volume followed by a 50 µL saline flush. Microbubble doses 
were administered before each imaging time point. Before the start of treatment, 100 µL of 
prepared mRBCs were injected followed by 50 µL of heparinized saline.  
 
Ultrasound Imaging Protocol 
Mice were imaged with a Vevo 770 imaging system using a custom-built dual frequency 
transducer (VisualSonics, Toronto, ON, Canada). The ultrasound probe, mounted on a motion 
stage to allow for 3D data collection, transmits at 4 MHz and receives at 28 MHz. 16 mice were 
divided into the following four experimental groups: Cy5-Cbl-TAX (2) loaded mRBCs with light 
treatment, Cy5-Cbl-TAX (2) loaded mRBCs without light treatment (dark), Cy5-Cbl-H2O (3) loaded 
mRBCs with light treatment, and vehicle-loaded mRBCs with light treatment. First, a 3D B-mode 
scan was collected using a 3 Hz frame rate and a 100 µm step size. Scan length varied based on 
tumor size. Additional 3D acoustic angiography scans were collected before treatment (baseline) 
and at 5, 15, 25, 35, and 45 min following the beginning of treatment. Light-treated animals were 
exposed to a 655 nm 100 mW laser that was aligned at the tumor site. The tumor was illuminated 
for a total of 5 min.   
 
Ultrasound Data Analysis 
Data was analyzed using a custom-built MATLAB program (MathWorks, Natick, MA, USA). 
Individual regions of interest (ROIs) were drawn slice by slice on the B-mode set for each animal. 
These ROIs were applied to the contrast images and adjusted as necessary to account for animal 
motion and breathing. Images were binarized using Otsu’s method and the area of thresholded 
signal within the 3D ROI set was calculated. This value was divided by the area of the entire 3D 





each animal. A two-factor ANOVA evaluating imaging time points and experimental group was 
performed to test for statistical significance. This was followed by Dunnett’s multiple comparison 
for imaging time points and Fisher’s Least Significant Difference multiple comparison for 
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3.1 Introduction to Photoactivated RBCs as Drug Depots for Arthritis 
Stimuli-responsive drug delivery systems offer the promise of improved efficacy and 
reduced toxicity of therapeutic agents. Ultrasound, heat, radiation, and light can be directed at the 
diseased site and, when coupled with a drug delivery system, can be used to guide the drug to 
its intended target. An especially compelling case for targeted drug delivery is inflammatory 
arthritis, a debilitating autoimmune disease with symptoms of extreme pain and cartilage 
degradation predominantly presenting in the joints of the hands and feet. Current first-line 
treatments include nonsteroidal anti-inflammatory drugs and corticosteroids, such as 
dexamethasone (Dex). Unfortunately, the prolonged use of Dex is responsible for a variety of 
significant side effects, including bone-thinning, weight gain, diabetes, and immunosuppression.1 
Novel therapies designed to maintain Dex’s circulatory presence while minimizing its systemic 
side effects employ slow release carrier-based systems such as liposomes, polymer-drug 
conjugates, and red blood cells (RBCs).2 Indeed, RBCs present a potentially elegant solution to 
the challenge of creating a long term (months) drug depot that circulates throughout the body in 
an innocuous, dormant form. A variety of RBC-based therapeutic carrier systems have been 





interior of RBCs.3-6 Most studies reported to date employ an internally loaded prodrug that slowly 
hydrolyzes to create a membrane permeable parent therapeutic, which subsequently diffuses out 
of the RBC carrier.4 This strategy provides a continuous stream of systemically released 
therapeutic. By contrast, we describe herein the construction and application of engineered RBCs 
that stably house a Dex derivative that is released upon exposure to long wavelength light. 
Although light, as a targeting agent, enjoys a number of potential advantages (tight spatial, 
temporal, and flux control, wavelength modulation),7, 8 one especially noteworthy attribute is that 
light can be easily focused on the inflamed and painful joints by the patient.9 The patient-guided 
delivery of an anti-inflammatory agent to diseased sites could prove useful in controlling the most 
devasting aspects of inflammatory arthritis while limiting the consequent side-effects. 
A key element of our design strategy is the covalent attachment of Dex to vitamin B12 
(cobalamin, Cbl), where Cbl serves three roles.10 First, Cbl is membrane impermeable, which 
ensures that the internally loaded Cbl-Drug is retained by the RBC. Second, Dex is appended to 
the central Co of Cbl via a light responsive Co-C bond. Exposure to the appropriate wavelength 
cleaves Dex from the Cbl anchor, enabling the drug to freely diffuse from the RBC. Third, although 
the corrin ring of Cbl absorbs only short wavelength light (330 - 575 nm), installation of 
fluorophores on the Cbl11-13 adjusts photo-release of the appended drug to longer, tissue-
penetrating wavelengths (650 - 800 nm).14, 15 With these attributes in mind,  we report herein the 
preparation and characterization of RBC loaded photoactivatable Dex and its application to a 










3.2 Synthesis of Cbl-Dex  
Both Cy5-Cbl-Dex (1) and Cy5-Cbl-H2O (2) (Figure 3.1) were synthesized and introduced 
into RBCs in order to assess drug photo-delivery as a potential therapeutic strategy for the 
treatment of inflammatory arthritis. Cy5-Cbl-H2O served as an inactive control that lacks the Dex 
therapeutic agent. In brief, Dex was appended to the aminopropyl ligand on the Co and Cy5 
subsequently coupled to an ethylenediamine linker on the ribose of Cbl (see section 3.8.1). The 
Cy5 fluorophore extends the light capturing wavelengths of Cbl from 330 - 575 nm to 650 nm, 










Figure 3.1 Structures of photoactivatable Cy5-Cbl-Dex (1) and control compound Cy5-








































































































3.3  Assembly of Cy5-Cbl-Dex RBCs  
RBCs internally loaded with either 1 or 2 were prepared using a hypotonic swelling 
procedure (Figure 3.2).10, 11, 16 In brief, exposure of RBCs to a low ionic strength buffer solution 
induces cell swelling and pore formation within the cell membrane, which enables otherwise 
impermeable compounds to enter RBCs. The pores are subsequently resealed upon exposure to 
a high salt solution to reestablish an isotonic environment, which internally entraps the molecule 















Figure 3.2 Assembly of Cy5-Cbl-Dex RBC Phototherapeutics. Schematic representation of 
the isotonic-to-hypotonic-to-isotonic method by which phototherapeutics are loaded into RBCs. 
Pore formation in the RBC membrane occurs in the presence of 1 under hypotonic conditions 
(4 ˚C for 40 min). Pores are subsequently resealed by direct addition of high salt followed by 

















Figure 3.3 Widefield images of loaded RBCs. a) Transmitted (top) and fluorescent Cy5 
(bottom) images of internally loaded hRBCs containing 1 or 2, as well as native hRBCs. Scale 
bar represents 10 µm. b) Transmitted (top) and fluorescent Cy5 (bottom) images of internally 









The overwhelming majority of RBC drug loading studies have been performed with human 
erythrocytes (hRBCs). Although loading conditions are well established for hRBCs, mouse RBCs 
(mRBCs) are less stable than their human counterparts.10 We found that modification of the 
established loading protocol improves the stability of the loaded mRBCs.18-20 Key optimized 
parameters include lengthening the drug loading and membrane resealing times, the high salt 










Figure 3.4 In vivo circulation of mRBCs containing 2 (black bars) after 1 h loaded by the 
initial protocol (hRBC protocol used with mRBCs) and final optimized protocol as compared to 







































3.4 In vitro Characterization of Cy5-Cbl-Dex RBCs 
3.4.1 Morphology and Properties of Cy5-Cbl-Dex RBCs 
We characterized both hRBCs and mRBCs loaded with 1 or 2, including volume and 
hemoglobin content of the loaded RBCs, cellular distribution of the phototherapeutic, as well as 
loading homogeneity and quantity of Dex in loaded RBCs. These studies include an examination 
of native (isolated but unmodified) RBCs, RBCs loaded with 1 or 2, and RBCs surface modified 
with the lipidated indocarbocyanine fluorophore DiI (1, 1’-dioctadecyl-3, 3, 3’, 3’- 
tetramethylindocarbocyanine perchlorate; lex 550 nm, lem 570 nm). The DiI loaded cells have 
been used as a control circulation population and thus are a useful comparison for in vivo studies 
of internally loaded RBCs.22 The DiI loaded cells represent a population of RBCs that have 
undergone a loading procedure (external loading with DiI), but this procedure does not open pores 
in the membranes of the RBCs, nor does it affect their internal contents. The mean cell volume 
(MCV), mean cell hemoglobin (MCH), and mean cell hemoglobin concentration (MCHC) of both 
hRBCs and mRBCs were assessed by automated hemocytometry (Table 3-1).23 
RBCs internally loaded with 1 or 2 are smaller and contain less hemoglobin on average 
than native RBCs, while RBCs that are externally loaded with DiI display values similar to native 
RBCs (Table 3-1). Trends are comparable for both mRBCs and hRBCs, consistent with the notion 
that opening and resealing RBCs results in the loss of some of the intracellular contents. In 
addition, although the recovery of hRBCs following loading is essentially quantitative, a 
significantly lower recovery was obtained for mRBCs. These results are consistent with the 







Table 3-1 Automated hemocytometry measurements of in vitro properties of human and 
mouse RBCs. (Data presented as mean ± SD, n = 3) 
Properties Nativea) DiIa) 1a) 2a) Nativeb) DiIb) 1b) 2b) 
MCV [fl] 98 ± 5 100 ± 1 70 ± 7 76 ± 5 34 ± 1 36 ± 3 29 ± 3 33 ± 4 
MCH [pg] 28 ± 2 30 ± 1 18 ± 1 21 ± 2 13 ± 1 14 ± 1 8 ± 1 8 ± 1 
MCHC [g/dL] 29 ± 1 30 ± 1 25 ± 3 28 ± 2 38 ± 1 40 ± 1 27 ± 4 23 ± 1 
Cell recovery 
after loading  
NA 100% 100% 100% NA 100% 25-50% 25-50% 
a) human RBCs; b) mouse RBCs 
 
 
Imaging flow cytometry was used to qualitatively visualize the various RBC populations 
and to quantitively assess changes in diameter and granularity (side light scattering) (see section 
3.8.2). RBCs loaded with 1 or 2 are visually comparable to DiI and native controls (Figure 3.5). 
However, RBCs containing either 1 or 2 exhibit a decrease in both size (diameter) and  granularity  
compared to native or DiI loaded RBCs (Figure 3.6). The decrease in diameter of internally loaded 
RBCs is consistent with hemocytometry MCV analysis and suggests that loss of some of the 
hemoglobin during the drug loading process is responsible for the smaller cell size. Granularity is 
commonly related to the internal complexity (microparticles) of the cell. Since RBCs are presumed 
to have a relatively homogenous refractive index,24 this implies that the refractive index is altered 







Figure 3.5 Characterization of native and loaded RBCs by imaging flow cytometry. Brightfield images (left) and fluorescent 
images (right) of native, surface loaded (DiI), and internally loaded (1, 2) RBCs. Scale bar represents 7 µm. a) Flow images of 
















Figure 3.6 Characterization of native and loaded RBCs by flow cytometry diameter 
versus granularity dot plots. a) Plot of granularity versus diameter of loaded hRBCs. hRBCs 
loaded with 1 (red) display a greater variability in granularity compared to DiI (yellow) and native 
hRBCs (black x) (top). hRBCs loaded with 2 (blue) exhibit morphological changes comparable 
to those displayed by hRBCs containing 1 (red) (bottom). b) Plot of granularity versus diameter 
of loaded mRBCs. mRBCs loaded with 1 (red) display a greater variability in granularity 
compared to DiI (yellow) and native mRBCs (black x) (top). mRBCs loaded with 2 (blue) exhibit 
morphological changes comparable to those displayed by mRBCs containing 1 (red) (bottom).   






























































































We also assessed the uniformity of drug loading in RBCs as well as quantifying the amount 
of Dex loaded. Fluorescent imaging flow cytometry revealed a uniform peak of loaded 1 and 
slightly less uniform 2 in hRBCs and mRBCs (Figure 3.7). The amount of Cy5-Cbl-Dex and Cy5-
Cbl-H2O loaded was quantified by ethanol extraction of loaded RBC pellets and subsequent 
measurement of the absorbance of Cy5 at 649 nm (see section 3.8.2). mRBCs contain 0.4 mg 
Dex/100 µL of mRBCs while their human counterparts possess a comparable 0.5 mg Dex/100 µL 








Figure 3.7 ImageStream flow cytometry representative fluorescence histograms of RBCs 





























































3.4.2 Photolysis of Dex from Cbl-Dex hRBCs 
We subsequently examined the light-triggered release of Dex from loaded hRBCs. Given 
that the phototherapeutic is designed to respond to 645 nm photons, which penetrates tissue to 
greater depths than shorter wavelengths, we explored Dex release in the presence of the 
Fitzpatrick series of tissue phantoms. The latter are devised to mimic the tissue absorbing 
properties of human skin color, from lightly to heavily pigmented.25 The photo-release of Dex from 
hRBCs containing 1 was quantified by LC-MS (see section 3.8.3). Furthermore, following 
treatment, the RBC-containing solution was centrifuged and the presence of free Dex examined 
in both the pellet and the supernatant. We did not detect free Dex in the absence of 645 nm 
illumination (Figure 3.8a). By contrast, 5 min exposure to 645 nm light generated the vast majority 
(90 ± 5.8%) of free Dex in the supernatant, consistent with the notion that Dex, once released 
from the membrane impermeable Cbl, is free to diffuse out of the RBC (Figure 3.8a). 
We also examined the photolysis of 1 filtered through Fitzpatrick skin phantom solutions 
in order to mimic tissue absorption and scattering of light (Figure 3.8b,c).26 The phantoms 
employed are designed to reproduce the properties of light (Type I-II; [melanin] = 8.8 µg/mL), 
brown (Type III-IV; [melanin] = 66 µg/mL), and dark (Type V-VI; [melanin] = 130 µg/mL) skin.26 
Illumination (510 nm) through the Fitzpatrick phantoms fails to produce significant photolysis of a 
buffered solution of Cbl-Dex (see section 3.8.1). Nearly 90% of Cbl-Dex is unphotolyzed upon 6 
min of illumination in the presence of type I/II Fitzpatrick phantom (Figure 3.8b). As expected, 
tissue phantoms containing greater melanin concentrations are even more effective at blocking 
photolysis. By contrast, analogous experiments performed at 645 nm with 1 results in nearly 
complete photolysis after only 3 min (Figure 3.8c). Finally, we examined the photorelease (645 
nm) of Dex from hRBCs containing 1 in the presence of the tissue phantoms (Figure 3.8d). 
Reassuringly, illumination triggers the rapid photolysis of 1 and subsequent release of Dex from 






Figure 3.8 Photolysis of Cbl-Dex derivatives and release from hRBCs. a) hRBCs 
containing 1 were kept in the dark or exposed to 645 nm light for 5 min. Following illumination, 
the RBCs were centrifuged and the presence of free Dex in the supernatant (white bars) and 
pellet (black bars) quantified via LC-MS. Free Dex is not detected in the absence of illumination 
whereas, upon illumination, 90 ± 5.8% of free Dex is present in the supernatant. b) Illumination 
(510 nm) of Cbl-Dex in solution in the presence of Fitzpatrick phantom solutions: light (Type 
I/II, circle), brown (Type III/IV, square), and dark skin (Type V/VI, triangle). c) Illumination (645 
nm) of 1 in solution in the presence of Fitzpatrick phantom solutions. d) Illumination (645 nm) 
of 1 in hRBCs in the presence of Fitzpatrick phantom solutions. All samples were illuminated 



















3.4.3 Impact of Photoreleased Dex from Cy5-Cbl-Dex hRBCs on Human Cells 
Our initial studies on the potential therapeutic efficacy of photoactivatable Dex were performed 
on a variety of cultured human cells. Dex mediates its therapeutic action via the glucocorticoid 
receptor a (GRa), which is normally found in the cytoplasm but localizes to the nucleus in 
response to glucocorticoid binding.27 Upon entry into the nucleus, GRa associates with 
glucocorticoid responsive elements and stimulates or represses target gene expression.27, 28 We 
assessed the ability of Dex, photoreleased from RBCs bearing 1, to trigger GRa in HeLa cells 
and primary fibroblast-like synoviocytes (FLS). HeLa cells were used as a model cell line due to 
their established sensitivity to conventional Dex (Figure 3.9).29 In contrast, FLS are non-immune 
cells that have been demonstrated to participate in rheumatoid arthritis (RA) pathogenesis. The 






Figure 3.9 Immunohistological analysis of HeLa cells responding to a gradient of Dex 












Both HeLa and FLS cells were exposed to hRBCs bearing 1 in the dark and at 660 nm. In addition, 
RBCs containing 2 (i.e., no Dex) was used as a negative control and Dex itself was employed as 
a positive control. HeLa cells respond in a manner consistent with literature precedent (Figure 
3.10).29 In the absence of 660 nm exposure, GRa is primarily retained in the cytoplasm in 
untreated HeLa cells and in cells co-incubated with hRBCs containing either 1 or 2. By contrast, 
robust GRa nuclear localization is clear in Dex exposed HeLa cells. Analogous experiments were 
performed in the presence of 660 nm light. Untreated HeLa cells, as well as those co-incubated 
with hRBCs containing 2 (negative control), fail to display a nuclear GRa migration. However, 
hRBCs loaded with 1 trigger the anticipated GRa migration in a fashion consistent with that 
observed with the parent glucocorticoid. These experiments were recapitulated using primary FLS 
cells from RA patients (Figure 3.11). We do note that FLS cells are phenotypically heterogeneous 
and do not display the near 100% uniform GRa nuclear migration observed with HeLa cells. 
However, both 660 nm-exposed hRBCs bearing 1, and Dex itself, trigger the same degree of GRa 
















Figure 3.10 Immunocytochemical analysis of GRa nuclear localization in HeLa cells. 
HeLa cells were cultured in serum free media for 24 h and then left untreated (column 1), 
exposed to hRBCs containing 2 (column 2), Dex (250 nM) (column 3), or hRBCs containing 1 
(column 4) in the absence (row 1) or presence of 660 nm light (row 2). Cells were fixed and 
permeabilized, exposed to anti-GRa, and subsequently anti-rabbit secondary antibodies 
conjugated to Alexa Fluor 488 (green). Cells were also labeled with the nuclear Hoechst 33342 
stain (blue). Images display merged green and blue channels where scale bars represent 30 








Figure 3.11 Immunocytochemical analysis of GRa nuclear localization in FLS cells. FLS cells were left untreated (column 1), 
exposed to hRBCs containing 2 (column 2), Dex (250 nM; column 3), or hRBCs containing 1 (column 4) in the absence (row 1) or 
presence of 660 nm light (row 2). Cells were fixed and permeabilized, exposed to anti-GRa, and subsequently anti-rabbit secondary 

















Figure 3.12 Pearson’s coefficient quantification of co-localization in anti-GRa and 
Hoechst stained primary FLS cells. -1 represents anti-localization while 1 represents 
complete co-localization. GRa is not nuclear localized in FLS cells exposed to hRBCs loaded 
with 1 (Cy5-Cbl-Dex) in the dark (black bar), whereas GRa is nuclear localized under identical 
























Glucocorticoids are known to induce apoptosis in certain cell types, which has been shown 
to serve as both a mechanism of action for anti-inflammatory effects as well as a contributor to 
certain negative side effects (such as osteoporosis).27 With this in mind, we examined the impact 
that free Dex, or hRBCs containing 1 or 2, on Dex resistant and sensitive cells (see section 3.8.4). 
FLS cells experience minimal growth inhibition in response to treatment with Dex (Figure 3.13a). 
The viability of FLS cells is likewise minimally impacted upon exposure to illuminated hRBCs 
bearing either 1 or 2 (Figure 3.13b). However, unlike synoviocytes, B cells are known to be 
sensitive to Dex (Figure 3.13a).30, 31 We examined the effect of hRBCs loaded with either 1 or 2, 
in the presence of 660 nm light, on Sup-B15 lymphoma B cell viability. As expected, both Dex 
photo-released from Cy5-Cbl-Dex hRBCs, as well as the parent drug (Dex), impact B cell viability 
(Figure 3.13b). These results suggest that Dex, delivered to the site of inflammation, should 
reduce the localized immune response responsible for symptoms associated with arthritis. 
Furthermore, since synoviocytes play a key role in producing extracellular components of the 








Figure 3.13 Viability of cells exposed to Dex and Cbl-RBCs. a) Viability of FLS cells at a 
density of 5,000 cells/cm2 (left). FLS cells display a comparable, yet minimal, response to Dex 
(2 mM) and 1 hRBCs (Cy5-Cbl-Dex) illuminated at 660 nm (30 min). By contrast, the viability 
of FLS cells is not impacted by 2 hRBCs (Cy5-Cbl-H2O) in the presence of 660 nm. Viability of 
Sup-B15 cells in the presence of Dex (2 mM), 1 hRBCs, and 2 hRBCs following 30 min of 660 
nm illumination (right). The toxicity of illuminated 1 hRBCs (Cy5-Cbl-Dex) is similar to that of 2 
mM Dex, thereby demonstrating that both treatments have an analogous effect. By contrast, 
660 nm exposed 2 hRBCs have no cytotoxic effect on Sup-B15 cells, indicating that the 
cytotoxic effect is Dex-dependent. (n = 3, *P < 0.05, **P < 0.01, ***P < 0.005, NS = not 
significant). b) The effect of 660 nm illuminated hRBCs loaded with 1 or 2 on the viability of FLS 
and Sup-B15 B cells. hRBC treatments with 1 have a minimal impact on FLS cell viability, but 
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3.5 In vivo ADME of Cbl-Dex Red Blood Cells  
The circulatory integrity of modified RBCs was examined with a 1:1 mixture of two mRBC 
populations: (i) internally loaded with Cy5-Cbl-H2O (2) and (ii) externally loaded with DiI (Figure 
3.14a). A mixture of the two populations were tail vein injected into mice and a blood sample was 
subsequently acquired after 20 min. Flow cytometry revealed that both cell types constitute 
approximately 3% of all circulating RBCs. Subsequent blood sampling after 1 h revealed minimal 
loss of circulating modified RBCs. These results indicate that the loaded mRBCs were circulating 
during illumination. 
The distribution of mRBCs loaded with 1 in the kidneys, liver, and spleen of treated animals 
at 0 min, 30 min, and 24 h was visualized via histology (Figure 3.14b,c). Damaged RBCs are 
predominantly cleared by the spleen, which filters the blood through cords. Aged or damaged 
RBCs which have stiffer membranes cannot pass through these cords and are then cleared by 
splenic macrophages.32 Evidence of intracellular Cy5 RBCs in the blood (Figure 3.14a) and within 
the red pulp of the spleen after was observed 30 min and 24 h (Figure 3.14b,c). Cy5 was also 
present in the liver and renal tubules after 24 h (Figure 3.14d) suggesting hepatic clearance and 
urinary excretion of freed Cy5-Cbl, respectively. Mice from preliminary studies of 90% hematocrit 
























Figure 3.14 Circulatory Integrity of Modified mRBCs. a) Percent of loaded mRBCs 
circulating in mice (n = 3) at 20 min and 60 min. b) and c) RBCs containing 1 are not noticeably 
cleared in the liver or kidney within the first 0 (b) or 30 min (c). d) Renal histopathology shows 
evidence of extracellular Cy5 in the renal tubules, suggesting urinary excretion from the body 









































3.6 In vivo Photoactivated Treatment of Collagen Antibody-Induced Arthritis in a 
Mouse Model 
The phototherapeutic efficacy of mRBCs containing 1 was evaluated using the collagen-
antibody induced arthritis (CAIA) mouse model. CAIA is an accepted animal model of 
inflammatory arthritis in general and of RA in particular.33-36 CAIA shares several features with 
human RA, including a dependence on inflammatory mononuclear cells in acute inflammation, 
the presence of anti-collagen antibodies during disease expression, and joint erosion in end-stage 
disease.37  Particular advantages to the CAIA model include its rapid onset and highly consistent 
penetrance of disease with minimal inter-experimental variability.38  
In brief, CAIA was induced by an intraperitoneal (i.p.) injection of arthrogenic mAb 5-clone 
cocktail into DBA1/J mice on day 0 followed by i.p. injection of lipopolysaccharide (LPS) on day 2 
according to manufacturer instructions. Arthritis was measured daily by a blinded observer using 
a clinical disease score index 0 – 4, where 0 = normal paw; 1 = mild but definite swelling of the 
ankle or digits; 2 = moderate redness and swelling of an ankle ± any number of digits; 3 = 
moderate redness and swelling of the entire paw; and 4 = maximal redness and swelling of the 
entire paw and digits, with or without ankylosis.39 CAIA mice were tail vein injected with a 90% 
hematocrit of allogenic, strain-specific quality controlled mRBCs containing 1 or 2 (negative 
control). A single arthritic paw was illuminated with a 3 mW 635 nm laser for 5 min (see section 
3.8.6). In addition, a positive control treatment group was treated with (0.5 mg/kg) dexamethasone 
sodium phosphate i.p. (“IP Dex”). Within 24 h following treatment, only mice exposed to mRBCs 
containing 1, with illumination of the inflamed paw, displayed statistically diminished arthritic 
severity relative to animals treated with mRBCs containing 2 (P = 0.01). By contrast, there is no 
statistical difference in arthritic severity of laser treated paws of animals receiving IP Dex at 24 h 
compared to inactive control 2 mRBC treatment (Figure 3.15a). If clinical paw swelling was still 





achieved. Thus, IP Dex mice received between one to four doses of steroid, depending on 
persisting severity of disease (Figure 3.15b). Specifically, on the second day of treatment, 8 of 
11 IP Dex mice had clinical inflammation and were treated with a second dose of IP Dex. Similarly, 
mice treated with photoresponsive 1 or 2 mRBCs continued to receive daily laser treatments on 
the arthritic paw until clinical inflammation was resolved or study end. All mice were terminated 
after 4 days of treatment for all groups. The disease curves of both serially dosed IP Dex and 
serially lasered mRBCs containing 1 achieve statistical difference in arthritis severity when 
compared to the serially lasered inactive 2 mRBCs control (P = 0.0001 and P = 0.0002 
respectively) and are comparable to each other (P = 0.9). 78% less Dex was administered in the 
single 1 mRBC treatment dose with serial laser treatments as compared to the average IP Dex 



















Figure 3.15 Light stimulated Dex treatment of CAIA mice. a) There is significantly less 
inflammation (*P = 0.01) in mice treated with RBCs containing 1 (dotted line) than mice exposed 
to RBCs loaded with 2 (gray line) after the first 24 h of treatment. IP Dex serves as a positive 
treatment control (black line), but does not achieve a statistically significant improvement at 24 
h. b) Mice treated with mRBCs loaded with 1 and illuminated daily (dotted line, n = 13, P = 
0.0002) continued to maintain remission of inflammation while arthritis in IP Dex treated mice 
(black line, n = 11, P = 0.0001) continued to improve after 1 - 4 injections, depending on the 
persisting severity in the arthritic paw. Both treatments are significantly different over time when 
compared to the illuminated daily inactive control (2) loaded mRBCs which continued to worsen 
(gray line, n = 12), despite daily laser treatment, but are comparable to each other (P = 0.9). c) 
Administered Dex from loaded mRBCs (gray, n = 13) compared to average IP Dex (hatched, n 
= 11). Shaded bars furnish the ratio of mice that received additional doses (black) of IP Dex 
over the treatment course to achieve remission and the total dose received. Mice treated with 
1 loaded mRBCs only required 1 intravenous infusion on day 0 followed by daily illumination of 
the arthritic paw to achieve remission of inflammation (gray). Mice treated with 1 mRBCs 
received 78% less Dex (mg/kg) than mice treated with IP Dex to achieve similar clinical 





































Arthritis therapies are constrained by (1) the failure to deliver sufficient quantities of drug 
to the inflamed site to achieve the desired therapeutic effect, (2) the range of moderate to severe 
side effects associated with long-term systemic exposure, and (3) the inability of the patient to 
self-administer therapeutics in a site-targeted as-needed fashion. There is a compelling 
biomedical need to develop a technology to address these issues, especially given the chronic 
nature and prevalence of arthritis, the capricious acute episodes of pain and inflammation, and 
different disease subtypes of arthritis that affect a broad swath of the population. We have 
developed a light activation strategy that triggers the delivery of the anti-inflammatory agent, Dex, 
in a site-specific fashion. RBCs conveying the photoactivatable therapeutic offer the means to 
employ the circulatory system as a drug depot, which offers the opportunity to target inflamed 
diseased sites in a patient-directed fashion. We have shown that RBCs harboring the 
phototherapeutic agent display properties similar to those of native and surface labelled 
erythrocytes. Furthermore, given the long wavelength responsiveness of the carrier system, drug 
release is efficiently triggered through tissue phantoms that mimic the entire range of pale to dark 
skin types. Finally, we have demonstrated that the RBC-conveyed photo-anti-inflammatory agent 
not only induces the desired reduction in inflammation but does so at a dose that is significantly 











3.8 Supporting Information, Figures, and Methods 
Chemicals and Materials 
All chemical reagents were purchased from suppliers as noted below and used as 
received. Spectra/ Por 1 kDa dialysis tubing, Fisher Bioreagents 10X PBS, Gibco DMEM, Vybrant 
DiI, and Enzymax LLC mini-spin columns were purchased from Thermo Fisher Scientific 
(Waltham, MA). Ficoll-Paque Premium 1.084, Absolute ethanol, dexamethasone, and fetal bovine 
serum were purchased from MilliporeSigma (St. Louis, MO); Arthrogen-CIA 5 Clone Cocktail Kit 
and e. coli LPS were purchased from Chondrex (Redmond, WA, USA), dexamethasone sodium 
phosphate Injection from USP Mylan (IL, USA), and Isothesia Isoflurane from Henry Schein 
Animal (India). All water was filtered using Milli-Q Reference water purification system. 
 
Animals 
Male DBA/1J mice aged 8-10 weeks were purchased from Jackson Laboratories (Bar 
Harbor, ME, USA) and housed at UNC-CH or Duke University under the care of the respective 
institutions Division of Laboratory Animal Resources. All procedures performed were approved 
by the Institutional Animal Care and Use Committees of UNC-CH (#19-048.0) and Duke 
University Medical Center (#A185-17-08). 
 
Cell Culture  
Human fibroblast-like synoviocytes (FLS) from the Tarrant lab were previously obtained 
by Mainz et al.40 Briefly, cells were collected from 6 individuals who fulfilled the American College 
of Rheumatology 1987 criteria for the diagnosis of RA during a synovectomy or total joint 
replacement.41 FLS were de-identified and existed in a repository, thus making them exempt from 
IRB approval (Study #14-1569). FLS were isolated from samples and cells were grown in DMEM, 





5.0% CO2. Cells were used from the 6th to the 10th passage. Human HeLa cells were purchased 
from ATCC (ATCC®CLL-2™). Cells were grown in DMEM, 10% FBS, 1% Penicillin Streptomycin 
and 1% GlutaMAX at 37 °C under a humidified atmosphere containing 5.0% CO2. Human Sup-
B15 cells were purchased from ATCC (ATCC®CRL-1929™). Cells were grown in Iscove’s 
Modified Dulbecco’s medium, 20% FBS, 2% GlutaMAX, and 0.05 mM 2-mercaptoethanol at 37 °C 
under a humidified atmosphere containing 5.0% CO2. Human RBCs stored in acid citrate dextrose 
were purchased from ZenBio. 
 
3.8.1 Synthesis of Cbl Conjugates 
Synthesis of Fmoc-Cbl-CN 
Fmoc-Cbl-CN was synthesized per previously published protocols.42 Briefly, 
cyanocobalamin (Cbl-CN, 0.5 g, 0.35 mmol) was dissolved in dry DMSO (10 mL) to form a dark 
red solution. To the solution was added 1,1-carbonyldiiimidazole (CDT, 1.4 mmol) to activate the 
5’ ribose hydroxyl group of the nucleotide loop. The solution was allowed to stir for 4 h, at which 
time ethylenediamine (EDA, 2.9 mmol) was added to the solution. The reaction mixture was 
stirred for an additional 4 h. Upon LC-MS confirmation of the formation of the desired amide bond, 
the solution was diluted to 50 mL with a 2:1 solution of diethyl ether:DCM, which induced 
precipitation of the Cbl derivative. The mixture was centrifuged for 4 min to pellet the modified Cbl, 
decanted, and the pellet was allowed to dry. The pellet was dissolved in dry DMF (10 mL). 9-
fluorenylmethyl N-succinimidyl carbonate (Fmoc-OSu, 492 mg, 1.5 mmol) was added to the 
solution and stirred for 4 h. The solution was split into two 5 mL aliquots and both aliquots were 
diluted with diethyl ether (to 50 mL). The solutions were centrifuged to pellet the Fmoc-linker-Cbl 
and decanted, leaving red pellets. The pellets were allowed to dry, dissolved in MeOH (10 mL 
each), and re-centrifuged. Unreacted Fmoc-OSu and trace Cbl formed light pink pellets. The 





diluted to 40% MeOH with DI water. A 12 g Biotage C18 column with sample was prepped with 
5:95 MeOH:H2O (0.1% TFA) and the solution was eluted using an MeOH:H2O (0.1%TFA) gradient 
from 5% to 80% MeOH. Fractions were analyzed for purity via LC-MS and combined, 
concentrated under reduced pressure, and lyophilized to yield a powdered red solid (59.5% yield). 
 
Synthesis of Fmoc-Cbl-Propylamine  
Fmoc-Cbl-Propylamine was synthesized per previous protocols.42 Briefly, Fmoc-Cbl-CN 
(0.2 mmol) was dissolved in MeOH (20 mL). NH4Br (5% w/v, 1 g) was dissolved in the solution, 
and Zn (0.022 mol) was added to the solution. The solution was shaken vigorously by hand for 
30 s, then placed on a shake plate for 30 min. The solution turned black, indicating reduction of 
Co+3 to Co+. 3-bromopropylamine hydrobromide (0.9 mmol) was added to the solution, and it was 
returned to the shake plate for 4 h. The mixture was spun to pellet the Zn, then decanted. A 30 g 
Biotage C18 column with the orange sample was prepped with 5:95 MeOH:H2O (0.1% TFA) and 
the solution was eluted using an MeOH:H2O (0.1%TFA) gradient from 5% to 60% MeOH. 
Fractions were analyzed for purity via LC-MS and combined, concentrated under reduced 
pressure, and lyophilized to yield a powdered orange solid (45% yield). 
 
Synthesis of Ethylenediamine-Cbl-Dex (EDA-Cbl-Dex, Scheme 3-1)  
Succinyl-Dex43 (0.041 mmol) was dissolved in dry DMF (5 mL) along with DIPEA (0.32 
mmol) and HATU (0.047 mmol). The solution was stirred for 5 min to activate the carboxylic acid. 
After 5 min, Fmoc-Cbl-Propylamine (0.041 mmol) was added to the solution, and the reaction 
vessel was placed on a shake plate for 4 h. After 4 h, the solution was diluted with diethyl ether 
(to 50 mL) and spun down to pellet the product. Then the supernatant was decanted. The Fmoc-
Cbl-Dex pellet was allowed to dry for 4 h, then dissolved in dry DMF (5 mL). Piperidine (0.29 





then diluted with diether ethyl (to 50 mL) to precipitate the product, which was pelleted via 
centrifugation. The pellet was dissolved in MeOH (10 mL) and then diluted with DI water (to 40 
mL). A 12 g Biotage C18 column with sample was prepped with 5:95 MeOH:H2O (0.1% TFA) and 
the solution was eluted using an MeOH:H2O (0.1%TFA) gradient from 10% to 80% MeOH. 
Fractions were analyzed for purity via LC-MS (Figure 3.16) and combined, concentrated under 
reduced pressure, and lyophilized to yield a powdered orange solid. 1H NMR (Figure 3.17; 500 
MHz, MeOD) δ 9.34 (s, 1H), 7.68 (s, 1H), 7.54 (s, 1H), 7.44 (d, J = 10.1 Hz, 1H), 6.89 (s, 1H), 
6.53 (d, J = 5.2 Hz, 1H), 6.31 (dd, J = 10.1, 1.9 Hz, 1H), 6.10 (t, J = 1.7 Hz, 1H), 5.05 (d, J = 17.7 
Hz, 1H), 4.83 (s, 1H), 4.57 (d, J = 10.7 Hz, 1H), 4.36 – 4.22 (m, 5H), 3.93 (dd, J = 9.1, 5.0 Hz, 
1H), 3.53 – 3.35 (m, 2H), 3.25 (dd, J = 13.7, 4.9 Hz, 1H), 3.14 – 3.00 (m, 3H), 2.84 – 2.75 (m, 
2H), 2.77 – 2.67 (m, 1H), 2.67 – 2.54 (m, 3H), 2.54 (s, 3H), 2.53 – 2.44 (m, 10H), 2.40 (s, 1H), 
2.40 – 2.28 (m, 3H), 2.25 (t, J = 10.0 Hz, 1H), 2.24 – 2.09 (m, 1H), 2.06 – 2.00 (m, 2H), 1.98 (d, 
J = 10.5 Hz, 2H), 1.87 (s, 3H), 1.86 – 1.70 (m, 2H), 1.68 (d, J = 5.4 Hz, 3H), 1.68 – 1.62 (m, 1H), 
1.61 (s, 3H), 1.53 (s, 3H), 1.45 (s, 3H), 1.38 – 1.30 (m, 1H), 1.27 – 1.19 (m, 5H), 1.09 (s, 3H), 
0.99 (d, J = 27.6 Hz, 6H), 0.88 (d, J = 7.2 Hz, 3H), 0.29 (dt, J = 10.5, 4.9 Hz, 1H), 0.14 – 0.04 (m, 
1H), -0.47 (dd, J = 12.3, 6.9 Hz, 1H). (ESI) m/z: [M+2H]2+ calculated for C94H133CoFN16O22P, 975.0; 














Figure 3.16 LC-MS chromatogram of purified EDA-Cbl-Dex detected by the UV detector 
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Synthesis of Cy5-Cbl-Dex (1, Scheme 3-2) 
Cy5 (0.0204 g, 0.04 mmol) was dissolved in dry DMF (5 mL) creating a dark blue solution. 
DIPEA (0.0481 g, 0.37 mmol) and HATU (0.0113 g, 0.03 mmol) were added to solution and the 
reaction mixture was placed on a shake plate for 10 min. EDA-Cbl-Dex (0.0495 g, 0.025 mmol) 
was then added to the solution and the reaction vessel shaken for an additional 2.5 h. The solution 
was diluted with diethyl ether (to 50 mL) and centrifuged to pellet the Cbl conjugate. Residual 
ether was removed by “air drying” for 4 h in the dark. The pellet was then dissolved in MeOH (4 
mL) and diluted with DI water (to 15 mL). A 30 g Biotage C18 column with sample was prepped 
with MeOH:H2O (0.1% TFA) and the solution was eluted using an MeOH:H2O (0.1%TFA) gradient 
from 0% to 80% MeOH. Fractions were analyzed for purity via LC-MS (Figure 3.18) and combined, 
concentrated under reduced pressure, and lyophilized to yield a blue solid (49.2 g, 80.2% yield). 
1H NMR (Figure 3.19; 500 MHz, MeOH-d4): 8.26 (td, J=13.03 Hz, 3H), 7.68 (s, 1H), 7.50 (dd, 
J=4.94, 3H), 7.42 (m, 4H), 7.28 (dq, J=7.66, 5H), 6.85 (s, 1H), 6.63 (t, J=12.35, 2H) 6.53 (d, 
J=5.26, 1H) 6.30 (t, J=10.52, 4H) 6.10 (s, 1H), 5.07 (s, 1H), 5.07, (s, 1H), 4.89 (s, 3H) 4.82 (s, 
1H), 4.55 (d, J= 10.71, 1H), 4.37 (s, 1H), 4.33 (t, J=9.61, 3H), 4.29 (d, J=10.39, 2H), 4.22 (m, 1H), 
4.11 (t, J= 7.58, 2H), 3.92 (dd, J=5.00, 1H), 3.67 (s, 1H), 3.64 (s, 3H), 3.49 (t, J=5.07, 1H), 3.29 
(t, J=5.91, 3H), 3.21 (q, J=5.53, 2H), 3.04 (m, 2H), 2.80 (s, 2H), 2.32 (t of d, 2H), 2.68 (s, 5H), 
2.64 (d, J=5.96, 1H), 2.60 (dt, J=3.89, 4H), 2.56 (d, J=2.56, 1H), 2.53 (s, 3H), 2.51 (s, 2H) 2.48 
(m, 3H), 2.46 (s, 4H), 2.43 (s, 4H), 2.42 (s, 4H), 3.40 (s, 1H), 2.36 (m, 3H), 2.33 (t, J=7.65, 5H), 
2.25 (t, J=7.65, 5H), 2.19 (m, 2H) 2.11 (m, 2H), 2.02 (d, J=9.91, 2H), 2.00 (d, J= 6.61, 2H) 1.96 
(d, 3H), 1.89 (s, J=7.16, 3H), 1.82 (q, J=7.89 4H), 1.74 (s, 7H), 1.73, (s, 7H) 1.70 (t, J= 7.57, 3H), 
1.67 (dd, J=6.23, 4H), 1.63 (t, 2H), 1.61 (s, 4H), 1.52 (s, 3H), 1.47 (quart, 4H) 1.44 (s, 3H), 1.33 
(m, 5H), 1.31 (s, 4H), 1.24 (m, 2H), 1.20 (d, J=6.36, 5H), 1.08 (s, 3H), 1.01 (s, 4H), 0.94 (t. 3H), 






















































































































Figure 3.18 LC-MS chromatogram of purified Cy5-Cbl-Dex (1) detected by the fluorescent 
detector (top, lex = 640 nm; lem = 670 nm) and by the UV detector (bottom, monitored at 254 
nm). 
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Synthesis of Cbl-Dex (Scheme 3-3) 
Succinyl-Dex44 (100 mM, 37.2 µL in DMF), HCTU (100 mM, 37.2 µL in DMF), DIPEA (200 
mM, 37.2 µL in DMF) were mixed for 1 min. The mixture was then added to a solution of β-(3-
aminopropyl)cobalamin13 (4.3 mg, 3.1 µmol) in DMF (0.5 mL) and stirred for 0.5 h. The mixture 
was then added to a solution of Cbl-NH2 β-(3-aminopropyl)cobalamin13 (4.3 mg, 3.1 µmol) in DMF 
(0.5 mL) and stirred for 0.5 h. The reaction mixture was purified via a 12 g Biotage C18 column 
with a Acetonitrile:H2O (0.1% TFA) binary solvent system and the solution was eluted. Fractions 
were analyzed for purity via LC-MS and combined, concentrated under reduced pressure, and 
lyophilized to yield the final product (Figure 3.20). 1H NMR (500 MHz, DMSO-d6): δ 7.84 (s, 1H), 
7.68 (s, 2H), 7.61 (s, 1H), 7.54 (s, 1H), 7.36 (s, 1H), 7.31 (d, J = 10.1 Hz, 1H), 7.22 (d, J = 16.3 
Hz, 2H), 7.14 (s, 1H), 6.98 (s, 1H), 6.92 (s, 1H), 6.80 (s, 1H), 6.70 (s, 1H), 6.61 (s, 1H), 6.41 (s, 
1H), 6.24 (dd, J = 10.1, 1.9 Hz, 1H), 6.17 (d, J = 3.6 Hz, 1H), 6.07 (s, 1H), 6.02 (s, 1H), 5.42 (d, J 
= 4.8 Hz, 1H), 5.17 (s, 1H), 5.03 (d, J = 17.7 Hz, 1H), 4.76 (d, J = 17.6 Hz, 1H), 4.51 (s, 1H), 4.29 
(d, J = 8.7 Hz, 1H), 4.16 (s, 1H), 4.03 (s, 1H), 3.96 (d, J = 8.7 Hz, 2H), 3.66 (s, 1H), 3.54 (s, 1H), 
3.41 – 3.38 (m, 6H), 3.14 (d, J = 10.1 Hz, 1H), 2.86 (s, 1H), 2.55 (s, 18H), 2.45 (d, J = 9.8 Hz, 
9H), 2.40 (s, 4H), 2.32 (s, 2H), 2.22 – 2.16 (m, 9H), 2.15 – 2.09 (m, 2H), 2.01 (t, J = 14.9 Hz, 3H), 
1.84 (s, 1H), 1.77 – 1.73 (m, 3H), 1.70 (s, 3H), 1.63 (d, J = 11.7 Hz, 2H), 1.54 (d, J = 13.5 Hz, 
2H), 1.49 (s, 3H), 1.45 (s, 1H), 1.39 (s, 3H), 1.35 (d, J = 11.0 Hz, 1H), 1.24 (d, J = 8.9 Hz, 5H), 
1.22 – 1.18 (m, 1H), 1.03 (d, J = 15.5 Hz, 4H), 0.87 (s, 3H), 0.79 (d, J = 7.2 Hz, 3H), 0.40 (s, 2H), 
0.07 (s, 1H), -0.38 (1H). Mass spec (ESI) m/z: [M+2H]2+ calculated for C91H127CoFN14O21P, 931.9; 












Figure 3.20 LC-MS chromatogram of purified Cbl-Dex detected by the UV detector 




























































































3.8.2 Loading and in vitro Characterization of Cbl RBCs 
Encapsulation of 1 and 2 in mRBCs 
Mouse blood was collected from DBA-1J mice. mRBCs were isolated by filtering through 
Ficoll-Paque at 400 g for 30 min. The serum and white blood cells were removed and packed 
mRBCs were washed 3 times with 1X PBS at 500 g for 4 min. RBCs were loaded as previously 
described with slight modifications to allow for stable loading of larger RBC pellets.10 Most 
commonly, mRBC pellets (400 µL, 100% hematocrit) were prepared for loading by addition of a 
solution of 1 (13.8 mM, 8  µL) or 2 (19 mM, 6  µL) in DMSO and diluent C (164 µL) to create a 
mixture of mRBCs (70% hematocrit) and Cbl conjugate (200 µM). The RBC/Cbl mixture was 
dialyzed for 40 min in 400 mL of dialysis buffer (80 mOSm/L PBS, 0.25% glycerol, 10 mM glucose, 
2 mM ATP) at 4 °C. RBCs were removed from dialysis tubing and resealed by adding 0.1 volume 
10X PBS per vol of dialyzed RBCs and by incubating for 20 min at 37 °C. Loaded, resealed RBCs 
were washed 5x with 1X PBS or 3x with 1X PBS and 2x with FBS. All manipulations of light 
responsive compounds occurred in the dark room to prevent exposure to ambient light. 
 
Imaging Flow Cytometry 
RBCs loaded with the Cbl conjugates 1 or 2 or externally loaded with DiI were washed 
with 1X PBS and then diluted 1,000-fold with 1X PBS to achieve a concentration of 9 x 107 
RBCs/mL. Loaded cells were then evaluated using the ImageStreamX Mark II (Amnis, Seattle, 
USA). Samples were run at a speed of 25 µL/min and 100,000 unique cells were imaged in two 
brightfield channels (intensities of 64.6 mW and 93.94 mW), a side scatter channel (785 nm laser 
at an intensity of 2 mW with a 740 - 800 nm filter), a DiI channel (488 nm solid state laser at an 
intensity of 200 mW with a 560 - 595 nm filter), and a Cy5 Channel (658 nm diode laser at an 
intensity of 150 mW with a 660 - 740 nm filter) at 60X magnification. Cells were gated, first filtering 
for focus by requiring a gradient root mean square greater than 60, then analyzing for singlet cells 





cells was then analyzed using an intensity histogram of the appropriate fluorescence channel. 
General morphology of cells was analyzed by comparing cells using the diameter feature (Erode 
mask, pixel 03) as established in previous methods and intensity of channel 6 (the granularity 














Figure 3.21 Imaging flow analysis gating for RBC populations. Representative analysis of 
native mRBCs (top) and mRBCs containing 1 (bottom). RBCs were first selected for in focus 














Ethanol Extraction of Cbl Conjugates from RBCs 
Loaded RBCs were extracted using ethanol to detect the amount of Cbl conjugates 1 or 2 
loaded. Post loading, RBCs were separated into 100 µL 100% hematocrit pellets. Loaded RBCs 
were transferred to Enzymax LLC mini-spin columns and two equivalents by volume of ethanol 
were added to extract the Cbl conjugate. After sitting for 15 min, the extract was filtered from the 
RBC membranes and residual cell components at 13,000 g for 5 min. The extract was left 
overnight at 4 °C. The next day residual precipitate was removed by filtering in a mini-spin column 
at 13,000 g for 5 min. The extract was subsequently diluted to 1 mL with ethanol and the 
absorbance of the sample at 649 nm was measured using a DeNovix DS-11 FX+ 
spectrophotometer/fluorometer (Wilmington, DE, USA). Loaded Dex was calculated from a 









Figure 3.22 Quantification of RBCs containing 1 by ethanol extraction of a loaded RBC 
pellet and Cy5 absorbance measurement. a) Standard curve of 1 stock in ethanol. b) 
Quantified µg of Dex loaded in a 100 µL pellet at 100% hematocrit. c) Number of RBCs in a 



























































Figure 3.23 Quantification of RBCs containing 2 by ethanol extraction of a loaded RBC 
pellet and UV-Vis absorbance measurement of Cy5. a) Representative standard curve of 2 
stock in ethanol. b) Quantified µg of Dex loaded in a 100 µL pellet at 100% hematocrit. c) 





































































 hRBCs were prepared as 10% hematocrit hRBC samples as described above and then 
analyzed via the Siemens Advia 2120i – automated CBC.  RBCs were sphered and fixed and 
then automatically processed through a Flowcell where RBC Count, MCV and hemoglobin 
content were measured using a laser diode. Hemoglobin was measured in a colorimeter by lysing 
all RBCs to free hemoglobin. The free hemoglobin was converted to methemoglobin and then 
porphyrin and the color change was measured at 546 nm. MCH was calculated by the analyzer 
using the following  equation: MCH = Hgb x 10/RBC. mRBCs were prepared as 10% hematocrit 
mRBC samples as described above. Samples were then analyzed using the IDEXX ProCyte Dx 
automated hematology instrument (software version 00-34 Build57) using settings for mouse 
whole blood.  
 
3.8.3 Photolysis of Cbl-Dex from Solution RBCs 
Photorelease of Dex from Cy5-Cbl-Dex (1) hRBCs (Scheme 3-4) 
Cy5-Cbl-Dex (Loaded into hRBCs, 20% hematocrit in human platelet rich plasma, 500 µL) 
were photolyzed as described below. Release of Dex into supernatant after photolysis was 
assessed by extracting Dex from plasma and pellet with acetonitrile followed by LC-MS analysis, 
comparing photolyzed product fragment ion 510 and 373 in the supernatant and pellet. Exposure 
to the light source was performed 5 - 10 min so that Cy5-Cbl-Dex was fully photolyzed, as 






Scheme 3-4 Photolysis of Cy5-Cbl-Dex (1) in PBS to form photoproducts Cy5-Cbl-H2O (2) 






















































































































Figure 3.24 Photolysis of 1 from loaded hRBCs. Following incubation, and light/dark exposure, the solution was centrifuged, and 
the supernatant and pellet processed. a) hRBCs loaded with 1 in human platelet rich plasma were photolyzed at 645 ± 10 nm using 
an Oriel Xe flash lamp (800 mJ, 62 Hz) and appropriate bandpass filters. Analysis by LC-MS revealed that the overwhelming majority 
(90 ± 5.8%) of the photolyzed Dex product was present in the supernatant (bottom) and not the pellet (top). b) hRBCs loaded with 1 
in human platelet rich plasma were kept in the dark before analysis. Analysis by LC-MS revealed that the overwhelming majority of 












































Photolysis of Cy5-Cbl-Dex (1) and Cbl-Dex with Fitzpatrick Skin Phantom Solutions 
Fitzpatrick skin phantom solutions were prepared following a previously reported 
protocol.26 Hematocrit lysate stock solution (25% hematocrit) was prepared via sonicated lysis of 
RBCs in water followed by centrifuge to remove residual membranes. All skin phantom solutions 
contained 0.3% v/v Intralipid®, 1% hemoglobin, and erythrocyte lysate solution (1% v/v) in PBS. 
Melanin stock solution (3 mg/mL in 100 mM NH4OH solution) was added at varying concentrations 
depending on Fitzpatrick skin type (I – II ~8.8 µg/mL; III – IV ~66 µg/mL; V – VI ~130 µg/mL). The 
skin phantom solution was inserted between the sample and the light source before illumination.  
Cbl-Dex (20 µM in MeOH/PBS 1:1, 200 µL) or Cy5-Cbl-Dex (20 µM in MeOH/PBS 1:1, 100 µL) 
were placed in a cuvette and illuminated with a Xe Lamp with a 510 nm Newport filter for Cbl-Dex 
and a 645 nm Newport filter for Cy5-Cbl-Dex. The sample was exposed to a light intensity of 1.0 
mW/cm2. For Cbl-Dex, the progress of photolysis was monitored by observing an absorbance 
increase at 350 nm as previously described.46 For Cy5-Cbl-Dex, the progress of photolysis was 
monitored by observing the fluorescence decrease using at 675 nm (with lex at 645 nm). 
Completion of photolysis was confirmed by LC-MS (Figure 3.25). Analogous experiments were 
conducted using Cy5-Cbl-Dex loaded human RBCs (20% hematocrit in human platelet rich 
plasma, 100 µL), which were added to 0.5 mL of human platelet rich plasma (Zen-Bio, Inc). 
Photolysis of the samples was performed using an Oriel Xe flash lamp (800 mJ, 62 Hz) as the 
light source with selective bandpass filters for 645 ± 10 for 5 min (dark samples were incubated 
in the dark for 5 min). Photolyzed RBC suspensions were centrifuged at 1000 g for 3 min, and the 
supernatant removed from the pellet. Acetonitrile was added to the supernatant in a 1:1 ratio, 
centrifuged at 21,000 g for 5 min, and then analyzed by LC-MS (solvent A: 0.1% formic acid/H2O; 
solvent B: 0.1% formic acid/methanol). The pellet was extracted with 0.5 mL of acetonitrile and 





(Dex-aldehyde) and 373 (hydrolyzed Dex) and compared with standard photolyzed product from 












Figure 3.25 Complete photolysis of Cy5-Cbl-Dex after illumination at 645 nm for 30 min. 
a) Reverse-phase HPLC trace of Cy5-Cbl-Dex in PBS (25 μM, pH = 7.4) illuminated at 645 nm 
for 30 min. The chromatogram was recorded at 251 nm where “peak a” = Cy5-Cbl-H2O 
photoproduct and “peak b” = Dex photoproducts (Scheme 3-4). b) ES-MS spectrum of the 
photolyzed Cy5-Cbl-Dex was recorded in positive ion mode (peak a). Characteristic molecular 
and fragment ion: [(M - H2O) + H]+3 (m/z 627.2). c) ES-MS spectrum of photolyzed Cy5-Cbl-
Dex recorded in positive-ion mode (peak b). Characteristic molecular and fragment ion: [M - F 
















































3.8.4 Cy5-Cbl-Dex hRBC Impact on Human Cells 
GRa Localization in Human Cells  
Human HeLa or FLS cells were seeded in 24-well glass-bottom plates treated with 
polylysine at a density of 5 x 104 cells/mL and allowed to adhere overnight. HeLa cells were then 
serum starved for 24 h while FLS cells were immediately treated after adhering overnight. The 
cell cultures were subsequently exposed to 100 µL of 1 RBCs at 10% hematocrit (7.9 x 108 
cells/mL), or 100 µL of 2 RBCs at 10% hematocrit (8.5 x 108 cells/mL), or 500 µL Dex at 250 nM, 
or 500 µL ethanol vehicle in plain DMEM using Millicell Hanging Cell Culture Inserts (1 µm, 
polyethylene terephthalate, Millipore). Light treated samples had been exposed to a 660 nm LED 
board for 30 min at RT. After 30 min of exposure, hanging wells were removed and cells were 
incubated for an additional 30 min at 37 °C in a humidified environment at 5% CO2. Cells were 
then washed 3x with 1X PBS, fixed with 4% PFA in PBS for 10 min, washed with 2x 1X PBS (1 
mL), and treated with methanol for 5 min. Fixed cells were treated with a blocking buffer (5% 
Donkey serum; 0.1% Triton X-100; PBS) and stained for GRa using monoclonal rabbit anti-GRa 
antibody (Abcam 181327) at 1:200 dilution in antibody dilution buffer (1% BSA; 0.1% Triton-X-
100; PBS). Cells were then washed with PBS (3 x 5 min) while stirring before incubation with anti-
rabbit AlexaFluor 488 secondary antibody (Life Technologies A11034) at 1:500 dilution in 
antibody dilution buffer for 1 h at room temperature. Cells were washed (1 x 5 min) with PBS and 
imaged on an inverted Olympus IX81 microscope equipped with a Hamamatsu FLASH 4V3, 60X 
oil objective, and a FITC filter cube (Semrock). Images were analyzed using ImageJ. FLS cells 
and quantified using ImageJ’s Coloc 2 program. Regions of Interest (created from the Hoechst 
nuclear stain) were analyzed for colocalization between the Hoechst nuclear stain and anti-GRa 
488 fluorescence in the nuclear space. Pearson’s coefficients without thresholding were analyzed 






Cell Viability Upon Exposure to Dex 
Sup-B15 and FLS cell seeding densities were optimized to ensure cells linearly responded 
to MTS (Figure 3.26). Sup-B15 were then seeded in 24-well glass-bottom plates at a density of 
1.7x106 cells/mL and allowed to settle for 1 h, while primary FLS cells were plated at a density of 
1x104 cells/mL and allowed to adhere overnight. Cells were then treated with 100 µL of 1 RBCs 
at 50% hematocrit (4.45 x 109 cells/mL), or 100 µL of 2 RBCs at 50% hematocrit (4.3 x 109 
cells/mL), or 500 µL free Dex at 2 mM, or 500 µL plain DMEM which was added to wells in Millicell 
Hanging Cell Culture Inserts (1 µm, polyethylene terephthalate, Millipore). Samples were exposed 
to a 660 nm LED board for 30 min at RT. After 30 min of exposure, hanging wells were removed 
and cells were incubated for 24 h at 37 °C in a humidified environment at 5% CO2. Cells were 
then treated with 100 µL MTS/1 mL media for 2 h (Abcam 197010) after which absorption at 492 















    
Figure 3.26 Optimization of cell densities for cell viability (MTS) assays. a) FLS cells plated 
up to a density of 7,000 cells/cm2 display a linear response in media (triangle, dotted line) and 
are their viability is not affected by 100 mM Dex (filled circle). b) The MTS viability assay is 
linear up to 2 x 106 cells/mL in media (triangle, dotted line) for Sup-B15 cells. The viability of 














































3.8.5 In vivo Assessment of ADME 
Assessment of Circulatory Viability of Modified mRBCs 
Whole blood of DBA-1J, 8 - 10 week, male donors was harvested on the day of loading 
by cardiac puncture. Internally loaded and control RBCs were prepared as described above. 
mRBCs loaded with 2 were resuspended in PBS at 50% hematocrit and 100 µL of cell suspension 
was drawn into syringes circumferentially covered with tape to block light. Externally loaded 
control mRBCs (DiI) and internally (2) loaded mRBCs were mixed together 1:1 v/v and 100 µL of 
the mixture was loaded in a syringe at 90% hematocrit and circumferentially taped to block light. 
Samples were injected into DBA-1J mice via the tail vein. At the described time points, blood was 
collected from mice via tail nicks. Mice were euthanized via CO2 inhalation according to approved 
UNC IACUC protocol #19-048.0. Whole blood was diluted approximately 1,000 - 1,500-fold and 
analyzed on the Attune NxT flow cytometer as described below. 
 
Histology 
Soft tissues including liver, spleen, kidneys and tail were harvested for frozen sectioning 
to assess circulation and clearance pathways of phototherapeutics as these organs are most 
commonly involved in RBC, drug, and toxin clearance. Tissues were placed in 4% 
paraformaldehyde overnight and rinsed in PBS at 24 h, at which point the samples were placed 
in increasing concentrations of sucrose in PBS to achieve a 30% sucrose solution for prevention 
of ice crystallization during cryopreservation. Samples were placed in 15% sucrose in PBS for 24 
h. The samples were then transferred to 30% sucrose in PBS until freezing, when samples were 
covered with OCT in cryomolds and frozen via dry ice. The samples were then stored in -80 ºC 
until sectioning by cryostat. Frozen sections were obtained at 5 µm using the Thermo Scientific 
Cryostar NX70 Cryostat (Waltham, MA) and stored at -80 ºC. Immunofluorescence nuclear stain 





Microsystems Inc., Norwell, MA) using the Bond Research Detection System kit (Leica, DS9455). 
Slides were removed from -80 ºC and equilibrated to room temperature for 60 min before 
transferring to Bond Wash solution (AR9590). Nuclei were incubated with Hoechst 33258 
(Invitrogen, Carlsbad, CA) at 1:5000 dilution for 20 min. The stained slides were mounted with 
ProLong Gold antifade reagent (Life Technologies, P36930). 
 
3.8.6 In vivo Assessment of Efficacy 
Attune NxT Flow Cytometry 
mRBCs loaded with the Cbl conjugates 1 or 2, or externally loaded with DiI, or unmodified 
were diluted 1,000-fold with 1X PBS to achieve a concentration of 1 x 107 RBCs/mL. Diluted 
samples were analyzed using the Attune NxT (ThermoFisher). First, a scatter plot of side scatter 
area (SSC-A) to side scatter height (SSC-H) was used to gate for single cells. Then, Cy5 from 2 
was excited and measured using the 637 nm 100 mW laser and the RL1 detector (Mirror 654LP, 
Filter 670/14). Data was processed using FCS Express v.7.04 ensuring even flow of sample 
through the instrument by plotting time vs forward scatter area (FSC-A). Final data allowed for 
RBC size characterization via scatter plots of FSC-A vs SSC-A and loading uniformity via Cy5 










Figure 3.27 Quality control of mRBCs loaded for animal experiments. Representative flow 
cytometry analysis of mRBCs prepared on multiple days loaded with 1 or 2 mRBCs and 
subsequently injected into mice. Cy5 signal versus size (FSC) is presented in the top row, 
whereas the Cy5 fluorescence signal histogram is presented in the bottom row. The M1 gate 
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Collagen Antibody Induced Arthritis (CAIA) Animal Model 
Collagen Antibody Induced Arthritis (CAIA) was induced in forty-five 8 - 10 week-old male 
DBA/IJ mice via the i.p. injection of Chondrex Arthrogen-CIA 5-Clone Cocktail (1.6 mg/mouse) 
followed by an i.p. injection of lipopolysaccharide from E. coli (25 mg) 3 days later, as per the 
manufacturer’s instructions. Arthritis was measured daily by a blinded observer with a clinical 
disease score index and measurement of paw swelling. The clinical disease score index is 
performed with the following scoring system: 0 = normal paw; 1 = mild but definite swelling of the 
ankle or digits; 2 = moderate redness and swelling of an ankle ± any number of digits; 3 = 
moderate redness and swelling of the entire paw; and 4 = moderate redness and swelling of all 
three joints in the paw.47, 48 The maximum score/paw is 4. This method has been previously 
validated in inflammatory arthritis models.47, 48 Assessment of disease occurred while the mouse 
was anesthetized using isoflurane.  
 
Treatment of Mice with IP Dex or RBCs Containing 1 or 2 (Scheme 3-5) 
Mice were randomized after symptom onset in at least one paw with a clinical score ≥ 1 
to one of three groups that received the following injections: RBCs containing 1 delivered 
intravenously (1 mRBC; experimental treatment); RBCs containing 2 delivered intravenously (2 
mRBC; inactive control, no drug); or Dex sodium phosphate solution delivered i.p. (IP Dex; 
positive control). The 1 mRBC group (90% hematocrit, 100 μL) received mRBCs internally loaded 
with approximately 0.0065 mg Cy5-Cbl-Dex (1), equivalent to 0.31 mg/kg/mouse, and the IP Dex 
group received 0.5 mg/kg/mouse. The IP Dex group required additional injections of 0.5 mg/kg 
daily to achieve a clinical score of 0 in the arthritic paw that was receiving laser. Injections of 
loaded RBCs were performed via the tail vein by a single, blinded technician using a 27G needle. 
A laser was applied to the first observed affected joint (only one paw per mouse) in all groups for 





were euthanized via CO2 inhalation according to approved Duke IACUC protocol #A1851708. An 
RS laser diode (Power Technology Inc., Alexander AR, USA), 635 nm, 3 mW (Figure 3.28) was 
used for laser treatment of the arthritic paw (clinical score ≥ 1). If two or more joints were 
simultaneously affected, then the laser-treated paw was selected at random. A single, blinded 
experimenter performed all laser treatments and both lower and upper extremity paws were 
treated in the study. The laser was applied to the selected joint at an angle that allowed for 
illumination of the entire joint and paw and was held in position for a total of 5 min per animal. 
Mice were anesthetized using isoflurane during laser treatment. Treatment was applied to the 











Scheme 3-5 Scheme of treatment of arthritic animals with Dex (delivered intraperitoneally; 
“IP Dex”) and 90% hematocrit (hct) 100 µL mRBCs containing 1 or 2 (delivered via tail vein 
injection). a) CAIA was induced per the Chondrex protocol, and the animals exposed to one of 
three treatment protocols upon developing at least one arthritic paw (clinical score ≥ 1). b) 
Arthritic mice were treated with IP Dex or mRBCs containing 1 or 2 followed by daily 3 mW 
laser, 5 min illumination. IP Dex mice continued to receive treatment until complete remission 
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Figure 3.28 RS laser diode (Power Technology Inc., Alexander AR, USA) employed for 
photorelease (635 nm, 3 mW) of Dex from RBCs in the mouse hindlimb at an angle that allowed 
for illumination of the entire joint and paw. The RS laser diode was able to penetrate deep into 
the tissue of the a) human distal interphalangeal joint and the b) mouse hindlimb at an angle 






















All plots are presented as the mean ± standard deviation. Data was analyzed by an 
unpaired Student’s t test. GraphPad Prism software was used for statistical analysis. A P value 
of less than 0.05 is considered to be statistically significant. We have previously demonstrated 
that 10 animals per group are needed to achieve 80% power to detect a medium effect size (0.22) 
at a 0.05 level of significance in the CAIA model.47, 48 There were >10 animals per group for each 
of the three experimental groups in this study. The area under the curve (AUC) of the arthritis 
severity score-time curve was calculated for laser paws in each treatment group. AUC differences 
were estimated by ANOVA. Comparisons were made across all three treatment groups, and 
pairwise comparisons were performed using Tukey's test based on the LSMEANS statement. All 
analyses were conducted using SAS 9.4 (Cary, North Carolina). A one-way ANOVA was used for 
comparing laser-paw treatment groups at 24 h and was found to be significant (P = 0.05). A 
subsequent Mann Whitney U test comparing laser-paw Cy5-Cbl-Dex (1) RBCs (n = 13) with Cy5-
Cbl-H2O (2) RBC control (n = 12) identified significant difference (P = 0.01) at 24 h, whereas IP 
Dex (n = 11) did not achieve statistical significance from the control. An unpaired T test was used 
to analyze the cumulative steroid dose used to achieve clinical remission of the laser-treated paw 
between IP Dex (n = 11) mice and Cy5-Cbl-Dex (1) RBCs (n = 13) mice, where IP Dex mice were 
treated daily with 0.5 mg/kg IP until the arthritis subsided (ranging between 1 - 4 steroid doses + 
laser) and 1 RBC mice received a single dose (0.31 mg/kg intracellularly loaded within 50% Hct) 
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4 CHAPTER 4: PRE-CLINICAL DEVELOPMENT OF COBALAMIN 
PHOTOACTIVATABLE THERAPEUTICS: EXTENSIVE PROGRESS AND 
REMAINING CHALLENGES 
 
The photochemistry of cobalamin (Cbl) derivatives has been the subject of intensive 
investigations since the 1950s. Cbl’s photoresponsivity was first discovered when stored 
cyanocobalamin, a treatment for pernicious anemia since the 1920s, degraded in a lit 
environment.1-3 In general, Cbl derivatives are currently under development as targeting agents 
for cancer, as well as photoactivatable therapeutics.4, 5 The Lawrence group, specifically, has 
made extensive progress in developing Cbl as a photoactivatable therapeutic since the early 
2000’s. Cbl derivatives are promising photoactivatable therapeutics as their scaffold is derived 
from vitamin B12 and thus expected to introduce minimal toxicity but still maintain the inherent 
photoresponsivity to 330 - 575 nm wavelengths. This Chapter will review the progress the lab has 
made pre-clinically developing this photoresponsive moiety into a feasible photoactivatable 
therapeutic and the challenges that remain. The development path is shown in Figure 4.1, a 
modified version of Figure 1.12 originally introduced in Chapter 1. 
Initial investigations of Cbl focused on novel cancer treatments. Given the precedent of 
photodynamic therapy and targeted drug delivery systems (DDSs), cancer is an indication with 
numerous unmet clinical needs that localized delivery and treatment have begun to address. 
Photoactivatable Cbl, specifically, provides a means of localizing chemotherapeutic release, and 
thus minimizing systemic toxicity, by external light stimulation. By introducing carriers, we were 
able to expand the relevance of Cbl therapeutics beyond cancer into other indications, such as 
arthritis. Arthritis is an inflammatory disease with a prevalence of 5 patients per 1000 adults with 





hands and the feet.6, 7 Due to arthritis’ chronic nature, close monitoring for strict treat-to-target is 
required for successful remission. Given the treatment needs, as well as negative side effects of 
chronic use of glucocorticoid drugs (e.g., prednisone or dexamethasone), patient-directed 
targeted delivery of anti-inflammatory drugs may both support treatment adherence and efficacy 
while diminishing adverse effects of these therapeutics.8, 9 Thus, with a team of chemical, 
biological, and clinical experts, the Lawrence group has continued to make significant progress 

















Figure 4.1 Development of Cy5-Cbl-Dex RBCs. The path initially introduced in Chapter 1 is modified for the development of Cy5-
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4.1 Cbl: Initial Characterization and Optimization 
Photophysical Properties (lmax, e, and Φ) and Rates of Photolysis  
The capacity of a photoactivatable therapeutic to release therapeutic in response to 
illumination is defined by its photophysical properties, which are most easily measured in vitro. 
These properties include: the maximum wavelength (lmax) of photoresponsiveness, the ability to 
absorb photons of light (e), and the ability of the therapeutic to use the absorbed energy for 
therapeutic cargo release (Φ). Under in vivo conditions, the rate of photolysis will also significantly 
affect whether the therapeutic is locally released upon stimulation. For example, if the rate of 
photolysis is too slow the therapeutic could diffuse away from the treatment site before 
photorelease occurs. 
  Long-wavelength photoresponsiveness within the optical window of tissue (600 - 950 nm) 
is required for any non-superficial indications to penetrate tissue beyond 1 - 2 mm of depth.10 In 
2014, the Lawrence group discovered that synthetically appending a fluorophore to the 5’-OH of 
the Cbl ribose modulates the photoresponsivity of Cbl. The fluorophore acts as an antenna by 
both introducing the fluorophore’s lmax which is capable of causing photorelease and accelerating 
rates of photolysis.11 Studies of the appended fluorophore on Cbl demonstrated improved 
photolysis rates of TAMRA-Cbl-Adenosine (0.89 ± 0.32 s-1) as compared to Cbl-Adenosine (0.38 
± 0.04 s-1) at an illumination of 546 ± 10 nm (< 15 mW/ cm2) (Figure 4.2). Interestingly, the Φ for 
adenosine release of TAMRA-Cbl-Adenosine (0.066) is significantly lower when compared to Cbl-
Adenosine (0.3). The increase in rate is thus attributed to an increase in photon absorption: the e 
at 546 nm increases by more than 10-fold by appending the TAMRA antenna (Cbl-Adenosine’s 
8,100 M-1 cm-1 vs TAMRA-Cbl-Adenosine’s 86,000 M-1 cm-1). The dramatic increase in e, but less 
extreme increase in rates suggests that energy is still lost by other means, such as fluorescence.12 
Similarly, studies testing photolysis through Fitzpatrick tissue phantoms (solutions which include 





Cbl-Dex with illumination near their respective lmax (510 nm vs 645 nm) demonstrated significantly 
improved rates of photolysis of the Cy5 derivative. Cy5-Cbl-Dex is completely photolyzed in 3 min 
while minimal photolysis of Cbl-Dex occurs in that time as discussed in Chapter 3 (Figure 3.8).13 
Thus, the fluorophore antenna introduces photoresponsivity of Cbl into the tissue-penetrating 
long-wavelength range and improves the photolysis rate. However, a significant energy loss is 
still observed as indicated by the decreased Φ of TAMRA-Cbl-Adenosine and fluorescence of 
Cy5-Cbl species tracked in Chapter 2 (Figure 2.3).14  
Although fluorophore antennas introduce photoresponsivity in the optical window of tissue 
to Cbl, the diminished Φ of therapeutic release may affect therapeutic efficacy in vivo. Since light 
is significantly scattered as it diffuses through tissue (even at long wavelengths), ensuring high Φ 
is important for achieving therapeutic efficacy in thicker tissue. Further, the photoproducts of Cbl 
continue to absorb light further diminishing the available photons for therapeutic release. In 
general, Cbl’s Φ has also been found to depend on pH, the axial species attached, and solvent.3 
Fortunately, the joints of the hands and feet for arthritis treatment are superficially accessible and 
can easily be illuminated for extended periods of time. Thus, treating this more accessible tissue 
avoids the feasibility challenges of deeper tissue indications in potentially acidic environments 
(such as cancer), that may be exposed for more limited durations during surgery. In vivo 
quantification of therapeutic photorelease has yet to be performed. 
Fluorophore-Cbl species responsive in the optical window of tissue also present unique 
benefits. TAMRA, Cy5, Atto725, and DyLight 800 fluorophores have all been appended to Cbl 
and act as antennas that induce photocleavage from lmax of 546 through 800 nm. This tunability 
allows for preparing multiple therapeutics for wavelength-specific localized release employing the 
spatial and temporal benefits external laser-stimulation Cbl provides. Further, the persistent 
fluorescence of fluorophore-Cbl species may be applied for theranostic uses as described in 






Figure 4.2 Photolysis rates of TAMRA-Cbl (circles) versus Cbl (squares) as measured by 
production of the HO-Cbl photoproduct. The rate of photolysis is determined from the initial 


















Previously published research on vitamin B12 described how the body and cells absorb 
natural cyanocobalamins and alkylcobalamins. Specifically, Cbl bound to transcobalamin protein 
is recognized by CD320 receptors on the cell, which leads to endocytosis of the Cbl-
transcobalamin conjugate. These endosomes then transform into lysosomes within which Cbl is 
disassociated from the transcobalamin transporter protein. The pH change that occurs during 
endosomal transformation into lysosomes, as well as tumor overexpression of transcobalamin 
receptors has been exploited with a targeted Cbl-colchicine with an acid-labile linker.5 After 
release, Cbl is then transported into the cellular cytosol and associates with cytosolic cobalamin 
C. Cobalamin C can then decyanate cyanocobalamins or dealkylate alkylcobalamins. The 
processed Cbl remains in the cytosol or is trafficked into the mitochondria where it contributes as 
a co-enzyme role in nucleotide synthesis and the tricarboxylic acid cycle, respectively.15 Thus, 
there are multiple methods that photoresponsive Cbl-therapeutics could be inadvertently 
activated within the cell: 1) the lysosomal environment could cause hydrolysis of the axial bond, 
2) cobalamin C can cleave the Co-C bond releasing the therapeutic, and 3) the Cbl-therapeutic 
conjugate may maintain therapeutic activity even in its conjugated state, thus not requiring 
cleavage for therapeutic activity.12, 15  
Similar to the described literary findings of vitamin B12, cellular studies of Cbl-BODIPY 
demonstrated that Cbl can be endosomally sequestered until photolysis in cells (Figure 4.3).11 
However, subsequent studies with Cbl-monomethyl auristatin E (MMAE) exposed the potential 
inadvertent activity of Cbl appended therapeutics, especially potent cytotoxic therapeutics (Figure 
4.4). To target Cbl chemotherapeutic to glioblastoma cells, the photoindex of Cbl-MMAE 








Figure 4.3 Endosomal sequestration of Cbl-BODIPY in HeLa cells. a)  HeLa cells treated 
with 125 nM Cbl-BODIPY kept in the dark. b) Rhodamine B-dextran endosomal staining of 
dark treated HeLa cells. c) Overlay a and b. d) HeLa cells treated with 125 nM Cbl-BODIPY 
and illuminated for 15 min with light from an argon lamp filtered through a Cy5 filter cube (500 
or 1000 ms every min) e) Illuminated cells treated with Mito-Tracker Green mitochondrial 











   
Figure 4.4 Dark Activity of Cbl-MMAE. a) Structure of Cbl-MMAE. b) Percentage cell viability 
of neural stem cells (left) or glioblastoma cells (right) after 72 h of exposure to a range of 
concentrations (nM) of Cbl-MMAE (black or gray) or control free MMAE (white). Cbl-MMAE was 
either kept in the dark (black) or illuminated for 30 min at 488 nm (gray) and then incubated for 
72 h at 37 ºC. 
 
Table 4-1 EC50’s of Cbl-MMAE or MMAE treating Neural Stem Cells and Glioblastoma.  
Cell Type 
EC50 
Dark Cbl-MMAE Light Cbl-MMAE Free MMAE 
Neural Stem Cell 16 ± 4 nM 7.6 ± 0.9 nM 2.4 ± 0.3 nM 










































The effective concentration that inhibited 50% cell growth (EC50) was calculated for the 
tested conditions (Table 4-1). Although illumination and photorelease improves cytotoxicity of 
Cbl-MMAE by 2-fold, the nM cytotoxic levels of dark Cbl-MMAE, which only achieve a 10-fold 
diminished cytotoxicity when compared to free MMAE, suggests potent dark activity of Cbl-MMAE. 
Although, Cbl could be developed to counter cellular cleavage of therapeutic attachments, these 
modifications could also eliminate photoresponsivity to long-wavelength light. Thus, a means of 
sheltering Cbl is required to inhibit the dark therapeutic activity. 
The biodistribution of Cbl further underscores the need for a carrier. Initial studies with 
Cbl-BODIPY highlighted both the enhanced Cbl uptake of tumors, as well as Cbl distribution into 
the heart, brain, and lungs.4 More thorough pharmacokinetic (PK) studies observed similar 
distribution of Cy5-Cbl-Docetaxel (TAX) into the brain and tumor of a xenografted breast cancer 
mouse model (Figure 4.5). The PK of Cy5-Cbl-TAX was also compared to other TAX based DDSs 
conducted with similar methods in tumor-bearing mice.16-18 Similar to these other DDSs, Cy5-Cbl-
TAX was detected in the tumor at high concentrations up to 3 days. However, Cy5-Cbl-TAX was 
also detected in brain tissue for 3 days following injection. Unlike Cy5-Cbl-TAX, free TAX is 
completely cleared from the brain in 2 hours.16 The localization of a potent TAX derivative into the 
brain, and potentially other sensitive tissue such as the heart, raises concern for unintended 
toxicity and severe adverse events. Further, unlike free TAX, Cy5-Cbl-TAX is rapidly cleared from 
circulation. Cbl≡Cy5 is also similarly cleared as described in Chapter 2 (Figure 2.10). Thus, given 
Cbl’s potential dark activity, a strategy is required for sheltering photoactivatable Cbl, diminishing 










Figure 4.5 Biodistribution of Cy5-Cbl-TAX. a) The structure of Cy5-Cbl-TAX. b) 
Concentration of Cy5-Cbl-TAX over 96 h in MDA-MB-231 xenografted mice brains (circles), 


















































4.2 Sheltering Cy5-Cbl Photoactivatable Therapeutics within Carriers 
Potential DDSs for arthritis should be able to target the joints. Cbl photoactivatable 
therapeutics can target therapeutic release to the joints by external stimulation of laser light. 
However, as discussed in section 4.1 we realized the need to shelter Cbl and modify its 
biodistribution to improve Cbl-therapeutic bioavailable for targeting to the joints. We preferred a 
long-circulating carrier to diminish the amount of infusions required during treatment of this 
chronic disease, which eliminated many NPs as potential options. Further, although direct 
injection of slow-release hydrogels has been approved for arthritis, we preferred avoiding painful 
injections into the joints.19 Thus, when considering potential carriers to shelter Cbl therapeutics, 
we considered a membrane-based carrier which could take advantage of Cbl’s inherent non-cell 
permeable properties. Given the carriers discussed in Chapter 1, internally loaded long-circulating 
red blood cells (RBCs) provide multiple benefits as a carrier. Not only can RBCs shelter and 
improve circulation of Cbl species (clinically tested internally loaded RBCs circulate up to ~25 
days) diminishing the number of intravenous infusions, but also the availability of home laser 
devices provides the opportunity for patient-directed therapeutic release.20, 21 
 
4.2.1 Optimization and Validation of RBC carriers 
Initial optimization studies of RBC carriers with already synthesized Cy5-Cbl-
chemotherapeutic species focused on ensuring internally loaded RBCs preserve the light-
dependent activity of Cbl and minimize the previously observed dark activity discussed in section 
4.1. Methotrexate (MTX), colchicine, paclitaxel, and docetaxel (TAX) were appended to Cy5-Cbl 
or FL800-Cbl which were subsequently loaded into RBCs. Initial studies with Cbl-BODIPY RBCs 
confirmed BODIPY release and escape from RBCs after 3 min of LED illumination. Subsequent 
in vitro photoindex studies of photoreleased MTX confirmed a 3-fold increase in the activity of 





of colchicine, paclitaxel, and TAX photorelease.14, 22 The potential orthogonal benefits of Cbl 
species were also preserved as tested by co-loaded RBCs carrying FL800-Cbl-colchine and Cbl-
BODIPY (Figure 4.6).22 Thus, internally loaded Cy5-Cbl RBCs were validated as a method of 
sheltering Cbl and inhibiting dark activity of multiple chemotherapeutics until light-triggered 











Figure 4.6 Effects of BODIPY or Colchicine orthogonally released from co-loaded  FL800-
Cbl-Colchicine Cbl-BODIPY RBCs on HeLa cells. The left column shows immunostaining 
with an anti-tubulin antibody while the right column shows BODIPY fluorescence. a) Release 
of both colchicine (which disrupts the microtubules) and BODIPY (which is uptaken by HeLa 
cells endosomally) by illumination with 780 nm and 660 nm light respectively. b) Release of 
BODIPY with 660 nm illumination only. c) Release of colchicine with 780 nm illumination only. 




















After validating RBCs can shelter and preserve the light-dependent and orthogonal 
benefits of Cbl PACTs, the RBC Cbl therapeutic system was prepared for in vivo validation of 
chemotherapeutic activity as discussed in Chapter 2.14 In preparation for animal studies the 
loading protocol was tested on and optimized for mouse RBCs (mRBCs). Briefly, results 
demonstrated loaded mRBCs do not affect Cy5 fluorescence of Cy5-Cbl species thus preserving 
their theranostic potential. Further, a high concentration of Cy5-Cbl-TAX is uniformly loaded into 
mRBCs (Figure 2.4; Figure 2.5). Although mRBCs do display significantly diminished integrity as 
compared to human RBCs (hRBCs), in vivo studies were still able to validate that RBCs improve 
the biodistribution of non-photocleavable Cbl≡Cy5 by localizing the Cbl to the circulation for 
extended periods of time as compared to free Cbl≡Cy5 (Figure 2.10). Further, a localized effect 
of TAX release is observed in both healthy mouse vasculature and in SVR angiosarcoma mice 
tumor vasculature (Figure 2.11; Figure 2.13). The localized in vivo effects and general improved 
biodistribution solidified RBCs as an ideal carrier for Cbl photoactivatable therapeutics. RBSs 
successfully retain (and potentially enhance) the benefits of Cbl phototherapeutics while 
overcoming the toxicity risks of dark activity and distribution throughout the body. 
 
4.2.2 Neural Stem Cell-RBC Backpacks 
Given the initial success of RBCs to shelter Cy5-Cbl-chemotherapeutics, we also 
considered the development of neural stem cells (NSCs) as carriers for targeted Cy5-Cbl PACT 
delivery to gliomas. NSCs have been observed to migrate towards malignant brain tumors.23, 24 
We had initially sought to use NSCs as a means of targeting Cy5-Cbl-MMAE directly to cancerous 
cells, however, the noted dark activity and high levels of cytotoxicity of MMAE to the NSC posed 
a challenge to this approach (Figure 4.4). Thus, we instead introduced human RBC (hRBC) 
“backpacks” onto the NSCs as a means of sheltering and inactivating Cy5-Cbl-MMAE while also 





other by covalently linking biotin to their surfaces (via an amine-reactive sulfo-NHS-biotin), 
followed by exposure to tetrameric avidin which has a 1 x 10-15 M dissociation constant from biotin 
(Figure 4.7a). Initial optimization of the biotin-avidin linkage resulted in successful biotinylation 
and avidinylation and further investigation of ideal RBC concentrations showed the degree of 
backpacking possible (from 1:1 to >10:1 hRBCs:NSCs) (Figure 4.7b,c). Both bovine serum 
albumin - Texas Red fluorophore (BSA-TxRed) internally loaded hRBCs and 1,1-dioctadecyl-
3,3,3,3-tetra-methylindodicarbocyanine (DiD) externally loaded hRBCs were successfully 
adhered to NSCs (Figure 4.7d). Further, studies of NSC-RBC migration towards glioblastoma 










Figure 4.7 Construction of NSC-RBC backpacks. a) Scheme of RBC (red) conjugated to 
NSC (blue) via a biotin (B) avidin (A) linkage. b) Alexafluor555-streptavidin binding to the NSC 
surface shows successful biotinylation. c) and d) ImageStream images of composite Cy5 and 
green fluorescent protein (GFP) images are shown in the left column and transmitted in the 
right. c) hRBCs internally loaded with BSA-TxRed were conjugated to GFP expressing NSCs. 
A 0.5:1 or 100:1 hRBC: NSC mixture generates 1:1 or >10:1 RBC:NSC conjugates respectively. 
The No-Avidin control shows non-conjugated hRBCs to an NSC. d) Both BSA-TxRed internally 



















































Figure 4.8 Migration of NSC-hRBC backpacks. 10X Olympus widefield images of externally 
loaded DiD hRBCs were conjugated to GFP expressing NSCs and then plated and allowed to 
migrate for 24 h toward mCherry expressing GBMs. On day 0 (top) NSC groups were not 
interspersed with GBM cells. On day 1 (bottom) NSCs (green) or live NSC-RBCs (yellow) 
migrate toward GBM cells. Mixtures of 100:1 RBC:NSCs show clear, persistent conjugation 


























In preparation for multi-day in vivo studies of NSC migration to GBM across the mouse 
brain, the attachment of hRBCs and NSCs over multiple days was assessed with widefield 
microscopy and ImageStream flow cytometry. While both externally loaded and internally loaded 
hRBCs (with external biotinylation and streptavidinylation) display minimal lysis and leakage at 
37 °C over multiple days (Figure 4.9), breakdown of the attachment was qualitatively observed 
after 3 days at 37 °C for both internally and externally loaded hRBCs (Figure 4.10a,b). 
ImageStream analysis of backpacked NSCs confirmed the loss of adhered RBCs after a 3 day 
period, potentially due to endosomal uptake of biotin labeling and release of attached hRBCs 
which then cluster with each other (Figure 4.10c). Although RBCs are a solution to shelter 
chemotherapeutics, backpack linkages face challenges with multi-day in vitro and in vivo studies 
























Figure 4.9 Internally loaded BSA-TxRed and externally loaded DiD hRBC integrity after 
incubating for 0, 1, and 3 days at 37 °C. a) Widefield images of internally loaded (top) and 
externally loaded hRBCs (bottom). b) Flow cytometry dot plots of forward light scatter (FSC) 




































































































































Figure 4.10 Breakdown of RBC-NSC backpacks over time. GFP expressing NSCs were 
conjugated to a) internally loaded BSA-TxRed RBCs or b) and c) externally loaded DiD RBCs. 
a) and b) Widefield images of conjugated cells over 3 days show breakdown of conjugation. c)  




















4.3 Pre-Clinical Development of Cy5-Cbl-Dex RBCs 
Thus, having validated Cbl RBCs as a photoactivatable therapeutic with localized delivery, 
we shifted development towards the arthritis indication. Cbl RBCs have the potential to address 
multiple unmet clinical needs in this indication including improving safety of chronically used drugs 
and providing a means for patient-directed treatment. We specifically decided to move forward 
with dexamethasone (Dex) a glucocorticoid. Glucocorticoids are often employed in the short-term 
transition to and establishment of disease modifying anti-rheumatic drug treatment.25 Although 
glucocorticoids are extremely effective at reducing symptoms of inflammation, pain, and disability, 
their chronic use is associated with severe adverse effects, including osteoporosis, fractures, 
diabetes, infections, and more.26 Since at least one-third of patients persistently use 
glucocorticoids as part of their treatment there is an unmet medical need to diminish the adverse 
effects of these potent drugs.27, 28 Many novel carrier-based delivery methods for glucocorticoids 
are under development, but only a few have been tested in clinic including delayed-release 
prednisone tablets, long-circulating liposomal prednisone, and slow-release Dex RBCs.28-31 
Photoactivatable Cy5-Cbl-Dex RBCs can expand current treatments by offering a means of 
patient-directed localized release to treatment sites, diminishing systemic adverse effects. Further, 
the long-circulation time of internally loaded RBCs (~25 days) will allow for chronic localized 
treatment over a month. 
My thesis work focused on finalizing the in vitro development of Cy5-Cbl-Dex RBCs and 
transitioning to in vivo pre-clinical development as discussed in Chapter 3. I first characterized 
loaded human RBCs (hRBCs), finding that although loaded mRBCs and hRBCs are similar to 
each other, the loading process dramatically decreases the mean cell hemoglobin and also affects 
the mean cell volume when compared to non-modified native RBCs (Table 3-1). Although these 
changes do not meet the pre-requisite of <20% changes in physical characteristics for long-term 





also conducted to assess the light-dependent nature and safety of Cy5-Cbl species. Illuminated 
Cy5-Cbl-Dex hRBCs had a comparable effect to similar concentrations of conventional Dex on 
HeLa cells, primary fibroblast like synoviocytes (FLS), and Sup-B15 cells. HeLa and FLS 
immunocytochemical studies further confirmed that Cy5-Cbl-Dex RBCs have a minimal effect on 
the Dex-target glucocorticoid receptor a (GRa) in the dark, but comparable to conventional Dex 
after illumination. Thus, Cy5-Cbl-Dex RBCs retain Dex’s pharmacological activity. In vitro toxicity 
studies confirmed that the illuminated control Cy5-Cbl-H2O hRBC has no effect on cell viability 
while illuminated Cy5-Cbl-Dex RBCs have a comparable effect to conventional Dex on Sup-B15 
and FLS cell viability (Figure 3.10; Figure 3.11; Figure 3.13). FLS and Sup-B15 were specifically 
investigated since FLS and B cells are crucial mediators of the inflammatory arthritic response 
and targets of Dex activity.32, 33  
In vivo studies were performed to quantify the bioavailability of Cy5-Cbl-Dex mRBCs. Cy5-
Cbl-Dex mRBCs loaded by an optimized protocol as compared to the protocol employed in 
Chapter 2, do circulate for at least 1 h, the required amount of time for illumination and therapeutic 
release. However, clearance is observed within 24 h (Figure 3.14). Excitingly, intravenously 
injected loaded Cy5-Cbl-Dex RBCs achieve the remission of arthritis in the acute collagen 
antibody induced arthritis (CAIA) model similar to that of conventional Dex injected 
intraperitoneally (Figure 3.15). Moreover, loaded RBCs produce a more efficient and persistent 
response as compared to conventional Dex. However, the exact cause of the difference is not yet 
clear due to differences in injection method (and thus bioavailability) along with treatment.  
Thus, both in vitro and in vivo studies served to characterize Cy5-Cbl-Dex RBCs. 
Specifically, studies demonstrated their in vitro properties, confirmed in vitro safety of Cy5-Cbl 
RBCs, and confirmed minimal dark activity in the nM sensitive HeLa immunohistochemical assay. 






4.4 Next Steps for Cy5-Cbl RBC Development 
 As demonstrated by the exciting pre-clinical results, Cy5-Cbl-Dex RBCs are poised for a 
more thorough pre-clinical investigation (see Figure 4.1). Although experiments with Cy5-Cbl-
TAX have demonstrated localized release in both tumor and healthy vasculature, the localized 
effect of Dex needs to be similarly assessed. In both the acute CAIA model, as well as in a more 
chronic but less aggressive mouse model, Dex could be locally released from Cy5-Cbl-Dex RBCs 
in mice who present inflammation in more than one paw.34, 35 In such models, the efficacy should 
be limited to only the illuminated paw. However, such studies require long-term circulation of 
mRBCs. If the therapeutic is systemically released within 24 h, these studies will not properly 
assess long-term Cy5-Cbl-Dex efficacy for more chronic treatment and subsequent chronic 
indications. The in-depth discussion in section 4.4.1 describes the current status of Cy5-Cbl-Dex 
mRBC integrity, PK, and clearance studies. Another control that should be included in future 
animal studies is a dark mouse control, which receives Cy5-Cbl-Dex RBCs but is not illuminated. 
Such a control will help assess for dark activity and begin to establish an in vivo photoindex of 
spatial and temporal delivery of Dex from circulating Cy5-Cbl-Dex mRBCs. Along with an in vivo 
photoindex, a more rigorously quantified in vitro photoindex could support in vivo findings. Multiple 
in vitro studies have already validated light-dependent efficacy and consistently indicated an 
improved photoindex. However, quantification of the photoindex is still required and can be 
performed by quantifying GRa localization in sensitive GRa cell lines in response to Cy5-Cbl-Dex 
RBCs.36  
Another facet that should be thoroughly investigated before conducting more rigorous 
animal studies is ensuring the light dosage is sufficiently high to photoactivate Dex in mouse paws. 
Although thorough PK studies of the joint tissue and vasculature would be the ideal method to 
quantify and ensure therapeutic release after the 5 mW 5 min treatment, previous groups have 





light penetrates tissue and activates the photoactivatable therapeutic.37 Another option is 
employing Cbl-BODIPY650 similar to its previous use in assessing biodistribution of Cbl in 
tumors.4 BODIPY650 is highly cell permeable and when conjugated to Cbl should still activate 
photocleavage in response to near infrared wavelengths similar to previous results from studies 
of Cbl-BODIPY. Initial studies with Cbl-BODIPY650 RBCs, or ideally FL800-Cbl-BODIPY650, 
would provide a means of measuring “therapeutic” release, distribution, and localization for both 
in vivo light dosage and localization studies.38 Of course, this system is only an imaging control 
and preliminary findings with the BODIPY derivative would need to be quantified with rigorous PK 
studies of the Dex derivative. 
Once these initial studies validate the in vivo localized efficacy of Cy5-Cbl-Dex RBCs, it is 
important to initiate toxicology studies and the optimization of manufacturing techniques for 
scaling up synthesis to clinical needs and meeting good manufacturing practice (GMP) 
requirements. Specifically, good laboratory practice (GLP) toxicology studies should thoroughly 
quantify the extent of therapeutic exposure as well as follow-up on the potential damage from 
Cy5-generated reactive oxygen species noted in Chapter 2 (Figure 2.12). Since Cy5-Cbl-Dex 
RBCs will be a chronic “slow-release” treatment, longer-term toxicity studies will need to be 
performed to account for the extended 28-day circulation of these modified RBCs. Manufacturing 
studies will require optimization of the light-sensitive Cbl syntheses as well as development of 
technology for loading RBCs. Conversely, a partnership with EryDel and their Red Cell Loader 
may minimize the RBC manufacturing required before clinical translation.39 However, initial pre-
clinical validation and characterization are required before considering GMP manufacturing and 








4.4.1 Cy5-Cbl mRBC Integrity Challenges  
Although extensive in vitro and in vivo investigations into mRBC loading processes have 
already been conducted, circulation of mRBCs from our current methods is still limited to at-most 
to 24 h. Initially, with the clinical precedent set by the Red Cell Loader, a hypotonic dialysis method 
was selected and optimized.39 As discussed in Chapter 2, mouse RBCs (mRBCs) display 
significant instability in vitro which is further decreased upon dialysis loading (Figure 2.6).14 Thus, 
in preparation for the animal efficacy studies conducted in Chapter 3, optimization of mRBC 
stability was further conducted. The dialysis and reseal conditions were optimized, supplemental 
stabilizing components were added, and a high-salt reseal step was introduced. Although these 
changes did extend circulation as noted in Chapter 3 (Figure 3.4), the current optimized protocol 
established still displays significant clearance from circulation within 3 h (Figure 4.11). Based on 
the histology results discussed in Chapter 3, a noted increase in fluorescence within the spleen 
occurs over 24 h and significant fluorescence emerges in the kidney at 24 h (Figure 3.14). The 
loaded mRBCs may be cleared from circulation by initial capture within the spleen, wherein they 
are broken down, and the remaining Cy5-Cbl species further processed in the liver and cleared 













Figure 4.11 Clearance of loaded mRBCs within 3 h. A mixture of internally stained 
carboxyfluorescein succinimidyl ester (CFSE) mRBCs and internally loaded Cy5-Cbl-Dex 
mRBCs were intravenously injected into healthy DBA1J mice. Circulation over 3 h was 
monitored by sacking and collecting blood from mice via cardiac puncture. Over 3 h, 
internally loaded Cy5-Cbl-Dex mRBCs (filled circle) are cleared from circulation while 



































Thus, I investigated alternate methods of internally loading mRBCs in preparation for 
multi-day animal studies. Specifically, a previously published method that further improved upon 
the high-salt loading protocol employed in Chapter 3 and successfully achieved 9 days of 
circulation with loaded mRBCs was tested. The protocol requires doubling the circulation and 
resealing times and addition of stabilizing factors (including ATP, adenine, inosine, glucose, etc.) 
to all solutions of the original protocol employed in Chapter 3.41, 42 Widefield images show 
morphologically similar loaded mRBCs from both the Chapter 3 protocol and the extended loading 
protocol. However, the extended loading produces less fluorescent mRBCs (Figure 4.12a). Semi-
qualitative analysis with flow cytometry confirms these findings, as the extended protocol 
produces non-uniformly fluorescent mRBCs unlike the original protocol which uniformly loads the 
mRBCs (Figure 4.12b). The morphology of native mRBCs, of mRBCs loaded with the Chapter 3 
protocol, and mRBCs loaded with the extended protocol was assessed by flow cytometry forward 
light scatter (FSC; which assesses mRBC shape) and side light scatter (SSC; which assess the 
granularity of the mRBC interior). Overlay of a native mRBC population gate onto the loaded 
mRBCs estimates nearly 3-fold more mRBCs from the extended loading fall within the native gate 
as compared to mRBCs loaded by the Chapter 3 protocol (Figure 4.12b). As previously discussed 
in Chapter 1, loaded RBCs should ideally demonstrate only a 20% change in characteristics from 
native RBCs to maintain necessary long-term circulation stability.20, 43 Thus, although the 
efficiency of therapeutic loading is decreased during the extended loading, the improved 
preservation of shape and granularity may improve circulation. Further, the loss in drug loading 
efficiency may be more in line with the Red Cell Loader, which only encapsulates 30 ± 3% drug.44 
Of course, animal circulation studies are the true standard by which an ideal loading protocol 
should be optimized. Future studies should continue to assess and optimize in vivo circulation in 








Figure 4.12 Analysis of two lead loading protocols for stabilizing mRBCs in vivo. a)  
Widefield images of mRBCs loaded by the protocol from Chapter 3 (left column), the 
experimental protocol (middle column), and native mRBCs (right column). b) Flow cytometry 
dot plots of forward light scatter (FSC) reflecting cell shape versus side light scatter (SSC) 
reflecting cell granularity over time of the protocol from Chapter 3, experimental protocol, and 
native mRBCs (top). Histogram of Cy5 signal of loaded mRBCs (bottom). 
 



































































































































Since the initial development of long-wavelength photoresponsive Cbl moieties in 2014, 
an array of Cy5-Cbl photoactivatable therapeutics have been described and multiple therapies 
have entered pre-clinical testing.11 Starting with the development of cancer treatments, Cbl 
derivatives maintain the pharmacological activity of appended chemotherapeutics and release 
chemotherapeutics in response to light. However, Cbl derivatives also significantly distribute 
throughout the body and display dark activity in vitro. Thus, RBCs were introduced as potential 
carriers for Cy5-Cbl therapeutics.22 Since then, these Cy5-Cbl RBC therapeutic DDSs have been 
shown to shelter Cy5-Cbl therapeutics, extend their circulation time, locally release the 
therapeutic, and achieve comparable efficacy to a standard of care control. Specifically, both Cy5-
Cbl-TAX and Cy5-Cbl-Dex RBCs have been tested in vivo.  
Currently, arthritis is our lead indication due to the persistent unmet clinical need to make 
glucocorticoids less toxic.28, 30 Cy5-Cbl-Dex RBCs can improve efficacy and safety as compared 
to these clinical therapeutics, as well as provide a novel means for patient-directed therapeutic 
release. In general, the Cbl RBC system has proven safe in vitro and in vivo. Further GLP studies 
are needed to assess potential toxicity from reactive oxygen species generated by Cy5. In 
addition, a long-term (weeks for rodents, months for primates) circulating system is required to 
validate the extent of directed treatment in small and large chronic arthritis animal models. Further 
controls showing light-dependent and localized efficacy in vivo need to be conducted before 
shifting into large-scale GLP toxicology and GMP manufacturing studies. The work conducted 
herein has established the required assays for quality assurance, poised Cy5-Cbl-Dex RBCs for 
further pre-clinical testing and eventual GXP studies, and set a path to the clinic for 
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